-DOCSTART-	O

Title	O
:	O
The	O
CABI	O
Trial	O
:	O
an	O
Unblinded	O
Parallel	O
Group	O
Randomised	O
Controlled	O
Feasibility	O
Trial	O
of	O
Long	B-I
-	I-I
Course	I-I
Antibiotic	I-I
Therapy	I-I
(	O
28	O
Days	O
)	O
Compared	O
with	O
Short	B-I
Course	I-I
(	O
?	O
10	O
Days	O
)	O
in	O
the	O
Prevention	O
of	O
Relapse	O
in	O
Adults	B-P
Treated	I-P
for	I-P
Complicated	I-P
Intra	I-P
-	I-P
Abdominal	I-P
Infection	I-P
.	O

METHODS	O
:	O
A	O
randomised	O
controlled	O
unblinded	O
feasibility	O
trial	O
was	O
conducted	O
.	O

Eligible	O
participants	O
were	O
adult	B-P
patients	I-P
with	I-P
a	I-P
cIAI	I-P
that	I-P
were	I-P
diagnosed	I-P
?	I-P
6	I-P
days	I-P
prior	I-P
to	I-P
screening	I-P
.	O

Randomisation	O
was	O
to	O
long	B-I
-	I-I
course	I-I
(	O
28	O
days	O
)	O
or	O
short	B-I
-	I-I
course	I-I
(	I-I
?10	I-I
days	I-I
)	I-I
antibiotic	I-I
therapy	I-I
.	O

Choice	O
of	O
antibiotics	O
was	O
determined	O
by	O
the	O
clinical	O
team	O
.	O

Participants	O
were	O
followed	O
up	O
for	O
90	O
days	O
.	O

Primary	O
outcomes	O
were	O
willingness	B-O
of	I-O
participants	I-O
to	I-O
be	I-O
randomised	I-O
and	O
feasibility	B-O
of	I-O
trial	I-O
procedures	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Trial	O
of	O
Lopinavir	B-I
-	O
Ritonavir	B-I
in	O
Adults	B-P
Hospitalized	I-P
with	I-P
Severe	I-P
Covid	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
controlled	O
,	O
open	O
-	O
label	O
trial	O
involving	O
hospitalized	B-P
adult	I-P
patients	I-P
with	I-P
confirmed	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
,	I-P
which	I-P
causes	I-P
the	I-P
respiratory	I-P
illness	I-P
Covid	I-P
-	I-P
19	I-P
,	I-P
and	I-P
an	I-P
oxygen	I-P
saturation	I-P
(	I-P
Sao2	I-P
)	I-P
of	I-P
94	I-P
%	I-P
or	I-P
less	I-P
while	I-P
they	I-P
were	I-P
breathing	I-P
ambient	I-P
air	I-P
or	I-P
a	I-P
ratio	I-P
of	I-P
the	I-P
partial	I-P
pressure	I-P
of	I-P
oxygen	I-P
(	I-P
Pao2	I-P
)	I-P
to	I-P
the	I-P
fraction	I-P
of	I-P
inspired	I-P
oxygen	I-P
(	I-P
Fio2	I-P
)	I-P
of	I-P
less	I-P
than	I-P
300	I-P
mm	I-P
Hg	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
either	O
lopinavir	B-I
-	O
ritonavir	B-I
(	O
400	O
mg	O
and	O
100	O
mg	O
,	O
respectively	O
)	O
twice	O
a	O
day	O
for	O
14	O
days	O
,	O
in	O
addition	O
to	O
standard	B-I
care	I-I
,	O
or	O
standard	B-C
care	I-C
alone	I-C
.	O

The	O
primary	O
end	O
point	O
was	O
the	B-O
time	I-O
to	I-O
clinical	I-O
improvement	I-O
,	O
defined	O
as	O
the	B-O
time	I-O
from	I-O
randomization	I-O
to	I-O
either	I-O
an	I-O
improvement	I-O
of	I-O
two	I-O
points	I-O
on	O
a	B-O
seven	I-O
-	I-O
category	I-O
ordinal	I-O
scale	I-O
or	O
discharge	B-O
from	I-O
the	I-O
hospital	I-O
,	O
whichever	O
came	O
first	O
.	O

-DOCSTART-	O

Title	O
:	O
Respiratory	B-I
rehabilitation	I-I
in	O
elderly	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
randomized	O
controlled	O
study	O
.	O

METHODS	O
:	O
This	O
paper	O
reported	O
the	O
findings	O
of	O
an	O
observational	O
,	O
prospective	O
,	O
quasi	O
-	O
experimental	O
study	O
,	O
which	O
totally	O
recruited	O
72	B-P
participants	I-P
,	O
of	O
which	O
36	O
patients	O
underwent	O
respiratory	B-I
rehabilitation	I-I
and	O
the	O
rest	O
without	O
any	B-C
rehabilitation	I-C
intervention	I-C
.	O

The	O
following	O
outcomes	O
were	O
measured	O
:	O
pulmonary	B-O
function	I-O
tests	I-O
including	O
plethysmography	B-O
and	O
diffusing	B-O
lung	I-O
capacity	I-O
for	I-O
carbon	I-O
monoxide	I-O
(	I-O
DLCO	I-O
)	I-O
,	O
functional	B-O
tests	I-O
(	O
6	B-O
-	I-O
min	I-O
walk	I-O
distance	I-O
test	I-O
)	O
,	O
Quality	B-O
of	I-O
life	I-O
(	I-O
QoL	I-O
)	I-O
assessments	I-O
(	O
SF	B-O
-	I-O
36	I-O
scores	I-O
)	O
,	O
activities	B-O
of	I-O
daily	I-O
living	I-O
(	O
Functional	B-O
Independence	I-O
Measure	I-O
,	O
FIM	B-O
scores	I-O
)	O
,	O
and	O
mental	B-O
status	I-O
tests	I-O
(	O
SAS	B-O
anxiety	I-O
and	O
SDS	B-O
depression	I-O
scores	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
progressive	B-I
muscle	I-I
relaxation	I-I
on	O
anxiety	O
and	O
sleep	O
quality	O
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
controlled	O
clinical	O
trial	O
,	O
a	B-P
total	I-P
of	I-P
51	I-P
patients	I-P
who	I-P
entered	I-P
the	I-P
isolation	I-P
ward	I-P
were	O
included	O
in	O
the	O
study	O
and	O
randomly	O
divided	O
into	O
experimental	O
and	O
control	O
groups	O
.	O

The	O
experimental	O
group	O
used	O
progressive	B-I
muscle	I-I
relaxation	I-I
(	I-I
PMR	I-I
)	I-I
technology	I-I
for	O
30	O
min	O
per	O
day	O
for	O
5	O
consecutive	O
days	O
.	O

During	O
this	O
period	O
,	O
the	O
control	O
group	O
received	O
only	B-C
routine	I-C
care	I-C
and	O
treatment	B-C
.	O

Before	O
and	O
after	O
the	O
intervention	O
,	O
the	B-O
Spielberger	I-O
State	I-O
-	I-O
Trait	I-O
Anxiety	I-O
Scale	I-O
(	I-O
STAI	I-O
)	I-O
and	O
Sleep	B-O
State	I-O
Self	I-O
-	I-O
Rating	I-O
Scale	I-O
(	I-O
SRSS	I-O
)	I-O
were	O
used	O
to	O
measure	O
and	O
record	O
patient	B-O
anxiety	I-O
and	O
sleep	B-O
quality	I-O
.	O

Finally	O
,	O
data	O
analysis	O
was	O
performed	O
using	O
SPSS	O
25	O
.	O
0	O
software	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
A	O
pilot	O
study	O
of	O
hydroxychloroquine	B-I
in	O
treatment	O
of	O
patients	B-P
with	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
]	O
.	O

METHODS	O
:	O
We	O
prospectively	O
enrolled	O
30	B-P
treatment	I-P
-	I-P
nave	I-P
patients	I-P
with	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
after	I-P
informed	I-P
consent	I-P
at	I-P
Shanghai	I-P
Public	I-P
Health	I-P
Clinical	I-P
Center	I-P
.	O

The	O
patients	O
were	O
randomized	O
1?1	O
to	O
HCQ	B-I
group	O
and	O
the	O
control	O
group	O
.	O

Patients	O
in	O
HCQ	B-I
group	O
were	O
given	O
HCQ	B-I
400	O
mg	O
per	O
day	O
for	O
5	O
days	O
plus	O
conventional	B-I
treatments	I-I
,	O
while	O
those	O
in	O
the	O
control	O
group	O
were	O
given	O
conventional	B-C
treatment	I-C
only	I-C
.	O

The	O
primary	O
endpoint	O
was	O
negative	B-O
conversion	I-O
rate	I-O
of	I-O
SARS	I-O
-	I-O
CoV	I-O
-	I-O
2	I-O
nucleic	I-O
acid	I-O
in	I-O
respiratory	I-O
pharyngeal	I-O
swab	I-O
on	O
days	O
7	O
after	O
randomization	O
.	O

This	O
study	O
has	O
been	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
Shanghai	O
Public	O
Health	O
Clinical	O
Center	O
and	O
registered	O
online	O
(	O
NCT04261517	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Triple	O
combination	O
of	O
interferon	B-I
beta	I-I
-	I-I
1	I-I
b	I-I
,	O
lopinavir	B-I
-	O
ritonavir	B-I
,	O
and	O
ribavirin	B-I
in	O
the	O
treatment	O
of	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
an	O
open	O
-	O
label	O
,	O
randomised	O
,	O
phase	O
2	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicentre	O
,	O
prospective	O
,	O
open	O
-	O
label	O
,	O
randomised	O
,	O
phase	O
2	O
trial	O
in	O
adults	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
who	I-P
were	I-P
admitted	I-P
to	I-P
six	I-P
hospitals	I-P
in	I-P
Hong	I-P
Kong	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
2	O
:	O
1	O
)	O
to	O
a	B-I
14	I-I
-	I-I
day	I-I
combination	I-I
of	I-I
lopinavir	I-I
400	O
mg	O
and	O
ritonavir	B-I
100	O
mg	O
every	O
12	O
h	O
,	O
ribavirin	B-I
400	O
mg	O
every	O
12	O
h	O
,	O
and	O
three	B-I
doses	I-I
of	I-I
8	I-I
million	I-I
international	I-I
units	I-I
of	I-I
interferon	I-I
beta	I-I
-	I-I
1	I-I
b	I-I
on	O
alternate	O
days	O
(	O
combination	O
group	O
)	O
or	O
to	O
14	B-C
days	I-C
of	I-C
lopinavir	I-C
400	O
mg	O
and	O
ritonavir	B-C
100	O
mg	O
every	O
12	O
h	O
(	O
control	O
group	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	B-O
time	I-O
to	I-O
providing	I-O
a	I-O
nasopharyngeal	I-O
swab	I-O
negative	I-O
for	I-O
severe	I-O
acute	I-O
respiratory	I-O
syndrome	I-O
coronavirus	I-O
2	I-O
RT	I-O
-	I-O
PCR	I-O
,	O
and	O
was	O
done	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

The	O
study	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04276688	O
.	O

-DOCSTART-	O

Title	O
:	O
Hydroxychloroquine	B-I
in	O
patients	B-P
with	I-P
mainly	I-P
mild	I-P
to	I-P
moderate	I-P
coronavirus	I-P
disease	I-P
2019	I-P
:	O
open	O
label	O
,	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
Multicentre	O
,	O
open	O
label	O
,	O
randomised	O
controlled	O
trial	O
.	O

16	O
government	O
designated	O
covid	O
-	O
19	O
treatment	O
centres	O
in	O
China	O
,	O
11	O
to	O
29	O
February	O
2020	O
.	O

150	B-P
patients	I-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
laboratory	I-P
confirmed	I-P
covid	I-P
-	I-P
19	I-P
were	O
included	O
in	O
the	O
intention	O
to	O
treat	O
analysis	O
(	O
75	O
patients	O
assigned	O
to	O
hydroxychloroquine	B-I
plus	O
standard	B-I
of	I-I
care	I-I
,	O
75	O
to	O
standard	B-C
of	I-C
care	I-C
alone	I-C
)	O
.	O

Hydroxychloroquine	B-I
administrated	O
at	O
a	O
loading	O
dose	O
of	O
1200	O
mg	O
daily	O
for	O
three	O
days	O
followed	O
by	O
a	O
maintenance	O
dose	O
of	O
800	O
mg	O
daily	O
(	O
total	O
treatment	O
duration	O
:	O
two	O
or	O
three	O
weeks	O
for	O
patients	O
with	O
mild	O
to	O
moderate	O
or	O
severe	O
disease	O
,	O
respectively	O
)	O
.	O

Negative	B-O
conversion	I-O
of	I-O
severe	I-O
acute	I-O
respiratory	I-O
syndrome	I-O
coronavirus	I-O
2	I-O
by	O
28	O
days	O
,	O
analysed	O
according	O
to	O
the	O
intention	O
to	O
treat	O
principle	O
.	O

Adverse	B-O
events	I-O
were	O
analysed	O
in	O
the	O
safety	O
population	O
in	O
which	O
hydroxychloroquine	B-I
recipients	O
were	O
participants	O
who	O
received	O
at	O
least	O
one	B-I
dose	I-I
of	I-I
hydroxychloroquine	I-I
and	O
hydroxychloroquine	B-I
non	O
-	O
recipients	O
were	O
those	O
managed	O
with	O
standard	O
of	O
care	O
alone	O
.	O

-DOCSTART-	O

Title	O
:	O
Remdesivir	B-I
in	O
adults	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicentre	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multicentre	O
trial	O
at	O
ten	O
hospitals	O
in	O
Hubei	O
,	O
China	O
.	O

Eligible	O
patients	O
were	O
adults	B-P
(	I-P
aged	I-P
?18	I-P
years	I-P
)	I-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
laboratory	I-P
-	I-P
confirmed	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
,	I-P
with	I-P
an	I-P
interval	I-P
from	I-P
symptom	I-P
onset	I-P
to	I-P
enrolment	I-P
of	I-P
12	I-P
days	I-P
or	I-P
less	I-P
,	I-P
oxygen	I-P
saturation	I-P
of	I-P
94	I-P
%	I-P
or	I-P
less	I-P
on	I-P
room	I-P
air	I-P
or	I-P
a	I-P
ratio	I-P
of	I-P
arterial	I-P
oxygen	I-P
partial	I-P
pressure	I-P
to	I-P
fractional	I-P
inspired	I-P
oxygen	I-P
of	I-P
300	I-P
mm	I-P
Hg	I-P
or	I-P
less	I-P
,	I-P
and	I-P
radiologically	I-P
confirmed	I-P
pneumonia	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
2	O
:	O
1	O
ratio	O
to	O
intravenous	B-I
remdesivir	I-I
(	O
200	O
mg	O
on	O
day	O
1	O
followed	O
by	O
100	O
mg	O
on	O
days	O
2	O
-	O
10	O
in	O
single	O
daily	O
infusions	O
)	O
or	O
the	B-C
same	I-C
volume	I-C
of	I-C
placebo	I-C
infusions	O
for	O
10	O
days	O
.	O

Patients	O
were	O
permitted	O
concomitant	O
use	O
of	O
lopinavir	O
-	O
ritonavir	O
,	O
interferons	O
,	O
and	O
corticosteroids	O
.	O

The	O
primary	O
endpoint	O
was	O
time	B-O
to	I-O
clinical	I-O
improvement	I-O
up	O
to	O
day	O
28	O
,	O
defined	O
as	O
the	B-O
time	I-O
(	I-O
in	I-O
days	I-O
)	I-O
from	I-O
randomisation	I-O
to	I-O
the	I-O
point	I-O
of	I-O
a	I-O
decline	I-O
of	I-O
two	I-O
levels	I-O
on	O
a	B-O
six	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
of	I-O
clinical	I-O
status	I-O
(	O
from	O
1	O
=	O
discharged	O
to	O
6	O
=	O
death	O
)	O
or	O
discharged	B-O
alive	I-O
from	I-O
hospital	I-O
,	O
whichever	O
came	O
first	O
.	O

Primary	O
analysis	O
was	O
done	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
population	O
and	O
safety	O
analysis	O
was	O
done	O
in	O
all	O
patients	O
who	O
started	O
their	O
assigned	O
treatment	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04257656	O
.	O

-DOCSTART-	O

Title	O
:	O
Remdesivir	B-I
for	O
the	O
Treatment	O
of	O
Covid	O
-	O
19	O
-	O
Final	O
Report	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
intravenous	B-I
remdesivir	I-I
in	O
adults	B-P
who	I-P
were	I-P
hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
and	I-P
had	I-P
evidence	I-P
of	I-P
lower	I-P
respiratory	I-P
tract	I-P
infection	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
remdesivir	B-I
(	O
200	O
mg	O
loading	O
dose	O
on	O
day	O
1	O
,	O
followed	O
by	O
100	O
mg	O
daily	O
for	O
up	O
to	O
9	O
additional	O
days	O
)	O
or	O
placebo	B-C
for	O
up	O
to	O
10	O
days	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
time	I-O
to	I-O
recovery	I-O
,	O
defined	O
by	O
either	O
discharge	B-O
from	I-O
the	I-O
hospital	I-O
or	O
hospitalization	B-O
for	I-O
infection	I-O
-	I-O
control	I-O
purposes	I-O
only	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Ruxolitinib	B-I
in	O
treatment	O
of	O
severe	O
coronavirus	O
disease	O
2019	O
(	O
COVID	O
-	O
19	O
)	O
:	O
A	O
multicenter	O
,	O
single	O
-	O
blind	O
,	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
prospective	O
,	O
multicenter	O
,	O
single	O
-	O
blind	O
,	O
randomized	O
controlled	O
phase	O
II	O
trial	O
involving	O
patients	B-P
with	I-P
severe	I-P
coronavirus	I-P
disease	I-P
2019	I-P
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Randomized	O
Trial	O
of	O
Hydroxychloroquine	B-I
as	O
Postexposure	O
Prophylaxis	O
for	O
Covid	O
-	O
19	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
across	O
the	O
United	O
States	O
and	O
parts	O
of	O
Canada	O
testing	O
hydroxychloroquine	B-I
as	O
postexposure	O
prophylaxis	O
.	O

We	O
enrolled	O
adults	B-P
who	I-P
had	I-P
household	I-P
or	I-P
occupational	I-P
exposure	I-P
to	I-P
someone	I-P
with	I-P
confirmed	I-P
Covid	I-P
-	I-P
19	I-P
at	I-P
a	I-P
distance	I-P
of	I-P
less	I-P
than	I-P
6	I-P
ft	I-P
for	I-P
more	I-P
than	I-P
10	I-P
minutes	I-P
while	I-P
wearing	I-P
neither	I-P
a	I-P
face	I-P
mask	I-P
nor	I-P
an	I-P
eye	I-P
shield	I-P
(	I-P
high	I-P
-	I-P
risk	I-P
exposure	I-P
)	I-P
or	I-P
while	I-P
wearing	I-P
a	I-P
face	I-P
mask	I-P
but	I-P
no	I-P
eye	I-P
shield	I-P
(	I-P
moderate	I-P
-	I-P
risk	I-P
exposure	I-P
)	I-P
.	O

Within	O
4	O
days	O
after	O
exposure	O
,	O
we	O
randomly	O
assigned	O
participants	O
to	O
receive	O
either	O
placebo	B-C
or	O
hydroxychloroquine	B-I
(	O
800	O
mg	O
once	O
,	O
followed	O
by	O
600	O
mg	O
in	O
6	O
to	O
8	O
hours	O
,	O
then	O
600	O
mg	O
daily	O
for	O
4	O
additional	O
days	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
incidence	I-O
of	I-O
either	I-O
laboratory	I-O
-	I-O
confirmed	I-O
Covid	I-O
-	I-O
19	I-O
or	O
illness	B-O
compatible	I-O
with	I-O
Covid	I-O
-	I-O
19	I-O
within	O
14	O
days	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
Xuebijing	B-I
injection	I-I
on	O
inflammatory	O
markers	O
and	O
disease	O
outcome	O
of	O
coronavirus	O
disease	O
2019	O
]	O
.	O

METHODS	O
:	O
Sixty	B-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
admitted	I-P
to	I-P
Changsha	I-P
Public	I-P
Health	I-P
Treatment	I-P
Center	I-P
(	I-P
North	I-P
Hospital	I-P
of	I-P
the	I-P
First	I-P
Hospital	I-P
of	I-P
Changsha	I-P
City	I-P
)	I-P
from	I-P
January	I-P
to	I-P
March	I-P
in	I-P
2020	I-P
were	O
randomly	O
divided	O
into	O
routine	B-C
treatment	I-C
group	O
,	O
Xuebijing	B-I
50	O
mL	O
group	O
and	O
Xuebijing	B-I
100	O
mL	O
group	O
,	O
with	O
20	O
cases	O
in	O
each	O
group	O
.	O

The	O
routine	O
treatment	O
group	O
was	O
treated	O
according	O
to	O
the	O
National	O
Health	O
Commission	O
'	O
s	O
guide	O
for	O
COVID	O
-	O
19	O
.	O

On	O
the	O
basis	O
of	O
conventional	O
treatment	O
,	O
Xuebijing	B-I
injection	O
was	O
injected	O
by	O
50	O
mL	O
twice	O
a	O
day	O
for	O
7	O
days	O
in	O
Xuebijing	B-I
50	O
mL	O
group	O
,	O
while	O
by	O
100	O
mL	O
twice	O
a	O
day	O
for	O
7	O
days	O
in	O
Xuebijing	B-I
100	O
mL	O
group	O
.	O

The	B-O
blood	I-O
routine	I-O
test	I-O
,	O
C	B-O
-	I-O
reactive	I-O
protein	I-O
(	I-O
CRP	I-O
)	I-O
,	O
erythrocyte	B-O
sedimentation	I-O
rate	I-O
(	I-O
ESR	I-O
)	I-O
,	O
acute	B-O
physiology	I-O
and	O
chronic	B-O
health	I-O
evaluation	I-O
II	I-O
(	I-O
APACHE	I-O
II	I-O
)	I-O
score	I-O
,	O
2019	B-O
novel	I-O
coronavirus	I-O
(	I-O
2019	I-O
-	I-O
nCoV	I-O
)	I-O
nucleic	I-O
acid	I-O
test	I-O
and	O
disease	B-O
classification	I-O
of	O
three	O
groups	O
before	O
and	O
8	O
days	O
after	O
treatment	O
were	O
observed	O
.	O

-DOCSTART-	O

Title	O
:	O
Oseltamivir	B-I
for	O
coronavirus	O
illness	O
:	O
post	O
-	O
hoc	O
exploratory	O
analysis	O
of	O
an	O
open	O
-	O
label	O
,	O
pragmatic	O
,	O
randomised	O
controlled	O
trial	O
in	O
European	O
primary	O
care	O
from	O
2016	O
to	O
2018	O
.	O

METHODS	O
:	O
Exploratory	O
analysis	O
of	O
data	O
from	O
an	O
open	O
-	O
label	O
,	O
pragmatic	O
,	O
randomised	O
controlled	O
trial	O
during	O
three	O
influenza	O
seasons	O
,	O
from	O
2016	O
to	O
2018	O
,	O
in	O
primary	O
care	O
research	O
networks	O
,	O
in	O
15	O
European	O
countries	O
.	O

Patients	B-P
aged	I-P
?1	I-P
year	I-P
presenting	I-P
to	I-P
primary	I-P
care	I-P
with	I-P
influenza	I-P
-	I-P
like	I-P
illness	I-P
(	I-P
ILI	I-P
)	I-P
,	I-P
and	I-P
who	I-P
tested	I-P
positive	I-P
for	I-P
coronavirus	I-P
(	I-P
not	I-P
including	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
)	I-P
,	O
were	O
randomised	O
to	O
usual	B-C
care	I-C
or	O
usual	B-I
care	I-I
plus	O
oseltamivir	B-I
.	O

The	O
primary	O
outcome	O
was	O
time	B-O
to	I-O
recovery	I-O
defined	O
as	O
a	B-O
return	I-O
to	I-O
usual	I-O
activities	I-O
,	O
with	O
minor	B-O
or	O
absent	B-O
fever	I-O
,	O
headache	B-O
,	O
and	O
muscle	B-O
ache	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Febuxostat	B-I
therapy	I-I
in	O
outpatients	B-P
with	I-P
suspected	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
clinical	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
clinical	O
trial	O
involving	O
adult	B-P
outpatients	I-P
with	I-P
the	I-P
moderate	I-P
respiratory	I-P
illness	I-P
following	I-P
COVID	I-P
-	I-P
19	I-P
infection	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
FBX	B-I
or	O
HCQ	B-I
for	O
5	O
days	O
.	O

The	O
measured	O
variables	O
were	O
needs	B-O
to	I-O
hospitalisation	I-O
,	O
clinical	B-O
and	O
laboratory	B-O
data	I-O
including	O
fever	B-O
,	O
cough	B-O
,	O
breathing	B-O
rate	I-O
,	O
C	B-O
-	I-O
Reactive	I-O
Protein	I-O
level	I-O
,	O
lymphocytes	B-O
count	I-O
at	O
onset	O
of	O
admission	O
and	O
was	O
well	O
as	O
at	O
5	O
days	O
of	O
treatments	O
.	O

In	O
addition	O
,	O
CT	B-O
findings	I-O
were	O
evaluated	O
on	O
admission	O
and	O
14	O
days	O
after	O
initiation	O
of	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Intravenous	B-I
high	I-I
-	I-I
dose	I-I
vitamin	I-I
C	I-I
for	O
the	O
treatment	O
of	O
severe	O
COVID	O
-	O
19	O
:	O
study	O
protocol	O
for	O
a	O
multicentre	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
The	O
investigators	O
designed	O
a	O
multicentre	O
prospective	O
randomised	O
placebo	O
-	O
controlled	O
trial	O
that	O
is	O
planned	O
to	O
recruit	O
308	B-P
adults	I-P
diagnosed	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
transferred	I-P
into	I-P
the	I-P
intensive	I-P
care	I-P
unit	I-P
.	O

Participants	O
will	O
randomly	O
receive	O
HIVC	B-I
diluted	O
in	O
sterile	O
water	O
or	O
placebo	B-C
for	O
7	O
days	O
once	O
enrolled	O
.	O

Patients	O
with	O
a	O
history	O
of	O
VC	O
allergy	O
,	O
end	O
-	O
stage	O
pulmonary	O
disease	O
,	O
advanced	O
malignancy	O
or	O
glucose	O
-	O
6	O
-	O
phosphate	O
dehydrogenase	O
deficiency	O
will	O
be	O
excluded	O
.	O

The	O
primary	O
outcome	O
is	O
ventilation	B-O
-	I-O
free	I-O
days	I-O
within	O
28	O
observational	O
days	O
.	O

This	O
is	O
one	O
of	O
the	O
first	O
clinical	O
trials	O
applying	O
HIVC	B-I
to	O
treat	O
COVID	O
-	O
19	O
,	O
and	O
it	O
will	O
provide	O
credible	O
efficacy	O
and	O
safety	O
data	O
.	O

We	O
predict	O
that	O
HIVC	B-I
could	O
suppress	O
cytokine	O
storms	O
caused	O
by	O
COVID	O
-	O
19	O
,	O
help	O
improve	O
pulmonary	O
function	O
and	O
reduce	O
the	O
risk	O
of	O
ARDS	O
of	O
COVID	O
-	O
19	O
.	O

-DOCSTART-	O

Title	O
:	O
Hydroxychloroquine	B-I
in	O
Nonhospitalized	B-P
Adults	I-P
With	I-P
Early	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
Randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
conducted	O
from	O
22	O
March	O
through	O
20	O
May	O
2020	O
.	O

(	O
ClinicalTrials	O
.	O
gov	O
:	O
NCT04308668	O
)	O
.	O

Internet	O
-	O
based	O
trial	O
across	O
the	O
United	O
States	O
and	O
Canada	O
(	O
40	O
states	O
and	O
3	O
provinces	O
)	O
.	O

Symptomatic	B-P
,	I-P
nonhospitalized	I-P
adults	I-P
with	I-P
laboratory	I-P
-	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
or	I-P
probable	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
high	I-P
-	I-P
risk	I-P
exposure	I-P
within	I-P
4	I-P
days	I-P
of	I-P
symptom	I-P
onset	I-P
.	O

Oral	B-I
hydroxychloroquine	I-I
(	O
800	O
mg	O
once	O
,	O
followed	O
by	O
600	O
mg	O
in	O
6	O
to	O
8	O
hours	O
,	O
then	O
600	O
mg	O
daily	O
for	O
4	O
more	O
days	O
)	O
or	O
masked	B-C
placebo	I-C
.	O

Symptoms	O
and	O
severity	O
at	O
baseline	O
and	O
then	O
at	O
days	O
3	O
,	O
5	O
,	O
10	O
,	O
and	O
14	O
using	O
a	B-O
10	I-O
-	I-O
point	I-O
visual	I-O
analogue	I-O
scale	I-O
.	O

The	O
primary	O
end	O
point	O
was	O
change	O
in	O
overall	B-O
symptom	I-O
severity	I-O
over	O
14	O
days	O
.	O

-DOCSTART-	O

Title	O
:	O
Exploring	O
an	O
Integrative	O
Therapy	O
for	O
Treating	O
COVID	O
-	O
19	O
:	O
A	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
A	B-I
putative	I-I
ARDS	I-I
-	I-I
suppressing	I-I
drug	I-I
Keguan	I-I
-	I-I
1	I-I
was	O
first	O
developed	O
and	O
then	O
evaluated	O
by	O
a	O
randomized	O
,	O
controlled	O
two	O
-	O
arm	O
trial	O
.	O

The	O
two	O
arms	O
of	O
the	O
trial	O
consist	O
of	O
a	O
control	O
therapy	O
(	O
alpha	B-C
interferon	I-C
inhalation	I-C
,	O
50	O
g	O
twice	O
daily	O
;	O
and	O
lopinavir	B-C
/	O
ritonavir	B-C
,	O
400	O
and	O
100	O
mg	O
twice	O
daily	O
,	O
respectively	O
)	O
and	O
a	O
testing	O
therapy	O
(	O
control	O
therapy	O
plus	O
Keguan	B-I
-	I-I
1	I-I
19	O
.	O
4	O
g	O
twice	O
daily	O
)	O
by	O
random	O
number	O
table	O
at	O
1	O
:	O
1	O
ratio	O
with	O
24	O
cases	O
each	O
group	O
.	O

After	O
2	O
-	O
week	O
treatment	O
,	O
adverse	B-O
events	I-O
,	O
time	B-O
to	I-O
fever	I-O
resolution	I-O
,	O
ARDS	B-O
development	I-O
,	O
and	O
lung	B-O
injury	I-O
on	O
newly	B-P
diagnosed	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Dexamethasone	B-I
in	O
Hospitalized	B-P
Patients	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
In	O
this	O
controlled	O
,	O
open	O
-	O
label	O
trial	O
comparing	O
a	O
range	O
of	O
possible	O
treatments	O
in	O
patients	B-P
who	I-P
were	I-P
hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
,	O
we	O
randomly	O
assigned	O
patients	O
to	O
receive	O
oral	B-I
or	O
intravenous	B-I
dexamethasone	I-I
(	O
at	O
a	O
dose	O
of	O
6	O
mg	O
once	O
daily	O
)	O
for	O
up	O
to	O
10	O
days	O
or	O
to	O
receive	O
usual	B-C
care	I-C
alone	I-C
.	O

The	O
primary	O
outcome	O
was	O
28	B-O
-	I-O
day	I-O
mortality	I-O
.	O

Here	O
,	O
we	O
report	O
the	O
final	O
results	O
of	O
this	O
assessment	O
.	O

-DOCSTART-	O

Title	O
:	O
Hydroxychloroquine	B-I
with	O
or	O
without	O
Azithromycin	B-I
in	O
Mild	O
-	O
to	O
-	O
Moderate	O
Covid	O
-	O
19	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
multicenter	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
three	O
-	O
group	O
,	O
controlled	O
trial	O
involving	O
hospitalized	B-P
patients	I-P
with	I-P
suspected	I-P
or	I-P
confirmed	I-P
Covid	I-P
-	I-P
19	I-P
who	I-P
were	I-P
receiving	I-P
either	I-P
no	I-P
supplemental	I-P
oxygen	I-P
or	I-P
a	I-P
maximum	I-P
of	I-P
4	I-P
liters	I-P
per	I-P
minute	I-P
of	I-P
supplemental	I-P
oxygen	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
1:1:1	O
ratio	O
to	O
receive	O
standard	B-C
care	I-C
,	O
standard	B-I
care	I-I
plus	O
hydroxychloroquine	B-I
at	O
a	O
dose	O
of	O
400	O
mg	O
twice	O
daily	O
,	O
or	O
standard	B-I
care	I-I
plus	O
hydroxychloroquine	B-I
at	O
a	O
dose	O
of	O
400	O
mg	O
twice	O
daily	O
plus	O
azithromycin	B-I
at	O
a	O
dose	O
of	O
500	O
mg	O
once	O
daily	O
for	O
7	O
days	O
.	O

The	O
primary	O
outcome	O
was	O
clinical	B-O
status	I-O
at	O
15	O
days	O
as	O
assessed	O
with	O
the	O
use	O
of	O
a	B-O
seven	I-O
-	I-O
level	I-O
ordinal	I-O
scale	I-O
(	O
with	O
levels	O
ranging	O
from	O
one	O
to	O
seven	O
and	O
higher	O
scores	O
indicating	O
a	O
worse	O
condition	O
)	O
in	O
the	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
population	O
(	O
patients	O
with	O
a	O
confirmed	O
diagnosis	O
of	O
Covid	O
-	O
19	O
)	O
.	O

Safety	B-O
was	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Historically	O
controlled	O
comparison	O
of	O
glucocorticoids	B-I
with	O
or	O
without	O
tocilizumab	B-I
versus	O
supportive	B-C
care	I-C
only	I-C
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
-	I-P
associated	I-P
cytokine	I-P
storm	I-P
syndrome	I-P
:	O
results	O
of	O
the	O
CHIC	O
study	O
.	O

METHODS	O
:	O
From	O
1	O
April	O
2020	O
,	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
-	I-P
associated	I-P
CSS	I-P
,	I-P
defined	I-P
as	I-P
rapid	I-P
respiratory	I-P
deterioration	I-P
plus	I-P
at	I-P
least	I-P
two	I-P
out	I-P
of	I-P
three	I-P
biomarkers	I-P
with	I-P
important	I-P
elevations	I-P
(	I-P
C	I-P
-	I-P
reactive	I-P
protein	I-P
>	I-P
100	I-P
mg	I-P
/	I-P
L	I-P
;	I-P
ferritin	I-P
>	I-P
900	I-P
g	I-P
/	I-P
L	I-P
;	I-P
D	I-P
-	I-P
dimer	I-P
>	I-P
1500	I-P
g	I-P
/	I-P
L	I-P
)	I-P
,	O
received	O
high	B-I
-	I-I
dose	I-I
intravenous	I-I
methylprednisolone	I-I
for	O
5	O
consecutive	O
days	O
(	O
250	O
mg	O
on	O
day	O
1	O
followed	O
by	O
80	O
mg	O
on	O
days	O
2	O
-	O
5	O
)	O
.	O

If	O
the	O
respiratory	O
condition	O
had	O
not	O
improved	O
sufficiently	O
(	O
in	O
43	O
%	O
)	O
,	O
the	B-I
interleukin	I-I
-	I-I
6	I-I
receptor	I-I
blocker	I-I
tocilizumab	I-I
(	O
8	O
mg	O
/	O
kg	O
body	O
weight	O
,	O
single	O
infusion	O
)	O
was	O
added	O
on	O
or	O
after	O
day	O
2	O
.	O

Control	O
patients	O
with	O
COVID	O
-	O
19	O
-	O
associated	O
CSS	O
(	O
same	O
definition	O
)	O
were	O
retrospectively	O
sampled	O
from	O
the	O
pool	O
of	O
patients	O
(	O
n=350	O
)	O
admitted	O
between	O
7	O
March	O
and	O
31	O
March	O
,	O
and	O
matched	O
one	O
to	O
one	O
to	O
treated	O
patients	O
on	O
sex	O
and	O
age	O
.	O

The	O
primary	O
outcome	O
was	O
?2	O
stages	O
of	O
improvement	O
on	O
a	B-O
7	I-O
-	I-O
item	I-O
WHO	I-O
-	I-O
endorsed	I-O
scale	I-O
for	O
trials	O
in	O
patients	B-P
with	I-P
severe	I-P
influenza	I-P
pneumonia	I-P
,	O
or	O
discharge	B-O
from	I-O
the	I-O
hospital	I-O
.	O

Secondary	O
outcomes	O
were	O
hospital	B-O
mortality	I-O
and	O
mechanical	B-O
ventilation	I-O
.	O

-DOCSTART-	O

Title	O
:	O
SARS	O
-	O
CoV	O
-	O
2	O
clearance	O
in	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
with	O
Novaferon	B-I
treatment	O
:	O
A	O
randomized	O
,	O
open	O
-	O
label	O
,	O
parallel	O
-	O
group	O
trial	O
.	O

METHODS	O
:	O
In	O
the	O
laboratory	O
,	O
Novaferon	B-I
'	O
s	O
inhibition	O
of	O
viral	O
replication	O
in	O
cells	O
infected	O
with	O
SARS	O
-	O
CoV	O
-	O
2	O
,	O
and	O
prevention	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
entry	O
into	O
healthy	O
cells	O
was	O
determined	O
.	O

Antiviral	O
effects	O
of	O
Novaferon	B-I
in	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
with	O
treatment	O
of	O
Novaferon	B-I
,	O
Novaferon	B-I
plus	O
Lopinavir	B-I
/	O
Ritonavir	B-I
,	O
or	O
Lopinavir	B-I
/	O
Ritonavir	B-I
were	O
evaluated	O
.	O

The	O
primary	O
endpoint	O
was	O
the	B-O
SARS	I-O
-	I-O
CoV	I-O
-	I-O
2	I-O
clearance	I-O
rates	I-O
on	O
day	O
six	O
of	O
treatment	O
,	O
and	O
the	O
secondary	O
endpoint	O
was	O
the	B-O
time	I-O
to	I-O
SARS	I-O
-	I-O
CoV	I-O
-	I-O
2	I-O
clearance	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Pakistan	O
Randomized	O
and	O
Observational	O
Trial	O
to	O
Evaluate	O
Coronavirus	O
Treatment	O
(	O
PROTECT	O
)	O
of	O
Hydroxychloroquine	B-I
,	O
Oseltamivir	B-I
and	O
Azithromycin	B-I
to	O
treat	O
newly	B-P
diagnosed	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
infection	I-P
who	I-P
have	I-P
no	I-P
comorbidities	I-P
like	I-P
diabetes	I-P
mellitus	I-P
:	O
A	O
structured	O
summary	O
of	O
a	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
An	O
adaptive	O
design	O
,	O
set	O
within	O
a	O
comprehensive	O
cohort	O
study	O
,	O
to	O
permit	O
flexibility	O
in	O
this	O
fast	O
-	O
changing	O
clinical	O
and	O
public	O
health	O
scenario	O
.	O

The	O
randomized	O
study	O
will	O
be	O
a	O
multicenter	O
,	O
multiarm	O
,	O
multistage	O
,	O
randomized	O
controlled	O
trial	O
with	O
a	O
parallel	O
design	O
.	O

An	O
observation	O
only	O
cohort	O
will	O
emerge	O
from	O
those	O
not	O
consenting	O
to	O
randomization	O
.	O

Eligible	O
will	O
be	O
newly	B-P
diagnosed	I-P
patients	I-P
,	I-P
either	I-P
hospitalized	I-P
or	I-P
in	I-P
self	I-P
-	I-P
isolation	I-P
,	I-P
without	I-P
any	I-P
comorbidities	I-P
or	I-P
with	I-P
controlled	I-P
chronic	I-P
medical	I-P
conditions	I-P
like	I-P
diabetes	I-P
mellitus	I-P
and	I-P
hypertension	I-P
.	O

Participants	O
of	O
any	O
gender	O
or	O
age	O
group	O
having	O
tested	O
positive	O
for	O
COVID	O
-	O
19	O
on	O
Real	O
-	O
Time	O
qRT	O
-	O
PCR	O
(	O
Quantitative	O
Reverse	O
Transcription	O
PCR	O
)	O
will	O
be	O
invited	O
to	O
take	O
part	O
in	O
study	O
at	O
twelve	O
centers	O
across	O
eight	O
cities	O
in	O
Pakistan	O
.	O

Those	O
pregnant	O
or	O
lactating	O
,	O
severely	O
dyspneic	O
or	O
with	O
respiratory	O
distress	O
,	O
already	O
undergoing	O
treatment	O
,	O
and	O
with	O
serious	O
comorbidities	O
like	O
liver	O
or	O
kidney	O
failure	O
will	O
be	O
excluded	O
.	O

METHODS	O
:	O
Participants	O
will	O
be	O
randomized	O
,	O
maintaining	O
concealment	O
of	O
allocation	O
sequence	O
,	O
using	O
a	O
computer	O
-	O
generated	O
random	O
number	O
list	O
of	O
variable	O
block	O
size	O
into	O
multiple	O
intervention	O
groups	O
in	O
the	O
allocation	O
ratio	O
of	O
1	O
:	O
1	O
for	O
all	O
groups	O
.	O

This	O
is	O
an	O
open	O
label	O
study	O
,	O
neither	O
physician	O
nor	O
participants	O
will	O
be	O
blinded	O
.	O

This	O
is	O
an	O
adaptive	O
design	O
and	O
parameters	O
for	O
formal	O
sample	O
size	O
calculation	O
in	O
a	O
new	O
disease	O
of	O
a	O
previously	O
unknown	O
virus	O
are	O
not	O
available	O
.	O

Thus	O
,	O
the	O
final	O
sample	O
size	O
will	O
be	O
subjected	O
to	O
periodic	O
reviews	O
at	O
each	O
stage	O
of	O
adaptive	O
design	O
and	O
subsequent	O
advice	O
of	O
National	O
Data	O
Safety	O
&	O
Management	O
Board	O
(	O
NDSMB	O
)	O
notified	O
by	O
Drug	O
Regulatory	O
Authority	O
of	O
Pakistan	O
.	O

Protocol	O
Version	O
1	O
.	O
7	O
dated	O
July	O
5	O
,	O
2020	O
.	O

By	O
July	O
03	O
,	O
2020	O
,	O
the	O
trial	O
had	O
recruited	O
a	O
total	O
of	O
about	O
470	O
participants	O
across	O
12	O
centers	O
after	O
approval	O
from	O
the	O
National	O
Bioethics	O
Committee	O
and	O
Drug	O
Regulatory	O
Authority	O
of	O
Pakistan	O
.	O

Recruitment	O
started	O
on	O
April	O
20	O
,	O
2020	O
.	O

The	O
recruitment	O
is	O
expected	O
to	O
continue	O
for	O
at	O
least	O
three	O
months	O
subject	O
to	O
review	O
by	O
the	O
National	O
Data	O
Safety	O
and	O
Management	O
Board	O
(	O
NDSMB	O
)	O
notified	O
by	O
Drug	O
Regulatory	O
Authority	O
of	O
Pakistan	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Huoxiang	B-I
Zhengqi	I-I
dropping	I-I
pills	I-I
and	O
Lianhua	B-I
Qingwen	I-I
granules	I-I
in	O
treatment	O
of	O
COVID	O
-	O
19	O
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
283	I-P
patients	I-P
participated	O
in	O
this	O
clinical	O
trial	O
,	O
and	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
either	O
1	O
)	O
Huoxiang	B-I
Zhengqi	I-I
dropping	I-I
pills	I-I
and	O
Lianhua	B-I
Qingwen	I-I
granules	I-I
or	O
2	O
)	O
Linahua	B-I
granules	I-I
,	O
both	O
combined	O
with	O
western	B-I
medicine	I-I
,	O
or	O
3	O
)	O
western	B-C
medicine	I-C
alone	I-C
for	O
14	O
days	O
.	O

At	O
the	O
end	O
of	O
the	O
trial	O
,	O
the	B-O
improvement	I-O
and	O
resolution	B-O
rates	I-O
of	I-O
clinical	I-O
symptoms	I-O
and	O
the	B-O
rate	I-O
of	I-O
patients	I-O
who	I-O
progressed	I-O
to	I-O
severe	I-O
disease	I-O
status	I-O
were	O
evaluated	O
.	O

-DOCSTART-	O

Title	O
:	O
Auxora	B-I
versus	O
standard	B-C
of	I-C
care	I-C
for	O
the	O
treatment	O
of	O
severe	O
or	O
critical	O
COVID	O
-	O
19	O
pneumonia	O
:	O
results	O
from	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
controlled	O
,	O
open	O
-	O
label	O
study	O
of	O
Auxora	B-I
was	O
conducted	O
in	O
adults	B-P
with	I-P
severe	I-P
or	I-P
critical	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
.	O

Patients	O
were	O
randomized	O
2	O
:	O
1	O
to	O
receive	O
three	B-I
doses	I-I
of	I-I
once	I-I
-	I-I
daily	I-I
Auxora	I-I
versus	O
standard	B-C
of	I-C
care	I-C
(	I-C
SOC	I-C
)	I-C
alone	I-C
.	O

The	O
primary	O
objective	O
was	O
to	O
assess	O
the	B-O
safety	I-O
and	O
tolerability	B-O
of	O
Auxora	B-I
.	O

Following	O
FDA	O
guidance	O
,	O
study	O
enrollment	O
was	O
halted	O
early	O
to	O
allow	O
for	O
transition	O
to	O
a	O
randomized	O
,	O
blinded	O
,	O
placebo	O
-	O
controlled	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Treatment	O
of	O
severe	O
COVID	O
-	O
19	O
with	O
human	B-I
umbilical	I-I
cord	I-I
mesenchymal	I-I
stem	I-I
cells	I-I
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
were	O
randomly	O
divided	O
into	O
2	O
groups	O
:	O
the	B-C
standard	I-C
treatment	I-C
group	O
and	O
the	B-I
standard	I-I
treatment	I-I
plus	O
hUC	B-I
-	I-I
MSC	I-I
infusion	I-I
group	O
.	O

The	B-O
incidence	I-O
of	I-O
progression	I-O
from	I-O
severe	I-O
to	I-O
critical	I-O
illness	I-O
,	O
28	B-O
-	I-O
day	I-O
mortality	I-O
,	O
clinical	B-O
symptom	I-O
improvement	I-O
,	O
time	B-O
to	I-O
clinical	I-O
symptom	I-O
improvement	I-O
,	O
hematologic	B-O
indicators	I-O
including	I-O
C	I-O
-	I-O
reactive	I-O
protein	I-O
,	O
lymphocyte	B-O
number	I-O
,	O
and	O
interleukin	B-O
6	I-O
,	O
and	O
imaging	B-O
changes	I-O
were	O
observed	O
and	O
compared	O
between	O
the	O
two	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Sofosbuvir	B-I
and	O
daclatasvir	B-I
compared	O
with	O
standard	B-C
of	I-C
care	I-C
in	O
the	O
treatment	O
of	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
moderate	I-P
or	I-P
severe	I-P
coronavirus	I-P
infection	I-P
(	I-P
COVID	I-P
-	I-P
19	I-P
)	I-P
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
an	O
open	O
-	O
label	O
,	O
multicentre	O
,	O
randomized	O
controlled	O
clinical	O
trial	O
in	O
adults	B-P
with	I-P
moderate	I-P
or	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
admitted	I-P
to	I-P
four	I-P
university	I-P
hospitals	I-P
in	I-P
Iran	I-P
.	O

Patients	O
were	O
randomized	O
into	O
a	O
treatment	O
arm	O
receiving	O
sofosbuvir	B-I
and	O
daclatasvir	B-I
plus	O
standard	B-I
care	I-I
,	O
or	O
a	O
control	O
arm	O
receiving	O
standard	B-C
care	I-C
alone	I-C
.	O

The	O
primary	O
endpoint	O
was	O
clinical	B-O
recovery	I-O
within	O
14	O
days	O
of	O
treatment	O
.	O

The	O
study	O
is	O
registered	O
with	O
IRCT	O
.	O
ir	O
under	O
registration	O
number	O
IRCT20200128046294N2	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
impact	O
of	O
sofosbuvir	B-I
/	O
daclatasvir	B-I
or	O
ribavirin	B-I
in	O
patients	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
a	I-P
positive	I-P
nasopharyngeal	I-P
swab	I-P
for	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
on	I-P
RT	I-P
-	I-P
PCR	I-P
or	I-P
bilateral	I-P
multi	I-P
-	I-P
lobar	I-P
ground	I-P
-	I-P
glass	I-P
opacity	I-P
on	I-P
their	I-P
chest	I-P
CT	I-P
and	I-P
signs	I-P
of	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
were	O
included	O
.	O

Subjects	O
were	O
divided	O
into	O
two	O
arms	O
with	O
one	O
arm	O
receiving	O
ribavirin	B-I
and	O
the	O
other	O
receiving	O
sofosbuvir	B-I
/	O
daclatasvir	B-I
.	O

All	O
participants	O
also	O
received	O
the	B-I
recommended	I-I
national	I-I
standard	I-I
treatment	I-I
which	O
,	O
at	O
that	O
time	O
,	O
was	O
lopinavir	B-I
/	O
ritonavir	B-I
and	O
single	B-I
-	I-I
dose	I-I
hydroxychloroquine	I-I
.	O

The	O
primary	O
endpoint	O
was	O
time	B-O
from	I-O
starting	I-O
the	I-O
medication	I-O
until	I-O
discharge	I-O
from	I-O
hospital	I-O
with	O
secondary	O
endpoints	O
of	O
duration	B-O
of	I-O
ICU	I-O
stay	I-O
and	O
mortality	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Anti	B-I
-	I-I
Thrombotic	I-I
Therapy	I-I
to	O
Ameliorate	O
Complications	O
of	O
COVID	O
-	O
19	O
(	O
ATTACC	O
)	O
:	O
Study	O
design	O
and	O
methodology	O
for	O
an	O
international	O
,	O
adaptive	O
Bayesian	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
An	O
international	O
,	O
open	O
-	O
label	O
,	O
adaptive	O
randomized	O
controlled	O
trial	O
.	O

Using	O
a	O
Bayesian	O
framework	O
,	O
the	O
trial	O
will	O
declare	O
results	O
as	O
soon	O
as	O
pre	O
-	O
specified	O
posterior	O
probabilities	O
for	O
superiority	O
,	O
futility	O
,	O
or	O
harm	O
are	O
reached	O
.	O

The	O
trial	O
uses	O
response	O
-	O
adaptive	O
randomization	O
to	O
maximize	O
the	O
probability	O
that	O
patients	O
will	O
receive	O
the	O
more	O
beneficial	O
treatment	O
approach	O
,	O
as	O
treatment	O
effect	O
information	O
accumulates	O
within	O
the	O
trial	O
.	O

By	O
leveraging	O
a	O
common	O
data	O
safety	O
monitoring	O
board	O
and	O
pooling	O
data	O
with	O
a	O
second	O
similar	O
international	O
Bayesian	O
adaptive	O
trial	O
(	O
REMAP	O
-	O
COVID	O
anticoagulation	O
domain	O
)	O
,	O
treatment	O
efficacy	O
and	O
safety	O
will	O
be	O
evaluated	O
as	O
efficiently	O
as	O
possible	O
.	O

The	O
primary	O
outcome	O
is	O
an	O
ordinal	O
endpoint	O
with	O
three	O
possible	O
outcomes	O
based	O
on	O
the	B-O
worst	I-O
status	I-O
of	I-O
each	I-O
patient	I-O
through	O
day	O
30	O
:	O
no	B-O
requirement	I-O
for	I-O
invasive	I-O
mechanical	I-O
ventilation	I-O
,	O
invasive	B-O
mechanical	I-O
ventilation	I-O
or	O
death	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Remdesivir	B-I
vs	O
Standard	B-C
Care	I-C
on	O
Clinical	O
Status	O
at	O
11	O
Days	O
in	O
Patients	B-P
With	I-P
Moderate	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Randomized	O
,	O
open	O
-	O
label	O
trial	O
of	O
hospitalized	B-P
patients	I-P
with	I-P
confirmed	I-P
severe	I-P
acute	I-P
respiratory	I-P
syndrome	I-P
coronavirus	I-P
2	I-P
(	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
)	I-P
infection	I-P
and	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
(	I-P
pulmonary	I-P
infiltrates	I-P
and	I-P
room	I-P
-	I-P
air	I-P
oxygen	I-P
saturation	I-P
>	I-P
94	I-P
%	I-P
)	I-P
enrolled	I-P
from	I-P
March	I-P
15	I-P
through	I-P
April	I-P
18	I-P
,	I-P
2020	I-P
,	I-P
at	I-P
105	I-P
hospitals	I-P
in	I-P
the	I-P
United	I-P
States	I-P
,	I-P
Europe	I-P
,	I-P
and	I-P
Asia	I-P
.	O

The	O
date	O
of	O
final	O
follow	O
-	O
up	O
was	O
May	O
20	O
,	O
2020	O
.	O

Patients	O
were	O
randomized	O
in	O
a	O
1:1:1	O
ratio	O
to	O
receive	O
a	B-I
10	I-I
-	I-I
day	I-I
course	I-I
of	I-I
remdesivir	I-I
(	O
n	O
=	O
197	O
)	O
,	O
a	B-I
5	I-I
-	I-I
day	I-I
course	I-I
of	I-I
remdesivir	I-I
(	O
n	O
=	O
199	O
)	O
,	O
or	O
standard	B-C
care	I-C
(	O
n	O
=	O
200	O
)	O
.	O

Remdesivir	B-I
was	O
dosed	O
intravenously	O
at	O
200	O
mg	O
on	O
day	O
1	O
followed	O
by	O
100	O
mg	O
/	O
d	O
.	O

The	O
primary	O
end	O
point	O
was	O
clinical	B-O
status	I-O
on	O
day	O
11	O
on	O
a	B-O
7	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
ranging	O
from	O
death	O
(	O
category	O
1	O
)	O
to	O
discharged	O
(	O
category	O
7	O
)	O
.	O

Differences	O
between	O
remdesivir	B-I
treatment	I-I
groups	O
and	O
standard	B-C
care	I-C
were	O
calculated	O
using	O
proportional	O
odds	O
models	O
and	O
expressed	O
as	O
odds	O
ratios	O
.	O

An	O
odds	O
ratio	O
greater	O
than	O
1	O
indicates	O
difference	O
in	O
clinical	O
status	O
distribution	O
toward	O
category	O
7	O
for	O
the	B-I
remdesivir	I-I
group	O
vs	O
the	B-C
standard	I-C
care	I-C
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Hydrocortisone	B-I
on	O
21	O
-	O
Day	O
Mortality	O
or	O
Respiratory	O
Support	O
Among	O
Critically	B-P
Ill	I-P
Patients	I-P
With	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Multicenter	O
randomized	O
double	O
-	O
blind	O
sequential	O
trial	O
conducted	O
in	O
France	O
,	O
with	O
interim	O
analyses	O
planned	O
every	O
50	O
patients	O
.	O

Patients	B-P
admitted	I-P
to	I-P
the	I-P
intensive	I-P
care	I-P
unit	I-P
(	I-P
ICU	I-P
)	I-P
for	I-P
COVID	I-P
-	I-P
19	I-P
-	I-P
related	I-P
acute	I-P
respiratory	I-P
failure	I-P
were	O
enrolled	O
from	O
March	O
7	O
to	O
June	O
1	O
,	O
2020	O
,	O
with	O
last	O
follow	O
-	O
up	O
on	O
June	O
29	O
,	O
2020	O
.	O

The	O
study	O
intended	O
to	O
enroll	O
290	O
patients	O
but	O
was	O
stopped	O
early	O
following	O
the	O
recommendation	O
of	O
the	O
data	O
and	O
safety	O
monitoring	O
board	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
low	B-I
-	I-I
dose	I-I
hydrocortisone	I-I
(	O
n	O
=	O
76	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
73	O
)	O
.	O

The	O
primary	O
outcome	O
,	O
treatment	B-O
failure	I-O
on	O
day	O
21	O
,	O
was	O
defined	O
as	O
death	B-O
or	O
persistent	B-O
dependency	I-O
on	I-O
mechanical	I-O
ventilation	I-O
or	O
high	B-O
-	I-O
flow	I-O
oxygen	I-O
therapy	I-O
.	O

Prespecified	O
secondary	O
outcomes	O
included	O
the	B-O
need	I-O
for	I-O
tracheal	I-O
intubation	I-O
(	O
among	O
patients	O
not	O
intubated	O
at	O
baseline	O
)	O
;	O
cumulative	B-O
incidences	I-O
(	I-O
until	I-O
day	I-O
21	I-O
)	I-O
of	I-O
prone	I-O
position	I-O
sessions	I-O
,	O
extracorporeal	B-O
membrane	I-O
oxygenation	I-O
,	O
and	O
inhaled	B-O
nitric	I-O
oxide	I-O
;	O
Pao2	B-O
:	I-O
Fio2	I-O
ratio	I-O
measured	O
daily	O
from	O
day	O
1	O
to	O
day	O
7	O
,	O
then	O
on	O
days	O
14	O
and	O
21	O
;	O
and	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
with	I-O
secondary	I-O
infections	I-O
during	O
their	O
ICU	O
stay	O
.	O

-DOCSTART-	O

Title	O
:	O
Early	O
use	O
of	O
nitazoxanide	B-I
in	O
mild	O
COVID	O
-	O
19	O
disease	O
:	O
randomised	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
In	O
a	O
multicentre	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
,	O
adult	B-P
patients	I-P
presenting	I-P
up	I-P
to	I-P
3	I-P
days	I-P
after	I-P
onset	I-P
of	I-P
coronavirus	I-P
disease	I-P
2019	I-P
(	I-P
COVID	I-P
-	I-P
19	I-P
)	I-P
symptoms	I-P
(	I-P
dry	I-P
cough	I-P
,	I-P
fever	I-P
and	I-P
/	I-P
or	I-P
fatigue	I-P
)	I-P
were	O
enrolled	O
.	O

After	O
confirmation	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
using	O
reverse	O
transcriptase	O
PCR	O
on	O
a	O
nasopharyngeal	O
swab	O
,	O
patients	O
were	O
randomised	O
1	O
:	O
1	O
to	O
receive	O
either	O
nitazoxanide	B-I
(	O
500	O
mg	O
)	O
or	O
placebo	B-C
,	O
three	O
times	O
daily	O
,	O
for	O
5	O
days	O
.	O

The	O
primary	O
outcome	O
was	O
complete	B-O
resolution	I-O
of	I-O
symptoms	I-O
.	O

Secondary	O
outcomes	O
were	O
viral	B-O
load	I-O
,	O
laboratory	B-O
tests	I-O
,	O
serum	B-O
biomarkers	I-O
of	I-O
inflammation	I-O
and	O
hospitalisation	B-O
rate	I-O
.	O

Adverse	B-O
events	I-O
were	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
COvid	O
-	O
19	O
and	O
high	B-I
-	I-I
dose	I-I
VITamin	I-I
D	I-I
supplementation	I-I
TRIAL	O
in	O
high	B-P
-	I-P
risk	I-P
older	I-P
patients	I-P
(	O
COVIT	O
-	O
TRIAL	O
)	O
:	O
study	O
protocol	O
for	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
The	O
COVIT	O
-	O
TRIAL	O
study	O
is	O
an	O
open	O
-	O
label	O
,	O
multicenter	O
,	O
randomized	O
controlled	O
superiority	O
trial	O
.	O

Patients	B-P
aged	I-P
?	I-P
65	I-P
years	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
(	I-P
diagnosed	I-P
within	I-P
the	I-P
preceding	I-P
3	I-P
days	I-P
with	I-P
RT	I-P
-	I-P
PCR	I-P
and	I-P
/	I-P
or	I-P
chest	I-P
CT	I-P
scan	I-P
)	I-P
and	I-P
at	I-P
least	I-P
one	I-P
worsening	I-P
risk	I-P
factor	I-P
at	I-P
the	I-P
time	I-P
of	I-P
inclusion	I-P
(	I-P
i	I-P
.	I-P
e	I-P
.	I-P
,	I-P
age	I-P
?	I-P
75	I-P
years	I-P
,	I-P
or	I-P
SpO2	I-P
?	I-P
94	I-P
%	I-P
in	I-P
room	I-P
air	I-P
,	I-P
or	I-P
PaO2	I-P
/	I-P
FiO2	I-P
?	I-P
300	I-P
mmHg	I-P
)	I-P
,	I-P
having	I-P
no	I-P
contraindications	I-P
to	I-P
vitamin	I-P
D	I-P
supplementation	I-P
,	I-P
and	I-P
having	I-P
received	I-P
no	I-P
vitamin	I-P
D	I-P
supplementation	I-P
>	I-P
800	I-P
IU	I-P
/	I-P
day	I-P
during	I-P
the	I-P
preceding	I-P
month	I-P
are	O
recruited	O
.	O

Participants	O
are	O
randomized	O
either	O
to	O
high	B-I
-	I-I
dose	I-I
cholecalciferol	I-I
(	O
two	O
200	O
,	O
000	O
IU	O
drinking	O
vials	O
at	O
once	O
on	O
the	O
day	O
of	O
inclusion	O
)	O
or	O
to	O
standard	B-C
-	I-C
dose	I-C
cholecalciferol	I-C
(	O
one	O
50	O
,	O
000	O
IU	O
drinking	O
vial	O
on	O
the	O
day	O
of	O
inclusion	O
)	O
.	O

Two	B-P
hundred	I-P
sixty	I-P
participants	I-P
are	O
recruited	O
and	O
followed	O
up	O
for	O
28	O
days	O
.	O

The	O
primary	O
outcome	O
measure	O
is	O
all	B-O
-	I-O
cause	I-O
mortality	I-O
within	O
14	O
days	O
of	O
inclusion	O
.	O

Secondary	O
outcomes	O
are	O
the	O
score	O
changes	O
on	O
the	B-O
World	I-O
Health	I-O
Organization	I-O
Ordinal	I-O
Scale	I-O
for	I-O
Clinical	I-O
Improvement	I-O
(	I-O
OSCI	I-O
)	I-O
scale	I-O
for	I-O
COVID	I-O
-	I-O
19	I-O
,	O
and	O
the	O
between	O
-	O
group	O
comparison	O
of	O
safety	B-O
.	O

These	O
outcomes	O
are	O
assessed	O
at	O
baseline	O
,	O
day	O
14	O
,	O
and	O
day	O
28	O
,	O
together	O
with	O
the	B-O
serum	I-O
concentrations	I-O
of	I-O
25	I-O
(	I-O
OH	I-O
)	I-O
D	I-O
,	O
creatinine	B-O
,	O
calcium	B-O
,	O
and	O
albumin	B-O
at	O
baseline	O
and	O
day	O
7	O
.	O

-DOCSTART-	O

Title	O
:	O
Tocilizumab	B-I
combined	O
with	O
favipiravir	B-I
in	O
the	O
treatment	O
of	O
COVID	O
-	O
19	O
:	O
A	O
multicenter	O
trial	O
in	O
a	O
small	O
sample	O
size	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
trial	O
in	O
adults	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
3:1:1	O
)	O
to	O
a	B-I
14	I-I
-	I-I
day	I-I
combination	I-I
of	I-I
favipiravir	I-I
combined	O
with	O
tocilizumab	B-I
(	O
combination	O
group	O
)	O
,	O
favipiravir	B-I
,	O
and	O
tocilizumab	B-I
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
cumulative	I-O
lung	I-O
lesion	I-O
remission	I-O
rate	I-O
(	O
lung	B-O
CT	I-O
examination	I-O
indicated	I-O
absorption	I-O
of	I-O
lung	I-O
inflammation	I-O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Nasopharyngeal	O
swab	O
-	O
induced	O
pain	O
for	O
SARS	O
-	O
CoV	O
-	O
2	O
screening	O
:	O
A	O
randomised	O
controlled	O
trial	O
of	O
conventional	O
and	O
self	O
-	O
swabbing	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
conducted	O
in	O
Clermont	O
-	O
Ferrand	O
medical	O
school	O
(	O
France	O
)	O
.	O

Overall	O
,	O
190	B-P
students	I-P
were	O
randomised	O
into	O
two	O
groups	O
and	O
experienced	O
either	O
self	B-I
-	I-I
or	O
conventional	B-C
-	I-C
swabbing	I-C
.	O

Each	O
subject	O
had	O
to	O
rate	O
pain	B-O
,	O
discomfort	B-O
and	O
acceptability	B-O
of	I-O
such	I-O
swabbing	I-O
on	O
a	B-O
0	I-O
-	I-O
10	I-O
numeric	I-O
rating	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Effect	O
of	O
moxibustion	B-I
on	O
clinical	O
symptoms	O
,	O
peripheral	O
inflammatory	O
indexes	O
and	O
T	O
lymphocyte	O
subsets	O
in	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
]	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
95	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
were	O
randomly	O
divided	O
into	O
a	B-I
moxibustion	I-I
group	O
(	O
45	O
cases	O
)	O
and	O
a	O
basic	O
treatment	O
group	O
(	O
50	O
cases	O
)	O
.	O

The	O
routine	O
treatment	O
of	O
western	O
medicine	O
was	O
applied	O
in	O
the	O
patients	O
of	O
both	O
groups	O
.	O

In	O
the	B-I
moxibustion	I-I
group	O
,	O
on	O
the	O
base	O
of	O
the	O
treatment	O
of	O
western	O
medicine	O
,	O
moxibustion	B-I
was	O
applied	O
to	O
Dazhui	O
(	O
GV	O
14	O
)	O
,	O
Feishu	O
(	O
BL	O
13	O
)	O
,	O
Qihai	O
(	O
CV	O
6	O
)	O
and	O
Zusanli	O
(	O
ST	O
36	O
)	O
,	O
once	O
daily	O
and	O
consecutively	O
for	O
14	O
days	O
.	O

At	O
the	O
end	O
of	O
treatment	O
courses	O
,	O
clinical	B-O
symptom	I-O
scores	I-O
for	I-O
cough	I-O
,	O
asthmatic	B-O
breathing	I-O
,	O
chest	B-O
oppression	I-O
and	O
short	B-O
breath	I-O
,	O
as	O
well	O
as	O
their	B-O
remission	I-O
rates	I-O
were	O
compared	O
between	O
the	O
two	O
groups	O
before	O
and	O
after	O
treatment	O
.	O

Before	O
and	O
after	O
treatment	O
,	O
the	B-O
white	I-O
blood	I-O
cell	I-O
(	I-O
WBC	I-O
)	I-O
count	I-O
,	O
the	B-O
levels	I-O
of	I-O
c	I-O
-	I-O
reactive	I-O
protein	I-O
(	I-O
CRP	I-O
)	I-O
and	O
interleukin	B-O
-	I-O
6	I-O
(	I-O
IL	I-O
-	I-O
6	I-O
)	I-O
and	O
the	B-O
absolute	I-O
number	I-O
of	I-O
T	I-O
lymphocyte	I-O
subsets	I-O
,	O
i	O
.	O
e	O
.	O
,	O
and	O
of	O
the	B-O
peripheral	I-O
blood	I-O
were	O
compared	O
in	O
the	O
patients	O
between	O
the	O
two	O
groups	O
.	O

The	O
principal	O
component	O
analysis	O
was	O
adopted	O
to	O
analyze	O
the	O
common	O
data	O
extracted	O
from	O
the	O
above	O
10	O
clinical	O
indexes	O
variables	O
and	O
comprehensively	O
evaluate	O
the	O
differences	O
in	O
the	O
therapeutic	O
effect	O
of	O
two	O
regimens	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Discontinuing	B-I
vs	O
Continuing	B-I
Angiotensin	I-I
-	I-I
Converting	I-I
Enzyme	I-I
Inhibitors	I-I
and	O
Angiotensin	B-I
II	I-I
Receptor	I-I
Blockers	I-I
on	O
Days	O
Alive	O
and	O
Out	O
of	O
the	O
Hospital	O
in	O
Patients	B-P
Admitted	I-P
With	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
clinical	O
trial	O
of	O
659	B-P
patients	I-P
hospitalized	I-P
in	I-P
Brazil	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
who	I-P
were	I-P
taking	I-P
ACEIs	I-P
or	I-P
ARBs	I-P
prior	I-P
to	I-P
hospitalization	I-P
(	I-P
enrolled	I-P
:	I-P
April	I-P
9	I-P
-	I-P
June	I-P
26	I-P
,	I-P
2020	I-P
;	I-P
final	I-P
follow	I-P
-	I-P
up	I-P
:	I-P
July	I-P
26	I-P
,	I-P
2020	I-P
)	I-P
.	O

Discontinuation	B-I
(	O
n	O
=	O
334	O
)	O
or	O
continuation	B-I
(	I-I
n	I-I
=	I-I
325	I-I
)	I-I
of	I-I
ACEIs	I-I
or	O
ARBs	B-I
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
number	I-O
of	I-O
days	I-O
alive	I-O
and	O
out	B-O
of	I-O
the	I-O
hospital	I-O
through	O
30	O
days	O
.	O

Secondary	O
outcomes	O
included	O
death	B-O
,	O
cardiovascular	B-O
death	I-O
,	O
and	O
COVID	B-O
-	I-O
19	I-O
progression	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Bamlanivimab	B-I
as	O
Monotherapy	O
or	O
in	O
Combination	O
With	O
Etesevimab	B-I
on	O
Viral	O
Load	O
in	O
Patients	B-P
With	I-P
Mild	I-P
to	I-P
Moderate	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
The	O
BLAZE	O
-	O
1	O
study	O
is	O
a	O
randomized	O
phase	O
2	O
/	O
3	O
trial	O
at	O
49	O
US	O
centers	O
including	O
ambulatory	B-P
patients	I-P
(	I-P
N	I-P
=	I-P
613	I-P
)	I-P
who	I-P
tested	I-P
positive	I-P
for	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
and	I-P
had	I-P
1	I-P
or	I-P
more	I-P
mild	I-P
to	I-P
moderate	I-P
symptoms	I-P
.	O

Patients	O
who	O
received	O
bamlanivimab	B-I
monotherapy	O
or	O
placebo	B-C
were	O
enrolled	O
first	O
(	O
June	O
17	O
-	O
August	O
21	O
,	O
2020	O
)	O
followed	O
by	O
patients	O
who	O
received	O
bamlanivimab	B-I
and	O
etesevimab	B-I
or	O
placebo	B-C
(	O
August	O
22	O
-	O
September	O
3	O
)	O
.	O

These	O
are	O
the	O
final	O
analyses	O
and	O
represent	O
findings	O
through	O
October	O
6	O
,	O
2020	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
a	B-I
single	I-I
infusion	I-I
of	I-I
bamlanivimab	I-I
(	O
700	O
mg	O
[	O
n	O
=	O
101	O
]	O
,	O
2800	O
mg	O
[	O
n	O
=	O
107	O
]	O
,	O
or	O
7000	O
mg	O
[	O
n	O
=	O
101	O
]	O
)	O
,	O
the	B-I
combination	I-I
treatment	I-I
(	O
2800	B-I
mg	I-I
of	I-I
bamlanivimab	I-I
and	O
2800	B-I
mg	I-I
of	I-I
etesevimab	I-I
[	O
n	O
=	O
112	O
]	O
)	O
,	O
or	O
placebo	B-C
(	O
n	O
=	O
156	O
)	O
.	O

The	O
primary	O
end	O
point	O
was	O
change	O
in	O
SARS	B-O
-	I-O
CoV	I-O
-	I-O
2	I-O
log	I-O
viral	I-O
load	I-O
at	O
day	O
11	O
(	O
4	O
days	O
)	O
.	O

Nine	O
prespecified	O
secondary	O
outcome	O
measures	O
were	O
evaluated	O
with	O
comparisons	O
between	O
each	O
treatment	O
group	O
and	O
placebo	B-C
,	O
and	O
included	O
3	B-O
other	I-O
measures	I-O
of	I-O
viral	I-O
load	I-O
,	O
5	B-O
on	I-O
symptoms	I-O
,	O
and	O
1	B-O
measure	I-O
of	I-O
clinical	I-O
outcome	I-O
(	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
with	I-O
a	I-O
COVID	I-O
-	I-O
19	I-O
-	I-O
related	I-O
hospitalization	I-O
,	O
an	B-O
emergency	I-O
department	I-O
[	I-O
ED	I-O
]	I-O
visit	I-O
,	O
or	O
death	B-O
at	O
day	O
29	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Early	O
Use	O
of	O
Corticosteroid	B-I
May	O
Prolong	O
SARS	O
-	O
CoV	O
-	O
2	O
Shedding	O
in	O
Non	B-P
-	I-P
Intensive	I-P
Care	I-P
Unit	I-P
Patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
Pneumonia	I-P
:	O
A	O
Multicenter	O
,	O
Single	O
-	O
Blind	O
,	O
Randomized	O
Control	O
Trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
prospective	O
,	O
multicenter	O
,	O
single	O
-	O
blind	O
,	O
randomized	O
control	O
trial	O
.	O

Adult	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
who	I-P
were	I-P
admitted	I-P
to	I-P
the	I-P
general	I-P
ward	I-P
were	O
randomly	O
assigned	O
to	O
either	O
receive	O
methylprednisolone	B-I
or	O
not	B-C
for	O
7	O
days	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	B-O
incidence	I-O
of	I-O
clinical	I-O
deterioration	I-O
14	O
days	O
after	O
randomization	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
anakinra	B-I
versus	O
usual	B-C
care	I-C
in	O
adults	B-P
in	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
pneumonia	I-P
(	O
CORIMUNO	O
-	O
ANA	O
-	O
1	O
)	O
:	O
a	O
randomised	O
controlled	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
multicentre	O
,	O
open	O
-	O
label	O
,	O
Bayesian	O
randomised	O
clinical	O
trial	O
(	O
CORIMUNO	O
-	O
ANA	O
-	O
1	O
)	O
,	O
nested	O
within	O
the	O
CORIMUNO	O
-	O
19	O
cohort	O
,	O
we	O
recruited	O
patients	B-P
from	I-P
16	I-P
University	I-P
hospitals	I-P
in	I-P
France	I-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
,	I-P
severe	I-P
acute	I-P
respiratory	I-P
syndrome	I-P
coronavirus	I-P
2	I-P
infection	I-P
confirmed	I-P
by	I-P
real	I-P
-	I-P
time	I-P
RT	I-P
-	I-P
PCR	I-P
,	I-P
requiring	I-P
at	I-P
least	I-P
3	I-P
L	I-P
/	I-P
min	I-P
of	I-P
oxygen	I-P
by	I-P
mask	I-P
or	I-P
nasal	I-P
cannula	I-P
but	I-P
without	I-P
ventilation	I-P
assistance	I-P
,	I-P
a	I-P
score	I-P
of	I-P
5	I-P
on	I-P
the	I-P
WHO	I-P
Clinical	I-P
Progression	I-P
Scale	I-P
(	I-P
WHO	I-P
-	I-P
CPS	I-P
)	I-P
,	I-P
and	I-P
a	I-P
C	I-P
-	I-P
reactive	I-P

protein	I-P
serum	I-P
concentration	I-P
of	I-P
more	I-P
than	I-P
25	I-P
mg	I-P
/	I-P
L	I-P
not	I-P
requiring	I-P
admission	I-P
to	I-P
the	I-P
intensive	I-P
care	I-P
unit	I-P
at	I-P
admission	I-P
to	I-P
hospital	I-P
.	O

Eligible	O
patients	O
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
using	O
a	O
web	O
-	O
based	O
secure	O
centralised	O
system	O
,	O
stratified	O
by	O
centre	O
and	O
blocked	O
with	O
varying	O
block	O
sizes	O
(	O
randomly	O
of	O
size	O
two	O
or	O
four	O
)	O
,	O
to	O
either	O
usual	B-I
care	I-I
plus	O
anakinra	B-I
(	O
200	O
mg	O
twice	O
a	O
day	O
on	O
days	O
1	O
-	O
3	O
,	O
100	O
mg	O
twice	O
on	O
day	O
4	O
,	O
100	O
mg	O
once	O
on	O
day	O
5	O
)	O
or	O
usual	B-C
care	I-C
alone	I-C
.	O

Usual	B-C
care	I-C
was	O
provided	O
at	O
the	O
discretion	O
of	O
the	O
site	O
clinicians	O
.	O

The	O
two	O
coprimary	O
outcomes	O
were	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
who	I-O
had	I-O
died	I-O
or	O
needed	B-O
non	I-O
-	I-O
invasive	I-O
or	O
mechanical	B-O
ventilation	I-O
by	O
day	O
4	O
(	O
ie	O
,	O
a	O
score	O
of	O
>	O
5	O
on	O
the	O
WHO	O
-	O
CPS	O
)	O
and	O
survival	B-O
without	I-O
need	I-O
for	I-O
mechanical	I-O
or	O
non	B-O
-	I-O
invasive	I-O
ventilation	I-O
(	O
including	O
high	O
-	O
flow	O
oxygen	O
)	O
at	O
day	O
14	O
.	O

All	O
analyses	O
were	O
done	O
on	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
.	O

The	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04341584	O
,	O
and	O
is	O
now	O
closed	O
to	O
accrual	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
sofosbuvir	B-I
/	O
ledipasvir	B-I
in	O
treatment	O
of	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
;	O
A	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Among	O
an	O
open	O
-	O
label	O
randomized	O
clinical	O
trial	O
,	O
82	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderated	I-P
COVID	I-P
-	I-P
19	I-P
were	O
assigned	O
to	O
receive	O
either	O
SOF	B-I
/	O
LDP	B-I
400	O
/	O
100	O
mg	O
daily	O
plus	O
the	B-I
standard	I-I
of	I-I
care	I-I
(	O
SOF	B-I
/	O
LDP	B-I
group	O
,	O
n=42	O
)	O
or	O
the	B-C
standard	I-C
of	I-C
care	I-C
alone	I-C
(	O
control	O
group	O
,	O
n=40	O
)	O
for	O
10	O
days	O
.	O

Time	B-O
to	I-O
clinical	I-O
response	I-O
,	O
rate	B-O
of	I-O
clinical	I-O
response	I-O
,	O
duration	B-O
of	I-O
hospital	I-O
and	O
ICU	B-O
stay	I-O
and	O
14	B-O
-	I-O
day	I-O
mortality	I-O
were	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Methylprednisolone	B-I
in	O
adults	B-P
hospitalized	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
:	O
An	O
open	O
-	O
label	O
randomized	O
trial	O
(	O
GLUCOCOVID	O
)	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
multicentric	O
open	O
-	O
label	O
trial	O
of	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
who	I-P
were	I-P
aged	I-P
?	I-P
18	I-P
years	I-P
,	I-P
receiving	I-P
oxygen	I-P
without	I-P
mechanical	I-P
ventilation	I-P
,	I-P
and	I-P
with	I-P
evidence	I-P
of	I-P
systemic	I-P
inflammatory	I-P
response	I-P
who	O
were	O
assigned	O
to	O
standard	B-C
of	I-C
care	I-C
(	I-C
SOC	I-C
)	I-C
or	O
SOC	B-I
plus	O
intravenous	B-I
MP	I-I
(	O
40	O
mg	O
bid	O
for	O
3	O
days	O
followed	O
by	O
20	O
mg	O
bid	O
for	O
3	O
days	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
a	B-O
composite	I-O
of	I-O
death	I-O
,	O
admission	B-O
to	I-O
the	I-O
intensive	I-O
care	I-O
unit	I-O
,	O
or	O
requirement	B-O
for	I-O
noninvasive	I-O
ventilation	I-O
.	O

Both	O
intention	O
-	O
to	O
-	O
treat	O
(	O
ITT	O
)	O
and	O
per	O
protocol	O
(	O
PP	O
)	O
analyses	O
were	O
performed	O
.	O

-DOCSTART-	O

Title	O
:	O
Azithromycin	B-I
in	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
(	O
RECOVERY	O
)	O
:	O
a	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
platform	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
adaptive	O
platform	O
trial	O
(	O
Randomised	O
Evaluation	O
of	O
COVID	O
-	O
19	O
Therapy	O
[	O
RECOVERY	O
]	O
)	O
,	O
several	O
possible	O
treatments	O
were	O
compared	O
with	O
usual	O
care	O
in	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
in	I-P
the	I-P
UK	I-P
.	O

The	O
trial	O
is	O
underway	O
at	O
176	O
hospitals	O
in	O
the	O
UK	O
.	O

Eligible	O
and	O
consenting	O
patients	O
were	O
randomly	O
allocated	O
to	O
either	O
usual	B-C
standard	I-C
of	I-C
care	I-C
alone	I-C
or	O
usual	B-I
standard	I-I
of	I-I
care	I-I
plus	O
azithromycin	B-I
500	O
mg	O
once	O
per	O
day	O
by	O
mouth	O
or	O
intravenously	O
for	O
10	O
days	O
or	O
until	O
discharge	O
(	O
or	O
allocation	O
to	O
one	O
of	O
the	O
other	O
RECOVERY	O
treatment	O
groups	O
)	O
.	O

Patients	O
were	O
assigned	O
via	O
web	O
-	O
based	O
simple	O
(	O
unstratified	O
)	O
randomisation	O
with	O
allocation	O
concealment	O
and	O
were	O
twice	O
as	O
likely	O
to	O
be	O
randomly	O
assigned	O
to	O
usual	O
care	O
than	O
to	O
any	O
of	O
the	O
active	O
treatment	O
groups	O
.	O

Participants	O
and	O
local	O
study	O
staff	O
were	O
not	O
masked	O
to	O
the	O
allocated	O
treatment	O
,	O
but	O
all	O
others	O
involved	O
in	O
the	O
trial	O
were	O
masked	O
to	O
the	O
outcome	O
data	O
during	O
the	O
trial	O
.	O

The	O
primary	O
outcome	O
was	O
28	B-O
-	I-O
day	I-O
all	I-O
-	I-O
cause	I-O
mortality	I-O
,	O
assessed	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

The	O
trial	O
is	O
registered	O
with	O
ISRCTN	O
,	O
50189673	O
,	O
and	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04381936	O
.	O

-DOCSTART-	O

Title	O
:	O
Peginterferon	B-I
lambda	I-I
for	O
the	O
treatment	O
of	O
outpatients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
phase	O
2	O
,	O
placebo	O
-	O
controlled	O
randomised	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
,	O
outpatients	B-P
with	I-P
laboratory	I-P
-	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
were	O
randomly	O
assigned	O
to	O
a	O
single	O
subcutaneous	O
injection	O
of	O
peginterferon	B-I
lambda	I-I
180	O
?g	O
or	O
placebo	B-C
within	O
7	O
days	O
of	O
symptom	O
onset	O
or	O
first	O
positive	O
swab	O
if	O
asymptomatic	O
.	O

Participants	O
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
using	O
a	O
computer	O
-	O
generated	O
randomisation	O
list	O
created	O
with	O
a	O
randomisation	O
schedule	O
in	O
blocks	O
of	O
four	O
.	O

At	O
the	O
time	O
of	O
administration	O
,	O
study	O
nurses	O
received	O
a	O
sealed	O
opaque	O
envelope	O
with	O
the	O
treatment	O
allocation	O
number	O
.	O

The	O
primary	O
endpoint	O
was	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
who	I-O
were	I-O
negative	I-O
for	I-O
severe	I-O
acute	I-O
respiratory	I-O
syndrome	I-O
coronavirus	I-O
2	I-O
(	I-O
SARS	I-O
-	I-O
CoV	I-O
-	I-O
2	I-O
)	I-O
RNA	I-O
on	O
day	O
7	O
after	O
the	O
injection	O
,	O
analysed	O
by	O
a	O
?2	O
test	O
following	O
an	O
intention	O
-	O
to	O
-	O
treat	O
principle	O
.	O

Prespecified	O
analysis	O
of	O
the	O
primary	O
endpoint	O
,	O
adjusted	O
for	O
baseline	O
viral	B-O
load	I-O
,	O
using	O
bivariate	O
logistic	O
regression	O
was	O
done	O
.	O

The	O
trial	O
is	O
now	O
complete	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04354259	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
online	B-I
multimedia	I-I
psychoeducational	I-I
interventions	I-I
on	O
the	O
resilience	O
and	O
perceived	O
stress	O
of	O
hospitalized	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
pilot	O
cluster	O
randomized	O
parallel	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
pilot	O
cluster	O
randomized	O
parallel	O
-	O
controlled	O
trial	O
with	O
hospital	O
wards	O
as	O
the	O
units	O
of	O
randomization	O
.	O

Participants	O
in	O
this	O
fully	O
online	O
trial	O
were	O
50	B-P
consecutive	I-P
patients	I-P
who	I-P
were	I-P
hospitalized	I-P
in	I-P
2	I-P
hospitals	I-P
in	I-P
Shiraz	I-P
,	I-P
after	I-P
being	I-P
diagnosed	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Before	O
the	O
beginning	O
of	O
the	O
intervention	O
,	O
four	O
inpatient	O
wards	O
inside	O
two	O
of	O
the	O
hospitals	O
were	O
randomly	O
assigned	O
to	O
either	O
intervention	O
or	O
control	O
conditions	O
.	O

All	O
eligible	O
participants	O
in	O
the	O
wards	O
allocated	O
to	O
the	O
intervention	O
condition	O
received	O
online	B-I
multimedia	I-I
psychoeducational	I-I
interventions	I-I
during	O
the	O
2	O
weeks	O
,	O
whilst	O
the	O
patients	O
in	O
the	O
wards	O
allocated	O
to	O
the	O
control	O
condition	O
were	O
offered	O
the	O
opportunity	O
to	O
receive	O
telephone	B-C
-	I-C
based	I-C
psychological	I-C
counseling	I-C
if	O
needed	O
.	O

Psychoeducational	B-I
interventions	I-I
mainly	O
included	O
cognitive	B-I
-	I-I
behavioural	I-I
techniques	I-I
,	O
stress	B-I
management	I-I
techniques	I-I
,	O
mindfulness	B-I
-	I-I
based	I-I
stress	I-I
reduction	I-I
and	O
positive	B-I
psychotherapy	I-I
.	O

The	O
patients	O
were	O
assessed	O
regarding	O
resilience	B-O
and	O
perceived	B-O
stress	I-O
at	O
baseline	O
and	O
after	O
two	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
effectiveness	O
of	O
high	B-I
-	I-I
dose	I-I
vitamin	I-I
C	I-I
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
randomized	O
open	O
-	O
label	O
clinical	O
trial	O
.	O

METHODS	O
:	O
An	O
open	O
-	O
label	O
,	O
randomized	O
,	O
and	O
controlled	O
trial	O
was	O
conducted	O
on	O
patients	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
infection	I-P
.	O

The	O
case	O
and	O
control	O
treatment	O
groups	O
each	O
consisted	O
of	O
30	O
patients	O
.	O

The	O
control	O
group	O
received	O
lopinavir	B-C
/	O
ritonavir	B-C
and	O
hydroxychloroquine	B-C
and	O
the	O
case	O
group	O
received	O
HDIVC	B-I
(	O
6	O
g	O
daily	O
)	O
added	O
to	O
the	O
same	O
regimen	O
.	O

-DOCSTART-	O

Title	O
:	O
Rationale	O
and	O
design	O
for	O
the	O
study	O
of	O
rivaroxaban	B-I
to	O
reduce	O
thrombotic	O
events	O
,	O
hospitalization	O
and	O
death	O
in	O
outpatients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
The	O
PREVENT	O
-	O
HD	O
study	O
.	O

METHODS	O
:	O
PREVENT	O
-	O
HD	O
is	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
pragmatic	O
,	O
event	O
-	O
driven	O
phase	O
3	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
rivaroxaban	B-I
in	O
symptomatic	B-P
outpatients	I-P
with	I-P
laboratory	I-P
-	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
at	I-P
risk	I-P
for	I-P
thrombotic	I-P
events	I-P
,	I-P
hospitalization	I-P
,	I-P
and	I-P
death	I-P
.	O

Several	O
challenges	O
posed	O
by	O
the	O
pandemic	O
have	O
necessitated	O
innovative	O
approaches	O
to	O
clinical	O
trial	O
design	O
,	O
start	O
-	O
up	O
,	O
and	O
conduct	O
.	O

Participants	O
are	O
randomized	O
in	O
a	O
1	O
:	O
1	O
ratio	O
,	O
stratified	O
by	O
time	O
from	O
COVID	O
-	O
19	O
confirmation	O
,	O
to	O
either	O
rivaroxaban	B-I
10	O
mg	O
once	O
daily	O
or	O
placebo	B-C
for	O
35	O
days	O
.	O

The	O
primary	O
efficacy	O
end	O
point	O
is	O
a	B-O
composite	I-O
of	I-O
symptomatic	I-O
venous	I-O
thromboembolism	I-O
,	O
myocardial	B-O
infarction	I-O
,	O
ischemic	B-O
stroke	I-O
,	O
acute	B-O
limb	I-O
ischemia	I-O
,	O
non	B-O
-	I-O
central	I-O
nervous	I-O
system	I-O
systemic	I-O
embolization	I-O
,	O
all	B-O
-	I-O
cause	I-O
hospitalization	I-O
,	O
and	O
all	B-O
-	I-O
cause	I-O
mortality	I-O
.	O

The	O
primary	O
safety	O
end	O
point	O
is	O
fatal	B-O
and	O
critical	B-O
site	I-O
bleeding	I-O
according	O
to	O
the	B-O
International	I-O
Society	I-O
on	I-O
Thrombosis	I-O
and	I-O
Haemostasis	I-O
definition	I-O
.	O

Enrollment	O
began	O
in	O
August	O
2020	O
and	O
is	O
expected	O
to	O
enroll	O
approximately	O
4	O
,	O
000	O
participants	O
to	O
yield	O
the	O
required	O
number	O
of	O
end	O
point	O
events	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Phase	O
II	O
Safety	O
and	O
Efficacy	O
Study	O
on	O
Prognosis	O
of	O
Moderate	O
Pneumonia	O
in	O
Coronavirus	B-P
Disease	I-P
2019	I-P
Patients	I-P
With	O
Regular	B-I
Intravenous	I-I
Immunoglobulin	I-I
Therapy	I-I
.	O

METHODS	O
:	O
An	O
open	O
-	O
label	O
,	O
multicenter	O
,	O
comparative	O
,	O
randomized	O
study	O
was	O
conducted	O
on	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
with	I-P
moderate	I-P
pneumonia	I-P
.	O

One	B-P
hundred	I-P
eligible	I-P
patients	I-P
were	O
randomized	O
in	O
1	O
:	O
1	O
ratio	O
either	O
to	O
receive	O
IVIG	B-I
+	O
standard	B-I
of	I-I
care	I-I
(	I-I
SOC	I-I
)	I-I
or	O
SOC	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
a	B-I
Single	I-I
High	I-I
Dose	I-I
of	I-I
Vitamin	I-I
D3	I-I
on	O
Hospital	O
Length	O
of	O
Stay	O
in	O
Patients	B-P
With	I-P
Moderate	I-P
to	I-P
Severe	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
conducted	O
in	O
2	O
sites	O
in	O
Sao	O
Paulo	O
,	O
Brazil	O
.	O

The	O
study	O
included	O
240	B-P
hospitalized	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
who	I-P
were	I-P
moderately	I-P
to	I-P
severely	I-P
ill	I-P
at	I-P
the	I-P
time	I-P
of	I-P
enrollment	I-P
from	I-P
June	I-P
2	I-P
,	I-P
2020	I-P
,	I-P
to	I-P
August	I-P
27	I-P
,	I-P
2020	I-P
.	I-P

The	I-P
final	I-P
follow	I-P
-	I-P
up	I-P
was	I-P
on	I-P
October	I-P
7	I-P
,	I-P
2020	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	B-I
single	I-I
oral	I-I
dose	I-I
of	I-I
200	I-I
000	I-I
IU	I-I
of	I-I
vitamin	I-I
D3	I-I
(	O
n	O
=	O
120	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
120	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
length	B-O
of	I-O
stay	I-O
,	O
defined	O
as	O
the	B-O
time	I-O
from	I-O
the	I-O
date	I-O
of	I-O
randomization	I-O
to	I-O
hospital	I-O
discharge	I-O
.	O

Prespecified	O
secondary	O
outcomes	O
included	O
mortality	B-O
during	O
hospitalization	O
;	O
the	B-O
number	I-O
of	I-O
patients	I-O
admitted	I-O
to	I-O
the	I-O
intensive	I-O
care	I-O
unit	I-O
;	O
the	B-O
number	I-O
of	I-O
patients	I-O
who	I-O
required	I-O
mechanical	I-O
ventilation	I-O
and	O
the	B-O
duration	I-O
of	I-O
mechanical	I-O
ventilation	I-O
;	O
and	O
serum	B-O
levels	I-O
of	I-O
25	I-O
-	I-O
hydroxyvitamin	I-O
D	I-O
,	O
total	B-O
calcium	I-O
,	O
creatinine	B-O
,	O
and	O
C	B-O
-	I-O
reactive	I-O
protein	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
placebo	O
-	O
controlled	O
pilot	O
clinical	O
trial	O
on	O
the	O
efficacy	O
of	O
ayurvedic	B-I
treatment	I-I
regime	I-I
on	O
COVID	B-P
-	I-P
19	I-P
positive	I-P
patients	I-P
.	O

METHODS	O
:	O
It	O
is	O
a	O
placebo	O
controlled	O
randomized	O
double	O
-	O
blind	O
pilot	O
clinical	O
trial	O
.	O

The	O
study	O
was	O
registered	O
with	O
Clinical	O
Trial	O
Registry	O
-	O
India	O
(	O
vide	O
Registration	O
No	O
.	O

CTRI	O
/	O
2020/05/025273	O
)	O
and	O
conducted	O
at	O
the	O
Department	O
of	O
Medicine	O
in	O
National	O
Institute	O
of	O
Medical	O
Sciences	O
and	O
Research	O
,	O
Jaipur	O
,	O
India	O
.	O

1	B-I
g	I-I
of	I-I
Giloy	I-I
Ghanvati	I-I
(	O
Tinospora	B-I
cordifolia	I-I
)	O
and	O
2	B-I
g	I-I
of	I-I
Swasari	I-I
Ras	I-I
(	O
traditional	B-I
herbo	I-I
-	I-I
mineral	I-I
formulation	I-I
)	O
and	O
0	B-I
.	I-I
5	I-I
g	I-I
each	I-I
of	I-I
Ashwagandha	I-I
(	O
Withania	B-I
somnifera	I-I
)	O
and	O
Tulsi	B-I
Ghanvati	I-I
(	O
Ocimum	B-I
sanctum	I-I
)	O
were	O
given	O
orally	O
to	O
the	O
patients	O
in	O
treatment	O
group	O
twice	O
per	O
day	O
for	O
7	O
days	O
.	O

Medicines	O
were	O
given	O
in	O
the	O
form	O
of	O
tablets	O
and	O
each	O
tablet	O
weighed	O
500	O
mg	O
.	O

While	O
,	O
Swasari	B-I
Ras	I-I
was	O
administered	O
in	O
powdered	O
form	O
,	O
30	O
min	O
before	O
breakfasts	O
and	O
dinners	O
,	O
rest	O
were	O
scheduled	O
for	O
30	O
min	O
post	O
-	O
meals	O
.	O

Patients	O
in	O
the	O
treatment	O
group	O
also	O
received	O
4	B-I
drops	I-I
of	I-I
Anu	I-I
taila	I-I
(	O
traditional	O
nasal	O
drop	O
)	O
in	O
each	O
nostril	O
every	O
day	O
1	O
h	O
before	O
breakfast	O
.	O

Patients	O
in	O
the	B-C
placebo	I-C
group	O
received	O
identical	B-C
-	I-C
looking	I-C
tablets	I-C
and	O
drops	B-C
,	O
post	O
randomization	O
and	O
double	O
blinded	O
assortments	O
.	O

RT	B-O
-	I-O
qPCR	I-O
test	I-O
was	O
used	O
for	O
the	O
detection	O
of	O
viral	B-O
load	I-O
in	O
the	O
nasopharyngeal	O
and	O
oropharyngeal	O
swab	O
samples	O
of	O
study	O
participants	O
during	O
the	O
study	O
.	O

Chemiluminescent	B-O
immunometric	I-O
assay	I-O
was	O
used	O
to	O
quantify	O
serum	B-O
levels	I-O
of	I-O
interleukin	I-O
-	I-O
6	I-O
(	I-O
IL	I-O
-	I-O
6	I-O
)	I-O
,	O
tumor	B-O
necrosis	I-O
factor	I-O
alpha	I-O
(	I-O
TNF	I-O
-	I-O
?	I-O
)	I-O
and	O
high	B-O
sensitivity	I-O
C	I-O
-	I-O
reactive	I-O
protein	I-O
(	I-O
hs	I-O
-	I-O
CRP	I-O
)	I-O
on	O
day	O
1	O
and	O
day	O
7	O
of	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Progesterone	B-I
in	O
Addition	O
to	O
Standard	B-I
of	I-I
Care	I-I
vs	O
Standard	B-C
of	I-C
Care	I-C
Alone	I-C
in	O
the	O
Treatment	O
of	O
Men	B-P
Hospitalized	I-P
With	I-P
Moderate	I-P
to	I-P
Severe	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
,	O
Controlled	O
Pilot	O
Trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
pilot	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
controlled	O
trial	O
of	O
subcutaneous	B-I
progesterone	I-I
in	O
men	B-P
hospitalized	I-P
with	I-P
confirmed	I-P
moderate	I-P
to	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
SOC	B-I
plus	O
progesterone	B-I
(	O
100	O
mg	O
subcutaneously	O
twice	O
daily	O
for	O
up	O
to	O
5	O
days	O
)	O
or	O
SOC	B-C
alone	I-C
.	O

In	O
addition	O
to	O
assessment	O
of	O
safety	O
,	O
the	O
primary	O
outcome	O
was	O
change	O
in	O
clinical	B-O
status	I-O
on	O
day	O
7	O
.	O

Length	B-O
of	I-O
hospital	I-O
stay	I-O
and	O
number	B-O
of	I-O
days	I-O
on	I-O
supplemental	I-O
oxygen	I-O
were	O
key	O
secondary	O
outcomes	O
.	O

-DOCSTART-	O

Title	O
:	O
Tocilizumab	B-I
in	O
Hospitalized	B-P
Patients	I-P
with	I-P
Severe	I-P
Covid	I-P
-	I-P
19	I-P
Pneumonia	I-P
.	O

METHODS	O
:	O
In	O
this	O
phase	O
3	O
trial	O
,	O
we	O
randomly	O
assigned	O
patients	B-P
who	I-P
were	I-P
hospitalized	I-P
with	I-P
severe	I-P
Covid	I-P
-	I-P
19	I-P
pneumonia	I-P
in	O
a	O
2	O
:	O
1	O
ratio	O
receive	O
a	B-I
single	I-I
intravenous	I-I
infusion	I-I
of	I-I
tocilizumab	I-I
(	O
at	O
a	O
dose	O
of	O
8	O
mg	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
or	O
placebo	B-C
.	O

Approximately	O
one	O
quarter	O
of	O
the	O
participants	O
received	O
a	B-I
second	I-I
dose	I-I
of	I-I
tocilizumab	I-I
or	O
placebo	B-C
8	O
to	O
24	O
hours	O
after	O
the	O
first	O
dose	O
.	O

The	O
primary	O
outcome	O
was	O
clinical	B-O
status	I-O
at	O
day	O
28	O
on	O
an	B-O
ordinal	I-O
scale	I-O
ranging	O
from	O
1	O
(	O
discharged	O
or	O
ready	O
for	O
discharge	O
)	O
to	O
7	O
(	O
death	O
)	O
in	O
the	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
population	O
,	O
which	O
included	O
all	O
the	O
patients	O
who	O
had	O
received	O
at	O
least	O
one	B-I
dose	I-I
of	I-I
tocilizumab	I-I
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
The	O
use	O
of	O
oxygen	B-I
hoods	I-I
in	O
patients	B-P
failing	I-P
on	I-P
conventional	I-P
high	I-P
-	I-P
flow	I-P
oxygen	I-P
delivery	I-P
systems	I-P
,	O
the	O
effects	O
on	O
oxygenation	O
,	O
mechanical	O
ventilation	O
and	O
mortality	O
rates	O
in	O
hypoxic	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

A	O
Prospective	O
Controlled	O
Cohort	O
Study	O
.	O

METHODS	O
:	O
DesignProspective	O
Controlled	O
Cohort	O
Study	O
.	O

SettingSingle	O
Center	O
.	O

ParticipantsAll	B-P
patients	I-P
admitted	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
COVID	I-P
-	I-P
19	I-P
were	O
reviewed	O
and	O
136	O
/	O
347	O
patients	O
met	O
inclusion	O
criteria	O
.	O

Study	O
period3	O
/	O
6	O
/	O
2020	O
to	O
5/1/2020	O
.	O

136	O
participants	O
completed	O
the	O
study	O
with	O
known	O
status	O
for	O
all	O
outcome	O
measures	O
.	O

Intervention	O
or	O
exposureOxygen	B-I
hoods	I-I
/	O
helmets	B-I
as	O
compared	O
to	O
conventional	B-C
high	I-C
-	I-C
flow	I-C
oxygen	I-C
delivery	I-C
systems	I-C
.	O

1	O
)	O
Pre	O
and	O
post	O
change	O
in	O
oxygen	B-O
saturation	I-O
(	I-O
SaO2	I-O
)	I-O
.	O

2	O
)	O
In	B-O
-	I-O
hospital	I-O
Mechanical	I-O
Ventilation	I-O
(	I-O
MV	I-O
)	I-O
.	O

3	O
)	O
In	B-O
-	I-O
hospital	I-O
Mortality	I-O
.	O

4	O
)	O
Length	B-O
of	I-O
hospitalization	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
guided	B-I
imagery	I-I
on	O
anxiety	O
,	O
muscle	O
pain	O
,	O
and	O
vital	O
signs	O
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
110	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
were	O
recruited	O
and	O
randomly	O
assigned	O
to	O
two	O
control	O
and	O
intervention	O
groups	O
.	O

Data	O
were	O
collected	O
using	O
the	B-O
Spielberger	I-O
Anxiety	I-O
Inventory	I-O
,	O
the	B-O
McGill	I-O
Pain	I-O
Questionnaire	I-O
,	O
and	O
the	B-O
Visual	I-O
Analogue	I-O
Scale	I-O
.	O

The	O
intervention	O
group	O
received	O
ten	O
training	O
sessions	O
of	O
guided	B-I
imagery	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
losartan	B-I
and	O
amlodipine	B-I
effects	O
on	O
the	O
outcomes	O
of	O
patient	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
primary	I-P
hypertension	I-P
:	O
A	O
randomised	O
clinical	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomised	O
clinical	O
trial	O
,	O
hospitalised	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
primary	I-P
HTN	I-P
were	O
enrolled	O
in	O
the	O
study	O
.	O

One	O
arm	O
received	O
losartan	B-I
,	O
25	O
mg	O
,	O
twice	O
a	O
day	O
and	O
the	O
other	O
arm	O
received	O
amlodipine	B-I
,	O
5	O
mg	O
per	O
day	O
for	O
2	O
weeks	O
.	O

The	O
main	O
outcomes	O
were	O
compare	B-O
30	I-O
-	I-O
day	I-O
mortality	I-O
rate	I-O
and	O
length	B-O
of	I-O
hospital	I-O
stay	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Early	B-I
versus	O
deferred	B-I
anti	I-I
-	I-I
SARS	I-I
-	I-I
CoV	I-I
-	I-I
2	I-I
convalescent	I-I
plasma	I-I
in	O
patients	B-P
admitted	I-P
for	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
randomized	O
phase	O
II	O
clinical	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Ivermectin	B-I
on	O
Time	O
to	O
Resolution	O
of	O
Symptoms	O
Among	O
Adults	B-P
With	I-P
Mild	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Double	O
-	O
blind	O
,	O
randomized	O
trial	O
conducted	O
at	O
a	O
single	O
site	O
in	O
Cali	O
,	O
Colombia	O
.	O

Potential	O
study	O
participants	O
were	O
identified	O
by	O
simple	O
random	O
sampling	O
from	O
the	O
state	O
'	O
s	O
health	O
department	O
electronic	O
database	O
of	O
patients	O
with	O
symptomatic	O
,	O
laboratory	O
-	O
confirmed	O
COVID	O
-	O
19	O
during	O
the	O
study	O
period	O
.	O

A	B-P
total	I-P
of	I-P
476	I-P
adult	I-P
patients	I-P
with	I-P
mild	I-P
disease	I-P
and	I-P
symptoms	I-P
for	I-P
7	I-P
days	I-P
or	I-P
fewer	I-P
(	I-P
at	I-P
home	I-P
or	I-P
hospitalized	I-P
)	I-P
were	O
enrolled	O
between	O
July	O
15	O
and	O
November	O
30	O
,	O
2020	O
,	O
and	O
followed	O
up	O
through	O
December	O
21	O
,	O
2020	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
ivermectin	B-I
,	O
300	O
?g	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
for	O
5	O
days	O
(	O
n	O
=	O
200	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
200	O
)	O
.	O

Primary	O
outcome	O
was	O
time	B-O
to	I-O
resolution	I-O
of	I-O
symptoms	I-O
within	O
a	O
21	O
-	O
day	O
follow	O
-	O
up	O
period	O
.	O

Solicited	B-O
adverse	I-O
events	I-O
and	O
serious	B-O
adverse	I-O
events	I-O
were	O
also	O
collected	O
.	O

-DOCSTART-	O

Title	O
:	O
Tocilizumab	B-I
plus	O
standard	B-I
care	I-I
versus	O
standard	B-C
care	I-C
in	O
patients	B-P
in	I-P
India	I-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
-	I-P
associated	I-P
cytokine	I-P
release	I-P
syndrome	I-P
(	O
COVINTOC	O
)	O
:	O
an	O
open	O
-	O
label	O
,	O
multicentre	O
,	O
randomised	O
,	O
controlled	O
,	O
phase	O
3	O
trial	O
.	O

METHODS	O
:	O
COVINTOC	O
is	O
an	O
open	O
-	O
label	O
,	O
multicentre	O
,	O
randomised	O
,	O
controlled	O
,	O
phase	O
3	O
trial	O
done	O
at	O
12	O
public	O
and	O
private	O
hospitals	O
across	O
India	O
.	O

Adults	B-P
(	I-P
aged	I-P
?18	I-P
years	I-P
)	I-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
(	I-P
Indian	I-P
Ministry	I-P
of	I-P
Health	I-P
grading	I-P
)	I-P
confirmed	I-P
by	I-P
positive	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
PCR	I-P
result	I-P
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
block	O
randomisation	O
)	O
to	O
receive	O
tocilizumab	B-I
6	O
mg	O
/	O
kg	O
plus	O
standard	B-I
care	I-I
(	O
the	B-I
tocilizumab	I-I
group	O
)	O
or	O
standard	B-C
care	I-C
alone	I-C
(	O
the	B-C
standard	I-C
care	I-C
group	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
progression	B-O
of	I-O
COVID	I-O
-	I-O
19	I-O
(	O
from	O
moderate	O
to	O
severe	O
or	O
from	O
severe	O
to	O
death	O
)	O
up	O
to	O
day	O
14	O
in	O
the	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
population	O
of	O
all	O
participants	O
who	O
had	O
at	O
least	O
one	O
post	O
-	O
baseline	O
assessment	O
for	O
the	O
primary	O
endpoint	O
.	O

Safety	B-O
was	O
assessed	O
in	O
all	O
randomly	O
assigned	O
patients	O
.	O

The	O
trial	O
is	O
completed	O
and	O
registered	O
with	O
the	O
Clinical	O
Trials	O
Registry	O
India	O
(	O
CTRI	O
/	O
2020/05/025369	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Sarilumab	B-I
in	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
severe	I-P
or	I-P
critical	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
phase	O
3	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
60	O
-	O
day	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multinational	O
phase	O
3	O
trial	O
at	O
45	O
hospitals	O
in	O
Argentina	O
,	O
Brazil	O
,	O
Canada	O
,	O
Chile	O
,	O
France	O
,	O
Germany	O
,	O
Israel	O
,	O
Italy	O
,	O
Japan	O
,	O
Russia	O
,	O
and	O
Spain	O
.	O

We	O
included	O
adults	B-P
(	I-P
?18	I-P
years	I-P
)	I-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
laboratory	I-P
-	I-P
confirmed	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
and	I-P
pneumonia	I-P
,	I-P
who	I-P
required	I-P
oxygen	I-P
supplementation	I-P
or	I-P
intensive	I-P
care	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
2:2:1	O
with	O
permuted	O
blocks	O
of	O
five	O
)	O
to	O
receive	O
intravenous	B-I
sarilumab	I-I
400	O
mg	O
,	O
sarilumab	B-I
200	O
mg	O
,	O
or	O
placebo	B-C
.	O

Patients	O
,	O
care	O
providers	O
,	O
outcome	O
assessors	O
,	O
and	O
investigators	O
remained	O
masked	O
to	O
assigned	O
intervention	O
throughout	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
primary	O
endpoint	O
was	O
time	B-O
to	I-O
clinical	I-O
improvement	I-O
of	I-O
two	I-O
or	O
more	B-O
points	I-O
(	O
seven	O
point	O
scale	O
ranging	O
from	O
1	O
[	O
death	O
]	O
to	O
7	O
[	O
discharged	O
from	O
hospital	O
]	O
)	O
in	O
the	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

The	O
key	O
secondary	O
endpoint	O
was	O
proportion	B-O
of	I-O
patients	I-O
alive	I-O
at	O
day	O
29	O
.	O

Safety	O
outcomes	O
included	O
adverse	B-O
events	I-O
and	O
laboratory	B-O
assessments	I-O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04327388	O
;	O
EudraCT	O
,	O
2020-001162-12	O
;	O
and	O
WHO	O
,	O
U1111	O
-	O
1249	O
-	O
6021	O
.	O

-DOCSTART-	O

Title	O
:	O
Azithromycin	B-I
for	O
community	O
treatment	O
of	O
suspected	O
COVID	O
-	O
19	O
in	O
people	B-P
at	I-P
increased	I-P
risk	I-P
of	I-P
an	I-P
adverse	I-P
clinical	I-P
course	I-P
in	I-P
the	I-P
UK	I-P
(	O
PRINCIPLE	O
)	O
:	O
a	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
adaptive	O
platform	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
UK	O
-	O
based	O
,	O
primary	O
care	O
,	O
open	O
-	O
label	O
,	O
multi	O
-	O
arm	O
,	O
adaptive	O
platform	O
randomised	O
trial	O
of	O
interventions	O
against	O
COVID	O
-	O
19	O
in	O
people	B-P
at	I-P
increased	I-P
risk	I-P
of	I-P
an	I-P
adverse	I-P
clinical	I-P
course	I-P
(	O
PRINCIPLE	O
)	O
,	O
we	O
randomly	O
assigned	O
people	B-P
aged	I-P
65	I-P
years	I-P
and	I-P
older	I-P
,	I-P
or	I-P
50	I-P
years	I-P
and	I-P
older	I-P
with	I-P
at	I-P
least	I-P
one	I-P
comorbidity	I-P
,	I-P
who	I-P
had	I-P
been	I-P
unwell	I-P
for	I-P
14	I-P
days	I-P
or	I-P
less	I-P
with	I-P
suspected	I-P
COVID	I-P
-	I-P
19	I-P
,	O
to	O
usual	B-I
care	I-I
plus	O
azithromycin	B-I
500	O
mg	O
daily	O
for	O
three	O
days	O
,	O
usual	B-I
care	I-I
plus	O
other	B-I
interventions	I-I
,	O
or	O
usual	B-C
care	I-C
alone	I-C
.	O

The	O
trial	O
had	O
two	O
coprimary	O
endpoints	O
measured	O
within	O
28	O
days	O
from	O
randomisation	O
:	O
time	B-O
to	I-O
first	I-O
self	I-O
-	I-O
reported	I-O
recovery	I-O
,	O
analysed	O
using	O
a	O
Bayesian	O
piecewise	O
exponential	O
,	O
and	O
hospital	B-O
admission	I-O
or	O
death	B-O
related	I-O
to	I-O
COVID	I-O
-	I-O
19	I-O
,	O
analysed	O
using	O
a	O
Bayesian	O
logistic	O
regression	O
model	O
.	O

Eligible	O
participants	O
with	O
outcome	O
data	O
were	O
included	O
in	O
the	O
primary	O
analysis	O
,	O
and	O
those	O
who	O
received	O
the	O
allocated	O
treatment	O
were	O
included	O
in	O
the	O
safety	O
analysis	O
.	O

The	O
trial	O
is	O
registered	O
with	O
ISRCTN	O
,	O
ISRCTN86534580	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
pegylated	B-I
interferon	I-I
alfa	I-I
-	I-I
2	I-I
b	I-I
in	O
moderate	O
COVID	O
-	O
19	O
:	O
A	O
phase	O
II	O
,	O
randomized	O
,	O
controlled	O
,	O
open	O
-	O
label	O
study	O
.	O

METHODS	O
:	O
In	O
this	O
phase	O
2	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
,	O
adult	B-P
subjects	I-P
aged	I-P
?18	I-P
years	I-P
with	I-P
RT	I-P
-	I-P
PCR	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
with	I-P
moderate	I-P
symptoms	I-P
were	O
randomized	O
in	O
a	O
1	O
:	O
1	O
to	O
receive	O
PEG	B-I
IFN	I-I
-	I-I
?2b	I-I
plus	O
SOC	B-I
,	O
or	O
SOC	B-C
alone	I-C
.	O

The	O
primary	O
endpoint	O
was	O
improvement	O
in	O
clinical	B-O
status	I-O
on	O
day	O
15	O
,	O
measured	O
by	O
the	B-O
WHO	I-O
7	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
randomized	O
trial	O
in	O
the	O
investigation	O
of	O
anxiety	O
and	O
depression	O
in	O
patients	B-P
with	I-P
coronavirus	I-P
disease	I-P
2019	I-P
(	I-P
COVID	I-P
-	I-P
19	I-P
)	I-P
.	O

METHODS	O
:	O
Sixty	B-P
-	I-P
five	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
were	O
randomly	O
enrolled	O
into	O
this	O
study	O
.	O

Anxiety	B-O
and	O
depression	B-O
among	O
participants	O
were	O
measured	O
through	O
the	O
completion	O
of	O
anonymous	B-O
Chinese	I-O
-	I-O
language	I-O
Zung	I-O
self	I-O
-	I-O
rating	I-O
anxiety	I-O
scale	I-O
and	O
self	B-O
-	I-O
rating	I-O
depression	I-O
scale	I-O
questionnaires	I-O
.	O

Data	O
were	O
analyzed	O
using	O
independent	O
samples	O
t	O
-	O
tests	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
,	O
and	O
?2	O
tests	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Intermediate	B-I
-	I-I
Dose	I-I
vs	O
Standard	B-C
-	I-C
Dose	I-C
Prophylactic	I-C
Anticoagulation	I-C
on	O
Thrombotic	O
Events	O
,	O
Extracorporeal	O
Membrane	O
Oxygenation	O
Treatment	O
,	O
or	O
Mortality	O
Among	O
Patients	B-P
With	I-P
COVID	I-P
-	I-P
19	I-P
Admitted	I-P
to	I-P
the	I-P
Intensive	I-P
Care	I-P
Unit	I-P
:	O
The	O
INSPIRATION	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Multicenter	O
randomized	O
trial	O
with	O
a	O
2	O
	O
2	O
factorial	O
design	O
performed	O
in	O
10	O
academic	O
centers	O
in	O
Iran	O
comparing	O
intermediate	B-I
-	I-I
dose	I-I
vs	O
standard	B-C
-	I-C
dose	I-C
prophylactic	I-C
anticoagulation	I-C
(	O
first	O
hypothesis	O
)	O
and	O
statin	B-I
therapy	I-I
vs	O
matching	B-C
placebo	I-C
(	O
second	O
hypothesis	O
;	O
not	O
reported	O
in	O
this	O
article	O
)	O
among	O
adult	B-P
patients	I-P
admitted	I-P
to	I-P
the	I-P
ICU	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Patients	O
were	O
recruited	O
between	O
July	O
29	O
,	O
2020	O
,	O
and	O
November	O
19	O
,	O
2020	O
.	O

The	O
final	O
follow	O
-	O
up	O
date	O
for	O
the	O
30	O
-	O
day	O
primary	O
outcome	O
was	O
December	O
19	O
,	O
2020	O
.	O

Intermediate	B-I
-	I-I
dose	I-I
(	I-I
enoxaparin	I-I
,	O
1	O
mg	O
/	O
kg	O
daily	O
)	O
(	O
n	O
=	O
276	O
)	O
vs	O
standard	B-C
prophylactic	I-C
anticoagulation	I-C
(	I-C
enoxaparin	I-C
,	O
40	O
mg	O
daily	O
)	O
(	O
n	O
=	O
286	O
)	O
,	O
with	O
modification	O
according	O
to	O
body	O
weight	O
and	O
creatinine	O
clearance	O
.	O

The	O
assigned	O
treatments	O
were	O
planned	O
to	O
be	O
continued	O
until	O
completion	O
of	O
30	O
-	O
day	O
follow	O
-	O
up	O
.	O

The	O
primary	O
efficacy	O
outcome	O
was	O
a	B-O
composite	I-O
of	I-O
venous	I-O
or	O
arterial	B-O
thrombosis	I-O
,	O
treatment	B-O
with	I-O
extracorporeal	I-O
membrane	I-O
oxygenation	I-O
,	O
or	O
mortality	B-O
within	O
30	O
days	O
,	O
assessed	O
in	O
randomized	O
patients	O
who	O
met	O
the	O
eligibility	O
criteria	O
and	O
received	O
at	O
least	O
1	O
dose	O
of	O
the	O
assigned	O
treatment	O
.	O

Prespecified	O
safety	O
outcomes	O
included	O
major	B-O
bleeding	I-O
according	O
to	O
the	B-O
Bleeding	I-O
Academic	I-O
Research	I-O
Consortium	I-O
(	I-O
type	I-O
3	I-O
or	I-O
5	I-O
definition	I-O
)	I-O
,	O
powered	B-O
for	I-O
noninferiority	I-O
(	O
a	O
noninferiority	O
margin	O
of	O
1	O
.	O
8	O
based	O
on	O
odds	O
ratio	O
)	O
,	O
and	O
severe	B-O
thrombocytopenia	I-O
(	O
platelet	O
count	O
<	O
20	O
103	O
/	O
L	O
)	O
.	O

All	O
outcomes	O
were	O
blindly	O
adjudicated	O
.	O

-DOCSTART-	O

Title	O
:	O
Safety	O
and	O
efficacy	O
of	O
Favipiravir	B-I
in	O
moderate	O
to	O
severe	O
SARS	O
-	O
CoV	O
-	O
2	O
pneumonia	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
multicenter	O
randomized	O
open	O
-	O
labeled	O
clinical	O
trial	O
on	O
moderate	O
to	O
severe	O
cases	O
infections	O
of	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

Patients	B-P
with	I-P
typical	I-P
ground	I-P
glass	I-P
appearance	I-P
on	I-P
chest	I-P
computerized	I-P
tomography	I-P
scan	I-P
(	I-P
CT	I-P
scan	I-P
)	I-P
and	I-P
oxygen	I-P
saturation	I-P
(	I-P
SpO2	I-P
)	I-P
of	I-P
less	I-P
than	I-P
93	I-P
%	I-P
were	O
enrolled	O
.	O

They	O
were	O
randomly	O
allocated	O
into	O
Favipiravir	B-I
(	O
1	O
.	O
6	O
gr	O
loading	O
,	O
1	O
.	O
8	O
gr	O
daily	O
)	O
and	O
Lopinavir	B-I
/	O
Ritonavir	B-I
(	O
800	O
/	O
200	O
mg	O
daily	O
)	O
treatment	O
regimens	O
in	O
addition	O
to	O
standard	B-I
care	I-I
.	O

In	B-O
-	I-O
hospital	I-O
mortality	I-O
,	O
ICU	B-O
admission	I-O
,	O
intubation	B-O
,	O
time	B-O
to	I-O
clinical	I-O
recovery	I-O
,	O
changes	O
in	O
daily	B-O
SpO2	I-O
after	O
5	O
min	O
discontinuation	O
of	O
supplemental	O
oxygen	O
,	O
and	O
length	B-O
of	I-O
hospital	I-O
stay	I-O
were	O
quantified	O
and	O
compared	O
in	O
the	O
two	O
groups	O
.	O

-DOCSTART-	O

Title	O
:	O
Itraconazole	B-I
for	O
COVID	O
-	O
19	O
:	O
preclinical	O
studies	O
and	O
a	O
proof	O
-	O
of	O
-	O
concept	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
Due	O
to	O
the	O
initial	O
absence	O
of	O
preclinical	O
models	O
,	O
the	O
effect	O
of	O
itraconazole	B-I
was	O
explored	O
in	O
a	O
clinical	O
,	O
proof	O
-	O
of	O
-	O
concept	O
,	O
open	O
-	O
label	O
,	O
single	O
-	O
center	O
study	O
,	O
in	O
which	O
hospitalized	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
standard	B-I
of	I-I
care	I-I
with	O
or	O
without	O
itraconazole	B-I
.	O

Primary	O
outcome	O
was	O
the	B-O
cumulative	I-O
score	I-O
of	I-O
the	I-O
clinical	I-O
status	I-O
until	O
day	O
15	O
based	O
on	O
the	B-O
7	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
of	I-O
the	I-O
World	I-O
Health	I-O
Organization	I-O
.	O

In	O
parallel	O
,	O
itraconazole	B-I
was	O
evaluated	O
in	O
a	O
newly	O
established	O
hamster	O
model	O
of	O
acute	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
and	O
transmission	O
,	O
as	O
soon	O
as	O
the	O
model	O
was	O
validated	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
Levamisole	B-I
treatment	I-I
in	O
clinical	O
presentations	O
of	O
non	B-P
-	I-P
hospitalized	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
prospective	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
controlled	O
clinical	O
trial	O
was	O
performed	O
in	O
adult	B-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
(	I-P
room	I-P
-	I-P
air	I-P
oxygen	I-P
saturation	I-P
>	I-P
94	I-P
%	I-P
)	I-P
from	I-P
late	I-P
April	I-P
2020	I-P
to	I-P
mid	I-P
-	I-P
August	I-P
2020	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	B-I
3	I-I
-	I-I
day	I-I
course	I-I
of	I-I
Levamisole	I-I
or	O
placebo	B-C
in	O
combination	O
with	O
routine	B-I
standard	I-I
of	I-I
care	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Helmet	B-I
Noninvasive	I-I
Ventilation	I-I
vs	O
High	B-I
-	I-I
Flow	I-I
Nasal	I-I
Oxygen	I-I
on	O
Days	O
Free	O
of	O
Respiratory	O
Support	O
in	O
Patients	B-P
With	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
Moderate	I-P
to	I-P
Severe	I-P
Hypoxemic	I-P
Respiratory	I-P
Failure	I-P
:	O
The	O
HENIVOT	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Multicenter	O
randomized	O
clinical	O
trial	O
in	O
4	O
intensive	O
care	O
units	O
(	O
ICUs	O
)	O
in	O
Italy	O
between	O
October	O
and	O
December	O
2020	O
,	O
end	O
of	O
follow	O
-	O
up	O
February	O
11	O
,	O
2021	O
,	O
including	O
109	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
moderate	I-P
to	I-P
severe	I-P
hypoxemic	I-P
respiratory	I-P
failure	I-P
(	I-P
ratio	I-P
of	I-P
partial	I-P
pressure	I-P
of	I-P
arterial	I-P
oxygen	I-P
to	I-P
fraction	I-P
of	I-P
inspired	I-P
oxygen	I-P
?200	I-P
)	I-P
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
continuous	B-I
treatment	I-I
with	I-I
helmet	I-I
noninvasive	I-I
ventilation	I-I
(	O
positive	O
end	O
-	O
expiratory	O
pressure	O
,	O
10	O
-	O
12	O
cm	O
H2O	O
;	O
pressure	O
support	O
,	O
10	O
-	O
12	O
cm	O
H2O	O
)	O
for	O
at	O
least	O
48	O
hours	O
eventually	O
followed	O
by	O
high	B-I
-	I-I
flow	I-I
nasal	I-I
oxygen	I-I
(	O
n	O
=	O
54	O
)	O
or	O
high	B-I
-	I-I
flow	I-I
oxygen	I-I
alone	I-I
(	O
60	O
L	O
/	O
min	O
)	O
(	O
n	O
=	O
55	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
number	I-O
of	I-O
days	I-O
free	I-O
of	I-O
respiratory	I-O
support	I-O
within	O
28	O
days	O
after	O
enrollment	O
.	O

Secondary	O
outcomes	O
included	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
who	I-O
required	I-O
endotracheal	I-O
intubation	I-O
within	O
28	O
days	O
from	O
study	O
enrollment	O
,	O
the	B-O
number	I-O
of	I-O
days	I-O
free	I-O
of	I-O
invasive	I-O
mechanical	I-O
ventilation	I-O
at	O
day	O
28	O
,	O
the	B-O
number	I-O
of	I-O
days	I-O
free	I-O
of	I-O
invasive	I-O
mechanical	I-O
ventilation	I-O
at	O
day	O
60	O
,	O
in	B-O
-	I-O
ICU	I-O
mortality	I-O
,	O
in	B-O
-	I-O
hospital	I-O
mortality	I-O
,	O
28	B-O
-	I-O
day	I-O
mortality	I-O
,	O
60	B-O
-	I-O
day	I-O
mortality	I-O
,	O
ICU	B-O
length	I-O
of	I-O
stay	I-O
,	O
and	O
hospital	B-O
length	I-O
of	I-O
stay	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effect	O
of	O
omega	B-I
-	I-I
3	I-I
fatty	I-I
acid	I-I
supplementation	I-I
on	O
clinical	O
and	O
biochemical	O
parameters	O
of	O
critically	B-P
ill	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
A	O
double	O
-	O
blind	O
,	O
randomized	O
clinical	O
trial	O
study	O
was	O
conducted	O
on	O
128	B-P
critically	I-P
ill	I-P
patients	I-P
infected	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
who	O
were	O
randomly	O
assigned	O
to	O
the	O
intervention	O
(	O
fortified	B-I
formula	I-I
with	I-I
n3	I-I
-	I-I
PUFA	I-I
)	O
(	O
n	O
=	O
42	O
)	O
and	O
control	O
(	O
n	O
=	O
86	O
)	O
groups	O
.	O

Data	O
on	O
1	B-O
month	I-O
survival	I-O
rate	I-O
,	O
blood	B-O
glucose	I-O
,	O
sodium	B-O
(	I-O
Na	I-O
)	I-O
,	O
potassium	B-O
(	I-O
K	I-O
)	I-O
,	O
blood	B-O
urea	I-O
nitrogen	I-O
(	I-O
BUN	I-O
)	I-O
,	O
creatinine	B-O
(	I-O
Cr	I-O
)	I-O
,	O
albumin	B-O
,	O
hematocrit	B-O
(	I-O
HCT	I-O
)	I-O
,	O
calcium	B-O
(	I-O
Ca	I-O
)	I-O
,	O
phosphorus	B-O
(	I-O
P	I-O
)	I-O
,	O
mean	B-O
arterial	I-O
pressure	I-O
(	I-O
MAP	I-O
)	I-O
,	O
O2	B-O
saturation	I-O
(	I-O
O2sat	I-O
)	I-O
,	O
arterial	B-O
pH	I-O
,	O
partial	B-O
pressure	I-O
of	I-O
oxygen	I-O
(	I-O
PO2	I-O
)	I-O
,	O
partial	B-O
pressure	I-O
of	I-O
carbon	I-O
dioxide	I-O
(	I-O
PCO2	I-O
)	I-O
,	O
bicarbonate	B-O
(	I-O
HCO3	I-O
)	I-O
,	O
base	B-O
excess	I-O
(	I-O
Be	I-O
)	I-O
,	O
white	B-O
blood	I-O
cells	I-O
(	I-O
WBCs	I-O
)	I-O
,	O
Glasgow	B-O
Coma	I-O
Scale	I-O
(	I-O
GCS	I-O
)	I-O
,	O
hemoglobin	B-O
(	I-O
Hb	I-O
)	I-O
,	O
platelet	B-O
(	I-O
Plt	I-O
)	I-O
,	O
and	O
the	B-O
partial	I-O
thromboplastin	I-O
time	I-O
(	I-O
PTT	I-O
)	I-O
were	O
collected	O
at	O
baseline	O

and	O
after	O
14	O
days	O
of	O
the	O
intervention	O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Observation	O
of	O
therapeutic	O
effect	O
on	O
coronavirus	O
disease	O
2019	O
with	O
insomnia	O
in	O
treatment	O
with	O
baduanjin	B-I
and	O
auricular	B-I
point	I-I
sticking	I-I
therapy	I-I
]	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
90	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
accompanied	I-P
with	I-P
insomnia	I-P
were	O
randomly	O
divided	O
into	O
an	O
observation	O
group	O
(	O
45	O
cases	O
,	O
3	O
cases	O
dropped	O
off	O
)	O
and	O
a	O
control	O
group	O
(	O
45	O
cases	O
)	O
.	O

In	O
the	O
observation	O
group	O
,	O
baduanjin	B-I
,	O
a	B-I
traditional	I-I
Chinese	I-I
fitness	I-I
activity	I-I
,	O
was	O
practiced	O
everyday	O
.	O

Besides	O
,	O
auricular	B-I
point	I-I
sticking	I-I
therapy	I-I
was	O
exerted	O
at	O
ear	O
-	O
shenmen	O
(	O
TF	O
4	O
)	O
,	O
subcortex	O
(	O
AT	O
4	O
)	O
,	O
heart	O
(	O
CO	O
15	O
)	O
,	O
occiput	O
(	O
AT	O
3	O
)	O
,	O
etc	O
.	O

These	O
auricular	O
points	O
were	O
pressed	O
and	O
kneaded	O
three	O
times	O
a	O
day	O
,	O
30	O
s	O
at	O
each	O
point	O
each	O
time	O
,	O
consecutively	O
for	O
12	O
days	O
.	O

In	O
the	O
control	O
group	O
,	O
estazolam	B-C
tablets	O
were	O
prescribed	O
for	O
oral	O
administration	O
,	O
1	O
mg	O
,	O
once	O
daily	O
,	O
consecutively	O
for	O
12	O
days	O
.	O

Before	O
and	O
after	O
treatment	O
,	O
the	B-O
score	I-O
of	I-O
Pittsburgh	I-O
sleep	I-O
quality	I-O
index	I-O
(	I-O
PSQI	I-O
)	I-O
,	O
the	B-O
score	I-O
of	I-O
self	I-O
-	I-O
rating	I-O
anxiety	I-O
scale	I-O
(	I-O
SAS	I-O
)	I-O
,	O
the	B-O
score	I-O
of	I-O
self	I-O
-	I-O
rating	I-O
depression	I-O
scale	I-O
(	I-O
SDS	I-O
)	I-O
and	O
the	B-O
score	I-O
of	I-O
symptoms	I-O
in	I-O
traditional	I-O
Chinese	I-O
medicine	I-O
(	I-O
TCM	I-O
)	I-O
were	O
observed	O
in	O
the	O
two	O
groups	O
and	O
the	O
clinical	O
therapeutic	O
effect	O
was	O
evaluated	O
.	O

-DOCSTART-	O

Title	O
:	O
Hydroxychloroquine	B-I
in	O
mild	O
-	O
to	O
-	O
moderate	O
coronavirus	O
disease	O
2019	O
:	O
a	O
placebo	O
-	O
controlled	O
double	O
blind	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
multicentre	O
randomized	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
evaluating	O
hydroxychloroquine	B-I
in	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
with	I-P
at	I-P
least	I-P
one	I-P
of	I-P
the	I-P
following	I-P
risk	I-P
factors	I-P
for	I-P
worsening	I-P
:	I-P
need	I-P
for	I-P
supplemental	I-P
oxygen	I-P
,	I-P
age	I-P
?75	I-P
years	I-P
,	I-P
age	I-P
between	I-P
60	I-P
and	I-P
74	I-P
years	I-P
and	I-P
presence	I-P
of	I-P
at	I-P
least	I-P
one	I-P
co	I-P
-	I-P
morbidity	I-P
.	O

Severely	O
ill	O
patients	O
requiring	O
oxygen	O
therapy	O
>	O
3	O
L	O
/	O
min	O
or	O
intensive	O
care	O
were	O
excluded	O
.	O

Eligible	O
patients	O
were	O
randomized	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
either	O
800	B-I
mg	I-I
hydroxychloroquine	I-I
on	O
day	O
0	O
followed	O
by	O
400	O
mg	O
per	O
day	O
for	O
8	O
days	O
or	O
a	B-C
placebo	I-C
.	O

The	O
primary	O
end	O
point	O
was	O
a	B-O
composite	I-O
of	I-O
death	I-O
or	O
start	B-O
of	I-O
invasive	I-O
mechanical	I-O
ventilation	I-O
within	O
14	O
days	O
following	O
randomization	O
.	O

Secondary	O
end	O
points	O
included	O
mortality	B-O
and	O
clinical	B-O
evolution	I-O
at	O
days	O
14	O
and	O
28	O
,	O
and	O
viral	B-O
shedding	I-O
at	O
days	O
5	O
and	O
10	O
.	O

-DOCSTART-	O

Title	O
:	O
Chloroquine	B-I
nasal	O
drops	O
in	O
asymptomatic	O
&	O
mild	O
COVID	O
-	O
19	O
:	O
An	O
exploratory	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
clinical	O
trial	O
was	O
done	O
with	O
a	O
sample	O
size	O
of	O
60	O
.	O

Reverse	B-P
transcription	I-P
-	I-P
polymerase	I-P
chain	I-P
reaction	I-P
(	I-P
RT	I-P
-	I-P
PCR	I-P
)	I-P
confirmed	I-P
asymptomatic	I-P
patients	I-P
or	I-P
those	I-P
with	I-P
mild	I-P
COVID	I-P
-	I-P
19	I-P
illness	I-P
[	I-P
National	I-P
Early	I-P
Warning	I-P
Score	I-P
(	I-P
NEWS	I-P
)	I-P
?4	I-P
]	I-P
were	O
included	O
.	O

Patients	O
were	O
randomized	O
in	O
a	O
1	O
:	O
1	O
manner	O
.	O

Control	O
arm	O
(	O
standard	B-C
supportive	I-C
treatment	I-C
,	O
n=30	O
)	O
was	O
compared	O
with	O
intervention	O
arm	O
(	O
n=30	O
)	O
of	O
standard	B-I
treatment	I-I
plus	O
CQN	B-I
eye	O
drops	O
(	O
0	O
.	O
03	O
%	O
)	O
repurposed	O
as	O
nasal	O
drops	O
administered	O
six	O
times	O
daily	O
(	O
0	O
.	O
5	O
ml	O
/	O
dose	O
)	O
for	O
10	O
days	O
.	O

Outcome	O
measures	O
were	O
adverse	B-O
events	I-O
and	O
adherence	B-O
;	O
clinical	B-O
progression	I-O
and	O
outcomes	O
were	O
measured	O
by	O
NEWS	B-O
;	O
sequential	B-O
RT	I-O
-	I-O
PCR	I-O
cycle	I-O
threshold	I-O
(	I-O
Ct	I-O
)	I-O
values	I-O
were	O
also	O
noted	O
on	O
days	O
0	O
,	O
3	O
,	O
7	O
and	O
10	O
.	O

-DOCSTART-	O

Title	O
:	O
Telemanagement	O
of	O
Home	B-P
-	I-P
Isolated	I-P
COVID	I-P
-	I-P
19	I-P
Patients	I-P
Using	O
Oxygen	B-I
Therapy	I-I
With	O
Noninvasive	B-I
Positive	I-I
Pressure	I-I
Ventilation	I-I
and	O
Physical	B-I
Therapy	I-I
Techniques	I-I
:	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
In	O
this	O
single	O
-	O
blinded	O
randomized	O
clinical	O
trial	O
,	O
60	B-P
patients	I-P
with	I-P
stage	I-P
1	I-P
pneumonia	I-P
caused	I-P
by	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
were	O
treated	O
.	O

Group	O
A	O
(	O
n=30	O
)	O
received	O
oxygen	B-I
therapy	I-I
with	O
bilevel	B-I
positive	I-I
airway	I-I
pressure	I-I
(	I-I
BiPAP	I-I
)	I-I
ventilation	I-I
,	O
and	O
Group	O
B	O
(	O
n=30	O
)	O
received	O
osteopathic	B-I
manipulative	I-I
respiratory	I-I
and	O
physical	B-I
therapy	I-I
techniques	I-I
.	O

Arterial	B-O
blood	I-O
gases	I-O
of	I-O
PaO2	I-O
and	O
PaCO2	B-O
,	O
pH	B-O
,	O
vital	B-O
signs	I-O
(	O
ie	O
,	O
temperature	B-O
,	O
respiratory	B-O
rate	I-O
,	O
oxygen	B-O
saturation	I-O
,	O
heart	B-O
rate	I-O
,	O
and	O
blood	B-O
pressure	I-O
)	O
,	O
and	O
chest	B-O
computed	I-O
tomography	I-O
scans	I-O
were	O
used	O
for	O
follow	O
-	O
up	O
and	O
for	O
assessment	O
of	O
the	B-O
course	I-O
and	O
duration	B-O
of	I-O
recovery	I-O
.	O

-DOCSTART-	O

Title	O
:	O
What	O
about	O
tocilizumab	B-I
?	O
A	O
retrospective	O
study	O
from	O
a	O
NYC	O
Hospital	O
during	O
the	O
COVID	O
-	O
19	O
outbreak	O
.	O

METHODS	O
:	O
In	O
this	O
retrospective	O
analysis	O
of	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
admitted	I-P
between	I-P
March	I-P
2	I-P
and	I-P
April	I-P
14	I-P
,	I-P
2020	I-P
to	I-P
a	I-P
large	I-P
academic	I-P
medical	I-P
center	I-P
in	I-P
New	I-P
York	I-P
City	I-P
,	O
we	O
describe	O
outcomes	O
associated	O
with	O
tocilizumab	B-I
400	O
mg	O
(	O
without	B-I
methylprednisolone	I-I
)	O
compared	O
to	O
a	B-C
propensity	I-C
-	I-C
matched	I-C
control	O
.	O

The	O
primary	O
endpoints	O
were	O
change	O
in	O
a	B-O
7	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
of	I-O
oxygenation	I-O
and	O
ventilator	B-O
free	I-O
survival	I-O
,	O
both	O
at	O
days	O
14	O
and	O
28	O
.	O

Secondary	O
endpoints	O
include	O
incidence	B-O
of	I-O
bacterial	I-O
superinfections	I-O
and	O
gastrointestinal	B-O
perforation	I-O
.	O

Primary	O
outcomes	O
were	O
evaluated	O
using	O
t	O
-	O
test	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
two	O
-	O
arm	O
,	O
randomized	O
,	O
controlled	O
,	O
multi	O
-	O
centric	O
,	O
open	O
-	O
label	O
phase	O
-	O
2	O
study	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
Itolizumab	B-I
in	O
moderate	B-P
to	I-P
severe	I-P
ARDS	I-P
patients	I-P
due	I-P
to	I-P
COVID	I-P
-	I-P
19	I-P

OBJECTTIVE	O
:	O
Efficacy	O
and	O
safety	O
of	O
Itolizumab	O
,	O
an	O
immunomodulatory	O
mAb	O
,	O
in	O
treating	O
moderate	O
-	O
to	O
-	O
severe	O
acute	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
due	O
to	O
cytokine	O
release	O
in	O
COVID	O
-	O
19	O
patients	O
was	O
evaluated	O
in	O
a	O
multi	O
-	O
centric	O
,	O
open	O
-	O
label	O
,	O
two	O
-	O
arm	O
,	O
controlled	O
,	O
randomized	O
,	O
phase	O
-	O
2	O
study	O
.	O

METHODS	O
:	O
Patients	O
were	O
randomized	O
(	O
2	O
:	O
1	O
)	O
to	O
Arm	O
-	O
A	O
(	O
best	B-I
supportive	I-I
care	I-I
[	I-I
BSC	I-I
]	I-I
+	O
Itolizumab	B-I
)	O
and	O
Arm	O
-	O
B	O
(	O
BSC	B-C
)	O
.	O

Primary	O
outcome	O
of	O
interest	O
was	O
reduction	O
in	O
mortality	B-O
30	O
-	O
days	O
after	O
enrollment	O
.	O

-DOCSTART-	O

Title	O
:	O
Methylprednisolone	B-I
or	O
dexamethasone	B-C
,	O
which	O
one	O
is	O
superior	O
corticosteroid	O
in	O
the	O
treatment	O
of	O
hospitalized	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
:	O
a	O
triple	O
-	O
blinded	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
prospective	O
triple	O
-	O
blinded	O
randomized	O
controlled	O
trial	O
,	O
we	O
enrolled	O
86	B-P
hospitalized	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
from	I-P
August	I-P
to	I-P
November	I-P
2020	I-P
,	I-P
in	I-P
Shiraz	I-P
,	I-P
Iran	I-P
.	O

The	O
patients	O
were	O
randomly	O
allocated	O
into	O
two	O
groups	O
to	O
receive	O
either	O
methylprednisolone	B-I
(	O
2	O
mg	O
/	O
kg	O
/	O
day	O
;	O
intervention	O
group	O
)	O
or	O
dexamethasone	B-C
(	O
6	O
mg	O
/	O
day	O
;	O
control	O
group	O
)	O
.	O

Data	O
were	O
assessed	O
based	O
on	O
a	B-O
9	I-O
-	I-O
point	I-O
WHO	I-O
ordinal	I-O
scale	I-O
extending	O
from	O
uninfected	O
(	O
point	O
0	O
)	O
to	O
death	O
(	O
point	O
8	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
nasal	B-I
corticosteroid	I-I
in	O
the	O
treatment	O
of	O
anosmia	O
due	O
to	O
COVID	O
-	O
19	O
:	O
A	O
randomised	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
study	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
designed	O
as	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
clinical	O
trial	O
.	O

In	O
total	O
,	O
276	B-P
PCR	I-P
-	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
who	I-P
were	I-P
presented	I-P
to	I-P
the	I-P
outpatient	I-P
clinic	I-P
with	I-P
anosmia	I-P
were	O
enrolled	O
in	O
the	O
study	O
.	O

In	O
the	B-I
betamethasone	I-I
group	O
,	O
138	O
participants	O
received	O
nasal	B-I
drops	I-I
of	I-I
betamethasone	I-I
3	O
times	O
daily	O
until	O
recovery	O
for	O
a	O
maximum	O
of	O
one	O
month	O
.	O

Similar	B-C
dose	I-C
of	I-C
9	I-C
%	I-C
NaCl	I-C
drops	O
was	O
administered	O
to	O
138	O
participants	O
in	O
the	B-C
placebo	I-C
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Severe	B-I
Acute	I-I
Respiratory	I-I
Syndrome	I-I
Coronavirus	I-I
2	I-I
Convalescent	I-I
Plasma	I-I
Versus	O
Standard	B-C
Plasma	I-C
in	O
Coronavirus	B-P
Disease	I-P
2019	I-P
Infected	I-P
Hospitalized	I-P
Patients	I-P
in	I-P
New	I-P
York	I-P
:	O
A	O
Double	O
-	O
Blind	O
Randomized	O
Trial	O
.	O

METHODS	O
:	O
Double	O
-	O
blind	O
randomized	O
controlled	O
trial	O
.	O

Hospital	O
in	O
New	O
York	O
.	O

Patients	B-P
with	I-P
polymerase	I-P
chain	I-P
reaction	I-P
documented	I-P
coronavirus	I-P
disease	I-P
2019	I-P
infection	I-P
.	O

Patients	O
were	O
randomized	O
(	O
4	O
:	O
1	O
)	O
to	O
receive	O
2	B-I
U	I-I
of	I-I
convalescent	I-I
plasma	I-I
versus	O
standard	B-C
plasma	I-C
.	O

Antibodies	B-O
to	I-O
severe	I-O
acute	I-O
respiratory	I-O
syndrome	I-O
coronavirus	I-O
2	I-O
were	O
measured	O
in	O
plasma	O
units	O
and	O
in	O
trial	O
recipients	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Ammonium	B-I
Chloride	I-I
in	O
addition	O
to	O
standard	B-I
of	I-I
care	I-I
in	O
outpatients	B-P
and	I-P
hospitalized	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
:	O
A	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
double	O
-	O
blind	O
,	O
single	O
-	O
center	O
study	O
,	O
we	O
enrolled	O
patients	B-P
with	I-P
positive	I-P
PCR	I-P
test	I-P
and	I-P
/	I-P
or	I-P
CT	I-P
findings	I-P
for	I-P
COVID	I-P
-	I-P
19	I-P
.	O

The	O
participants	O
of	O
each	O
group	O
were	O
randomly	O
assigned	O
to	O
Diphenhydramine	B-I
Compound	I-I
(	O
Diphenhydramine	B-I
+	O
Ammonium	B-I
Chloride	I-I
)	O
plus	O
standard	B-I
of	I-I
care	I-I
or	O
to	O
Diphenhydramine	B-C
alone	I-C
and	O
standard	B-C
of	I-C
care	I-C
groups	O
.	O

The	O
primary	O
outcome	O
was	O
all	B-O
-	I-O
cause	I-O
mortality	I-O
within	O
30	O
days	O
of	O
randomization	O
.	O

Secondary	O
outcomes	O
include	O
viral	B-O
burden	I-O
,	O
clinical	B-O
status	I-O
,	O
assessed	O
by	O
a	B-O
5	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
,	O
and	O
length	B-O
of	I-O
stay	I-O
in	O
hospitalized	O
patients	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Early	B-I
Treatment	I-I
With	I-I
Hydroxychloroquine	I-I
or	O
Lopinavir	B-I
and	O
Ritonavir	B-I
on	O
Risk	O
of	O
Hospitalization	O
Among	O
Patients	B-P
With	I-P
COVID	I-P
-	I-P
19	I-P
:	O
The	O
TOGETHER	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
clinical	O
trial	O
was	O
conducted	O
in	O
Brazil	O
.	O

Recently	B-P
symptomatic	I-P
adults	I-P
diagnosed	I-P
with	I-P
respiratory	I-P
symptoms	I-P
from	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
were	O
enrolled	O
between	O
June	O
2	O
and	O
September	O
30	O
,	O
2020	O
.	O

The	O
planned	O
sample	O
size	O
was	O
1476	O
patients	O
,	O
with	O
interim	O
analyses	O
planned	O
after	O
500	O
patients	O
were	O
enrolled	O
.	O

The	O
trial	O
was	O
stopped	O
after	O
the	O
interim	O
analysis	O
for	O
futility	O
with	O
a	O
sample	O
size	O
of	O
685	O
patients	O
.	O

Statistical	O
analysis	O
was	O
performed	O
in	O
December	O
2020	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
hydroxychloroquine	B-I
(	O
800	O
mg	O
loading	O
dose	O
,	O
then	O
400	O
mg	O
daily	O
for	O
9	O
days	O
)	O
,	O
lopinavir	B-I
-	O
ritonavir	B-I
(	O
loading	O
dose	O
of	O
800	O
mg	O
and	O
200	O
mg	O
,	O
respectively	O
,	O
every	O
12	O
hours	O
followed	O
by	O
400	O
mg	O
and	O
100	O
mg	O
,	O
respectively	O
,	O
every	O
12	O
hours	O
for	O
the	O
next	O
9	O
days	O
)	O
,	O
or	O
placebo	B-C
.	O

The	O
primary	O
outcomes	O
were	O
COVID	B-O
-	I-O
19	I-O
-	I-O
associated	I-O
hospitalization	I-O
and	O
death	B-O
assessed	O
at	O
90	O
days	O
after	O
randomization	O
.	O

COVID	B-O
-	I-O
19	I-O
-	I-O
associated	I-O
hospitalization	I-O
was	O
analyzed	O
with	O
a	O
Cox	O
proportional	O
hazards	O
model	O
.	O

The	O
trial	O
included	O
the	O
following	O
secondary	O
outcomes	O
:	O
all	B-O
-	I-O
cause	I-O
hospitalization	I-O
,	O
viral	B-O
clearance	I-O
,	O
symptom	B-O
resolution	I-O
,	O
and	O
adverse	B-O
events	I-O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
Efficacy	O
of	O
Computerized	B-I
Cognitive	I-I
Behavioral	I-I
Therapy	I-I
for	O
Depressive	O
and	O
Anxiety	O
Symptoms	O
in	O
Patients	B-P
With	I-P
COVID	I-P
-	I-P
19	I-P
:	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
We	O
customized	O
a	B-I
cCBT	I-I
program	I-I
focused	O
on	O
improving	O
depressive	O
and	O
anxiety	O
symptoms	O
among	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
,	O
and	O
then	O
,	O
we	O
assessed	O
its	O
effectiveness	O
.	O

Screening	O
was	O
based	O
on	O
symptoms	O
of	O
depression	O
or	O
anxiety	O
for	O
patients	O
who	O
scored	O
?7	O
on	O
the	O
Hamilton	O
Depression	O
Rating	O
Scale	O
(	O
HAMD17	O
)	O
or	O
the	O
Hamilton	O
Anxiety	O
Scale	O
(	O
HAMA	O
)	O
.	O

A	B-P
total	I-P
of	I-P
252	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
at	I-P
five	I-P
sites	I-P
were	O
randomized	O
into	O
two	O
groups	O
:	O
cCBT	B-I
+	O
treatment	B-I
as	I-I
usual	I-I
(	I-I
TAU	I-I
;	O
n=126	O
)	O
and	O
TAU	B-C
without	O
cCBT	B-C
(	O
n=126	O
)	O
.	O

The	B-I
cCBT	I-I
+	O
TAU	B-I
group	O
received	O
the	B-I
cCBT	I-I
intervention	I-I
program	I-I
for	O
1	O
week	O
.	O

The	O
primary	O
efficacy	O
measures	O
were	O
the	B-O
HAMD17	I-O
and	O
HAMA	B-O
scores	I-O
.	O

The	O
secondary	O
outcome	O
measures	O
were	O
the	B-O
Self	I-O
-	I-O
Rating	I-O
Depression	I-O
Scale	I-O
(	I-O
SDS	I-O
)	I-O
,	O
Self	B-O
-	I-O
Rating	I-O
Anxiety	I-O
Scale	I-O
(	I-O
SAS	I-O
)	I-O
,	O
and	O
Athens	B-O
Insomnia	I-O
Scale	I-O
(	I-O
AIS	I-O
)	I-O
.	O

Assessments	O
were	O
carried	O
out	O
pre	O
-	O
and	O
postintervention	O
.	O

The	B-O
patients	I-O
'	I-O
symptoms	I-O
of	I-O
anxiety	I-O
and	O
depression	B-O
in	O
one	O
of	O
the	O
centers	O
were	O
assessed	O
again	O
within	O
1	O
month	O
after	O
the	O
postintervention	O
assessment	O
.	O

-DOCSTART-	O

Title	O
:	O
Favipiravir	B-I
in	O
the	O
treatment	O
of	O
patients	B-P
with	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
RNA	I-P
recurrent	I-P
positive	I-P
after	I-P
discharge	I-P
:	O
A	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
randomized	O
trial	O
.	O

METHODS	O
:	O
This	O
is	O
a	O
multicenter	O
,	O
open	O
-	O
label	O
,	O
randomized	O
controlled	O
trial	O
in	O
SARS	B-P
-	I-P
CoV	I-P
-	I-P
2	I-P
RNA	I-P
re	I-P
-	I-P
positive	I-P
patients	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
2	O
:	O
1	O
ratio	O
to	O
receive	O
either	O
favipiravir	B-I
,	O
in	O
addition	O
to	O
standard	B-I
care	I-I
,	O
or	O
standard	B-C
care	I-C
alone	I-C
.	O

The	O
primary	O
outcome	O
was	O
time	B-O
to	I-O
achieve	I-O
a	I-O
consecutive	I-O
twice	I-O
(	I-O
at	I-O
intervals	I-O
of	I-O
more	I-O
than	I-O
24	I-O
h	I-O
)	I-O
negative	I-O
RT	I-O
-	I-O
PCR	I-O
result	I-O
for	I-O
SARS	I-O
-	I-O
CoV	I-O
-	I-O
2	I-O
RNA	I-O
in	I-O
nasopharyngeal	I-O
swab	I-O
and	O
sputum	B-O
sample	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
the	O
effectiveness	O
and	O
safety	O
of	O
adding	O
ivermectin	B-I
to	O
treatment	O
in	O
severe	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
severe	I-P
COVID19	I-P
pneumonia	I-P
were	O
included	O
in	O
the	O
study	O
,	O
which	O
was	O
planned	O
as	O
a	O
prospective	O
,	O
randomized	O
,	O
controlled	O
,	O
single	O
-	O
blind	O
phase	O
3	O
study	O
.	O

Two	O
groups	O
,	O
the	O
study	O
group	O
and	O
the	O
control	O
group	O
,	O
took	O
part	O
in	O
the	O
study	O
.	O

Ivermectin	B-I
200	O
mcg	O
/	O
kg	O
/	O
day	O
for	O
5	O
days	O
in	O
the	O
form	O
of	O
a	O
solution	O
prepared	O
for	O
enteral	O
use	O
added	O
to	O
the	B-I
reference	I-I
treatment	I-I
protocol	I-I
-	O
hydroxychloroquine	B-I
+	O
favipiravir	B-I
+	O
azithromycin	B-I
-	O
of	O
patients	O
included	O
in	O
the	O
study	O
group	O
.	O

Patients	O
in	O
the	O
control	O
group	O
were	O
given	O
only	B-C
reference	I-C
treatment	I-C
with	I-C
3	I-C
other	I-C
drugs	I-C
without	I-C
ivermectin	I-C
.	O

The	O
presence	O
of	O
mutations	O
was	O
investigated	O
by	O
performing	O
sequence	O
analysis	O
in	O
the	O
mdr1	O
/	O
abcab1	O
gene	O
with	O
the	O
Sanger	O
method	O
in	O
patients	O
included	O
in	O
the	O
study	O
group	O
according	O
to	O
randomization	O
.	O

Patients	O
with	O
mutations	O
were	O
excluded	O
from	O
the	O
study	O
and	O
ivermectin	B-I
treatment	I-I
was	O
not	O
continued	O
.	O

Patients	O
were	O
followed	O
for	O
5	O
days	O
after	O
treatment	O
.	O

At	O
the	O
end	O
of	O
the	O
treatment	O
and	O
follow	O
-	O
up	O
period	O
,	O
clinical	B-O
response	I-O
and	O
changes	O
in	O
laboratory	B-O
parameters	I-O
were	O
evaluated	O
.	O

-DOCSTART-	O

Title	O
:	O
Standard	B-C
Care	I-C
Versus	O
Awake	B-I
Prone	I-I
Position	I-I
in	O
Adult	B-P
Nonintubated	I-P
Patients	I-P
With	I-P
Acute	I-P
Hypoxemic	I-P
Respiratory	I-P
Failure	I-P
Secondary	I-P
to	I-P
COVID	I-P
-	I-P
19	I-P
Infection	I-P
-	O
A	O
Multicenter	O
Feasibility	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
60	B-P
patients	I-P
with	I-P
acute	I-P
hypoxic	I-P
respiratory	I-P
failure	I-P
secondary	I-P
to	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
requiring	I-P
4	I-P
or	I-P
more	I-P
liters	I-P
of	I-P
oxygen	I-P
to	I-P
maintain	I-P
a	I-P
saturation	I-P
of	I-P
?92	I-P
%	I-P
were	O
recruited	O
in	O
this	O
study	O
.	O

Thirty	O
patients	O
each	O
were	O
randomized	O
to	O
either	O
standard	B-C
care	I-C
or	O
awake	B-I
prone	I-I
group	O
.	O

Patients	O
randomized	O
to	O
the	B-I
prone	I-I
group	O
were	O
encouraged	O
to	O
self	O
-	O
prone	O
for	O
at	O
least	O
6	O
hours	O
a	O
day	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
proportion	I-O
of	I-O
patients	I-O
adhering	I-O
to	I-O
the	I-O
protocol	I-O
in	O
each	O
group	O
.	O

-DOCSTART-	O

Title	O
:	O
Ivermectin	B-I
in	O
combination	O
with	O
doxycycline	B-I
for	O
treating	O
COVID	O
-	O
19	O
symptoms	O
:	O
a	O
randomized	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
randomized	O
,	O
blinded	O
,	O
placebo	O
-	O
controlled	O
trial	O
in	O
patients	B-P
with	I-P
mild	I-P
-	I-P
to	I-P
-	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
symptoms	I-P
randomly	O
assigned	O
to	O
treatment	O
(	O
n	O
=	O
200	O
)	O
and	O
placebo	B-C
(	O
n	O
=	O
200	O
)	O
groups	O
.	O

The	O
primary	O
outcome	O
was	O
duration	B-O
from	I-O
treatment	I-O
to	I-O
clinical	I-O
recovery	I-O
.	O

Secondary	O
outcomes	O
were	O
disease	B-O
progression	I-O
and	O
persistent	B-O
COVID	I-O
-	I-O
19	I-O
positivity	I-O
by	I-O
RT	I-O
-	I-O
PCR	I-O
.	O

METHODS	O
:	O
Dryad	O
.	O

doi	O
:	O
10	O
.	O
5061	O
/	O
dryad	O
.	O
qjq2bvqf6	O
.	O

-DOCSTART-	O

Title	O
:	O
Cytokine	B-I
adsorption	I-I
in	O
patients	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
requiring	I-P
extracorporeal	I-P
membrane	I-P
oxygenation	I-P
(	O
CYCOV	O
)	O
:	O
a	O
single	O
centre	O
,	O
open	O
-	O
label	O
,	O
randomised	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
single	O
-	O
centre	O
,	O
open	O
-	O
label	O
,	O
randomised	O
,	O
controlled	O
trial	O
to	O
investigate	O
cytokine	B-I
adsorption	I-I
in	O
adult	B-P
patients	I-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
requiring	I-P
ECMO	I-P
.	O

Patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
selected	I-P
for	I-P
ECMO	I-P
at	I-P
the	I-P
Freiburg	I-P
University	I-P
Medical	I-P
Center	I-P
(	I-P
Freiburg	I-P
,	I-P
Germany	I-P
)	I-P
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
to	O
receive	O
cytokine	B-I
adsorption	I-I
using	O
the	B-I
CytoSorb	I-I
device	I-I
or	O
not	B-C
.	O

Randomisation	O
was	O
computer	O
-	O
generated	O
,	O
allocation	O
was	O
concealed	O
by	O
opaque	O
,	O
sequentially	O
numbered	O
sealed	O
envelopes	O
.	O

The	O
CytoSorb	O
device	O
was	O
incorporated	O
into	O
the	O
ECMO	O
circuit	O
before	O
connection	O
to	O
the	O
patient	O
circuit	O
,	O
replaced	O
every	O
24	O
h	O
,	O
and	O
removed	O
after	O
72	O
h	O
.	O

The	O
primary	O
endpoint	O
was	O
serum	B-O
interleukin	I-O
-	I-O
6	I-O
(	I-O
IL	I-O
-	I-O
6	I-O
)	I-O
concentration	I-O
72	O
h	O
after	O
initiation	O
of	O
ECMO	O
analysed	O
by	O
intention	O
to	O
treat	O
.	O

Secondary	O
endpoints	O
included	O
30	B-O
-	I-O
day	I-O
survival	I-O
.	O

The	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
(	O
NCT04324528	O
)	O
and	O
the	O
German	O
Clinical	O
Trials	O
Register	O
(	O
DRKS00021300	O
)	O
and	O
is	O
closed	O
.	O

-DOCSTART-	O

Title	O
:	O
Dexamethasone	B-I
vs	O
methylprednisolone	B-I
high	O
dose	O
for	O
Covid	O
-	O
19	O
pneumonia	O
.	O

METHODS	O
:	O
Ambispective	O
cohort	O
study	O
with	O
survival	O
analysis	O
of	O
216	B-P
patients	I-P
diagnosed	I-P
with	I-P
severe	I-P
Covid	I-P
-	I-P
19	I-P
pneumonia	I-P
confirmed	I-P
by	I-P
polymerase	I-P
chain	I-P
reaction	I-P
for	I-P
SARS	I-P
-	I-P
CoV2	I-P
by	I-P
Berlin	I-P
protocol	I-P
,	I-P
who	I-P
were	I-P
hospitalized	I-P
in	I-P
a	I-P
high	I-P
-	I-P
complexity	I-P
clinic	I-P
in	I-P
Medelln	I-P
,	I-P
Colombia	I-P
.	O

The	O
patients	O
should	O
also	O
have	O
supplementary	O
oxygen	O
and	O
radiological	O
confirmation	O
of	O
Pneumonia	O
by	O
chest	O
tomography	O
.	O

Sample	O
size	O
was	O
not	O
calculated	O
since	O
the	O
total	O
population	O
that	O
met	O
the	O
inclusion	O
criteria	O
was	O
evaluated	O
.	O

111	O
patients	O
were	O
treated	O
with	O
the	O
institutional	O
protocol	O
with	O
intravenous	B-I
dexamethasone	I-I
6	O
mg	O
QD	O
for	O
seven	O
to	O
10	O
days	O
if	O
they	O
required	O
oxygen	O
.	O

Since	O
September	O
15	O
,	O
2020	O
,	O
the	O
hospitalization	O
protocol	O
of	O
the	O
clinic	O
was	O
modified	O
by	O
the	O
Infectious	O
Diseases	O
and	O
Pulmonology	O
service	O
,	O
recommending	O
a	B-I
high	I-I
dose	I-I
of	I-I
methylprednisolone	I-I
of	O
250	O
to	O
500	O
mg	O
every	O
day	O
for	O
three	O
days	O
with	O
a	O
subsequent	O
change	O
to	O
oral	O
prednisone	O
50	O
mg	O
every	O
day	O
for	O
14	O
days	O
.	O

The	O
protocol	O
was	O
not	O
applied	O
in	O
the	O
intensive	O
care	O
unit	O
,	O
where	O
dexamethasone	B-I
continued	O
to	O
be	O
administered	O
.	O

The	B-O
clinical	I-O
outcome	I-O
and	O
differences	O
in	O
laboratory	B-O
results	I-O
of	O
the	O
patients	O
who	O
received	O
dexamethasone	B-I
vs	O
.	O
the	O
prospective	O
cohort	O
that	O
received	O
methylprednisolone	B-I
from	O
September	O
15	O
to	O
October	O
31	O
,	O
2020	O
,	O
were	O
evaluated	O
.	O

Follow	O
-	O
up	O
was	O
carried	O
out	O
by	O
outpatient	O
consultation	O
one	O
month	O
after	O
discharge	O
or	O
by	O
telephone	O
,	O
inquiring	O
about	O
readmission	B-O
or	O
living	B-O
-	I-O
dead	I-O
status	I-O
.	O

-DOCSTART-	O

Title	O
:	O
[	O
Post	O
-	O
COVID	O
-	O
19	O
asthenic	O
syndrome	O
]	O
.	O

METHODS	O
:	O
The	O
study	O
included	O
129	B-P
patients	I-P
with	I-P
an	I-P
average	I-P
age	I-P
of	I-P
49	I-P
.	I-P
88	I-P
.	I-P

9	I-P
years	I-P
who	I-P
had	I-P
undergone	I-P
COVID	I-P
-	I-P
19	I-P
using	I-P
a	I-P
continuous	I-P
sample	I-P
method	I-P
.	O

Patients	O
for	O
the	O
study	O
were	O
selected	O
at	O
the	O
clinical	O
bases	O
of	O
outpatient	O
clinics	O
in	O
Samara	O
(	O
Russia	O
)	O
in	O
July	O
-	O
August	O
2020	O
.	O

All	O
patients	O
signed	O
an	O
informed	O
consent	O
form	O
prior	O
to	O
enrollment	O
.	O

Patients	O
were	O
randomized	O
into	O
two	O
groups	O
:	O
in	O
the	O
main	O
group	O
(	O
n=64	O
)	O
,	O
ethylmethylhydroxypyridine	B-I
succinate	I-I
(	O
Neurox	B-I
)	O
was	O
prescribed	O
1	O
tablet	O
(	O
125	O
mg	O
)	O
3	O
times	O
a	O
day	O
for	O
4	O
weeks	O
;	O
in	O
the	O
comparison	O
group	O
(	O
n=65	O
)	O
,	O
medical	B-C
drugs	I-C
(	I-C
MD	I-C
)	I-C
did	O
not	O
contain	O
substances	O
from	O
the	O
pharmacological	O
group	O
related	O
to	O
antihypoxants	O
/	O
antioxidants	O
/	O
nootropics	O
.	O

Three	O
visits	O
(	O
V	O
)	O
were	O
conducted	O
:	O
the	O
first	O
(	O
V1	O
)	O
-	O
the	O
period	O
of	O
inclusion	O
,	O
the	O
second	O
(	O
V2	O
)	O
-	O
after	O
14	O
days	O
,	O
the	O
third	O
(	O
V3	O
)	O
-	O
on	O
the	O
28	O
th	O
day	O
from	O
the	O
start	O
of	O
therapy	O
.	O

The	B-O
dynamics	I-O
of	I-O
the	I-O
general	I-O
state	I-O
(	O
weakness	B-O
,	O
fatigue	B-O
,	O
concentration	B-O
,	O
dizziness	B-O
,	O
headache	B-O
,	O
sleep	B-O
disorders	I-O
)	O
were	O
evaluated	O
on	O
a	B-O
visual	I-O
-	I-O
analog	I-O
scale	I-O
(	I-O
VAS	I-O
)	I-O
,	O
the	B-O
assessment	I-O
of	I-O
the	I-O
subjective	I-O
feeling	I-O
of	I-O
severity	I-O
of	I-O
asthenia	I-O
(	O
fatigue	B-O
,	O
physical	B-O
and	O
mental	B-O
fatigue	I-O
,	O
decreased	B-O
motivation	I-O
and	O
activity	B-O
)	O
-	O
on	O
Multidimensional	B-O
Fatigue	I-O
Inventory	I-O
(	I-O
MFI	I-O
-	I-O
20	I-O
)	I-O
,	O
cognitive	B-O
functions	I-O
-	O
on	O
Mini	B-O
-	I-O
Mental	I-O
State	I-O
Examination	I-O
(	I-O
MMSE	I-O
)	I-O
,	O
vegetative	B-O
tone	I-O
-	O
according	O
to	O
the	B-O
Kerdo	I-O
index	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
sofosbuvir	B-I
/	O
velpatasvir	B-I
versus	O
the	B-C
standard	I-C
of	I-C
care	I-C
in	O
adults	B-P
hospitalized	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
single	O
-	O
centre	O
,	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
single	O
-	O
centre	O
,	O
randomized	O
,	O
open	O
-	O
labelled	O
,	O
prospective	O
clinical	O
trial	O
was	O
done	O
in	O
patients	B-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
admitted	I-P
to	I-P
Farabi	I-P
Hospital	I-P
in	I-P
Kermanshah	I-P
Province	I-P
,	I-P
Iran	I-P
.	O

Eligible	O
patients	O
were	O
randomly	O
assigned	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
the	B-I
SOF	I-I
/	O
VEL	B-I
arm	O
(	O
SOF	B-I
/	O
VEL	B-I
plus	O
the	B-I
national	I-I
standard	I-I
of	I-I
care	I-I
)	O
or	O
the	O
control	O
arm	O
(	O
the	B-C
national	I-C
standard	I-C
of	I-C
care	I-C
alone	I-C
)	O
.	O

The	O
main	O
outcome	O
of	O
the	O
study	O
was	O
the	B-O
mortality	I-O
on	O
Day	O
28	O
after	O
randomization	O
.	O

Secondary	O
outcomes	O
were	O
time	B-O
from	I-O
the	I-O
start	I-O
of	I-O
medication	I-O
to	I-O
clinical	I-O
improvement	I-O
,	O
hospital	B-O
length	I-O
of	I-O
stay	I-O
,	O
need	B-O
for	I-O
mechanical	I-O
ventilation	I-O
,	O
duration	B-O
of	I-O
mechanical	I-O
ventilation	I-O
and	O
conversion	B-O
of	I-O
RT	I-O
-	I-O
PCR	I-O
results	I-O
from	I-O
positive	I-O
to	I-O
negative	I-O
from	O
the	O
time	O
of	O
randomization	O
to	O
discharge	O
.	O

Adverse	B-O
events	I-O
were	O
evaluated	O
in	O
all	O
patients	O
who	O
started	O
their	O
assigned	O
treatment	O
.	O

-DOCSTART-	O

Title	O
:	O
Colchicine	B-I
for	O
community	B-P
-	I-P
treated	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
(	O
COLCORONA	O
)	O
:	O
a	O
phase	O
3	O
,	O
randomised	O
,	O
double	O
-	O
blinded	O
,	O
adaptive	O
,	O
placebo	O
-	O
controlled	O
,	O
multicentre	O
trial	O
.	O

METHODS	O
:	O
The	O
present	O
study	O
is	O
a	O
phase	O
3	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
adaptive	O
,	O
placebo	O
-	O
controlled	O
,	O
multicentre	O
trial	O
.	O

The	O
study	O
was	O
done	O
in	O
Brazil	O
,	O
Canada	O
,	O
Greece	O
,	O
South	O
Africa	O
,	O
Spain	O
,	O
and	O
the	O
USA	O
,	O
and	O
was	O
led	O
by	O
the	O
Montreal	O
Heart	O
Institute	O
.	O

Patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
diagnosed	I-P
by	I-P
PCR	I-P
testing	I-P
or	I-P
clinical	I-P
criteria	I-P
who	I-P
were	I-P
not	I-P
being	I-P
treated	I-P
in	I-P
hospital	I-P
were	O
eligible	O
if	O
they	O
were	O
at	O
least	O
40	O
years	O
old	O
and	O
had	O
at	O
least	O
one	O
high	O
-	O
risk	O
characteristic	O
.	O

The	O
randomisation	O
list	O
was	O
computer	O
-	O
generated	O
by	O
an	O
unmasked	O
biostatistician	O
,	O
and	O
masked	O
randomisation	O
was	O
centralised	O
and	O
done	O
electronically	O
through	O
an	O
automated	O
interactive	O
web	O
-	O
response	O
system	O
.	O

The	O
allocation	O
sequence	O
was	O
unstratified	O
and	O
used	O
a	O
1	O
:	O
1	O
ratio	O
with	O
a	O
blocking	O
schema	O
and	O
block	O
sizes	O
of	O
six	O
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
orally	B-I
administered	I-I
colchicine	I-I
(	O
05	O
mg	O
twice	O
per	O
day	O
for	O
3	O
days	O
and	O
then	O
once	O
per	O
day	O
for	O
27	O
days	O
thereafter	O
)	O
or	O
matching	B-C
placebo	I-C
.	O

The	O
primary	O
efficacy	O
endpoint	O
was	O
the	B-O
composite	I-O
of	I-O
death	I-O
or	O
hospital	B-O
admission	I-O
for	I-O
COVID	I-O
-	I-O
19	I-O
.	O

Vital	B-O
status	I-O
at	O
the	O
end	O
of	O
the	O
study	O
was	O
available	O
for	O
979	O
%	O
of	O
patients	O
.	O

The	O
analyses	O
were	O
done	O
according	O
to	O
the	O
intention	O
-	O
to	O
-	O
treat	O
principle	O
.	O

The	O
COLCORONA	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
(	O
NCT04322682	O
)	O
and	O
is	O
now	O
closed	O
to	O
new	O
participants	O
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
Single	I-I
Dose	I-I
of	I-I
Ivermectin	I-I
on	O
Viral	O
and	O
Clinical	O
Outcomes	O
in	O
Asymptomatic	B-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
Infected	I-P
Subjects	I-P
:	O
A	O
Pilot	O
Clinical	O
Trial	O
in	O
Lebanon	O
.	O

METHODS	O
:	O
A	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
in	O
100	B-P
asymptomatic	I-P
Lebanese	I-P
subjects	I-P
that	I-P
have	I-P
tested	I-P
positive	I-P
for	I-P
SARS	I-P
-	I-P
CoV2	I-P
.	O

Fifty	O
patients	O
received	O
standard	B-C
preventive	I-C
treatment	I-C
,	O
mainly	B-C
supplements	I-C
,	O
and	O
the	O
experimental	O
group	O
received	O
a	B-I
single	I-I
dose	I-I
(	I-I
according	I-I
to	I-I
body	I-I
weight	I-I
)	I-I
of	I-I
ivermectin	I-I
,	O
in	O
addition	O
to	O
the	B-I
same	I-I
supplements	I-I
the	O
control	O
group	O
received	O
.	O

-DOCSTART-	O

Title	O
:	O
Therapeutic	B-I
versus	O
prophylactic	B-C
anticoagulation	I-C
for	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
elevated	I-P
D	I-P
-	I-P
dimer	I-P
concentration	I-P
(	O
ACTION	O
)	O
:	O
an	O
open	O
-	O
label	O
,	O
multicentre	O
,	O
randomised	O
,	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
pragmatic	O
,	O
open	O
-	O
label	O
(	O
with	O
blinded	O
adjudication	O
)	O
,	O
multicentre	O
,	O
randomised	O
,	O
controlled	O
trial	O
,	O
at	O
31	O
sites	O
in	O
Brazil	O
.	O

Patients	B-P
(	I-P
aged	I-P
?18	I-P
years	I-P
)	I-P
hospitalised	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
elevated	I-P
D	I-P
-	I-P
dimer	I-P
concentration	I-P
,	I-P
and	I-P
who	I-P
had	I-P
COVID	I-P
-	I-P
19	I-P
symptoms	I-P
for	I-P
up	I-P
to	I-P
14	I-P
days	I-P
before	I-P
randomisation	I-P
,	O
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
to	O
receive	O
either	O
therapeutic	B-I
or	O
prophylactic	B-C
anticoagulation	I-C
.	O

Therapeutic	B-I
anticoagulation	I-I
was	O
in	B-I
-	I-I
hospital	I-I
oral	I-I
rivaroxaban	I-I
(	O
20	O
mg	O
or	O
15	O
mg	O
daily	O
)	O
for	O
stable	O
patients	O
,	O
or	O
initial	B-I
subcutaneous	I-I
enoxaparin	I-I
(	O
1	O
mg	O
/	O
kg	O
twice	O
per	O
day	O
)	O
or	O
intravenous	B-I
unfractionated	I-I
heparin	I-I
(	O
to	O
achieve	O
a	O
03	O
-	O
07	O
IU	O
/	O
mL	O
anti	O
-	O
Xa	O
concentration	O
)	O
for	O
clinically	O
unstable	O
patients	O
,	O
followed	O
by	O
rivaroxaban	B-I
to	O
day	O
30	O
.	O

Prophylactic	B-C
anticoagulation	I-C
was	O
standard	B-C
in	I-C
-	I-C
hospital	I-C
enoxaparin	I-C
or	O
unfractionated	B-C
heparin	I-C
.	O

The	O
primary	O
efficacy	O
outcome	O
was	O
a	O
hierarchical	O
analysis	O
of	O
time	B-O
to	I-O
death	I-O
,	O
duration	B-O
of	I-O
hospitalisation	I-O
,	O
or	O
duration	B-O
of	I-O
supplemental	I-O
oxygen	I-O
to	O
day	O
30	O
,	O
analysed	O
with	O
the	O
win	O
ratio	O
method	O
(	O
a	O
ratio	O
>	O
1	O
reflects	O
a	O
better	O
outcome	O
in	O
the	O
therapeutic	O
anticoagulation	O
group	O
)	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

The	O
primary	O
safety	O
outcome	O
was	O
major	B-O
or	O
clinically	B-O
relevant	I-O
non	I-O
-	I-O
major	I-O
bleeding	I-O
through	O
30	O
days	O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
(	O
NCT04394377	O
)	O
and	O
is	O
completed	O
.	O

-DOCSTART-	O

Title	O
:	O
Magnesium	B-I
treatment	I-I
on	O
methylation	O
changes	O
of	O
transmembrane	O
serine	O
protease	O
2	O
(	O
TMPRSS2	O
)	O
.	O

METHODS	O
:	O
This	O
study	O
is	O
nested	O
within	O
the	O
Personalized	O
Prevention	O
of	O
Colorectal	O
Cancer	O
Trial	O
,	O
a	O
double	O
-	O
blind	O
2	O
	O
2	O
factorial	O
randomized	O
controlled	O
trial	O
,	O
which	O
enrolled	O
250	B-P
participants	I-P
from	I-P
Vanderbilt	I-P
University	I-P
Medical	I-P
Center	I-P
.	O

-DOCSTART-	O

Title	O
:	O
Feasibility	O
and	O
outcome	O
of	O
an	B-I
online	I-I
streamed	I-I
yoga	I-I
intervention	I-I
on	O
stress	O
and	O
wellbeing	O
of	O
people	B-P
working	I-P
from	I-P
home	I-P
during	I-P
COVID	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
A	O
six	O
-	O
week	O
pilot	O
randomized	O
controlled	O
trial	O
(	O
RCT	O
)	O
yoga	O
intervention	O
was	O
designed	O
with	O
yoga	B-I
(	O
n	O
=	O
26	O
)	O
and	O
a	B-C
wait	I-C
-	I-C
list	I-C
control	I-C
group	O
(	O
n	O
=	O
26	O
)	O
.	O

A	O
mixed	O
two	O
-	O
way	O
ANOVA	O
was	O
used	O
to	O
assess	O
changes	O
in	O
standardised	O
outcome	O
measures	O
at	O
baseline	O
and	O
post	O
-	O
intervention	O
.	O

Likert	B-O
and	O
open	B-O
-	I-O
ended	I-O
questions	I-O
assessed	O
enjoyment	B-O
,	O
acceptability	B-O
and	O
perceived	B-O
benefits	I-O
of	I-O
the	I-O
program	I-O
,	O
which	O
were	O
analysed	O
thematically	O
.	O

-DOCSTART-	O

Title	O
:	O
Discontinuation	B-I
versus	O
continuation	B-I
of	I-I
renin	I-I
-	I-I
angiotensin	I-I
-	I-I
system	I-I
inhibitors	I-I
in	O
COVID	O
-	O
19	O
(	O
ACEI	O
-	O
COVID	O
)	O
:	O
a	O
prospective	O
,	O
parallel	O
group	O
,	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
trial	O
.	O

METHODS	O
:	O
ACEI	O
-	O
COVID	O
was	O
a	O
parallel	O
group	O
,	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
trial	O
done	O
at	O
35	O
centres	O
in	O
Austria	O
and	O
Germany	O
.	O

Patients	B-P
aged	I-P
18	I-P
years	I-P
and	I-P
older	I-P
were	O
enrolled	O
if	O
they	O
presented	O
with	O
recent	O
symptomatic	O
SARS	O
-	O
CoV	O
-	O
2	O
infection	O
and	O
were	O
chronically	O
treated	O
with	O
ACEIs	O
or	O
ARBs	O
.	O

Patients	O
were	O
randomly	O
assigned	O
1	O
:	O
1	O
to	O
discontinuation	B-I
or	O
continuation	B-I
of	I-I
RAS	I-I
inhibition	I-I
for	O
30	O
days	O
.	O

Primary	O
outcome	O
was	O
the	B-O
maximum	I-O
sequential	I-O
organ	I-O
failure	I-O
assessment	I-O
(	I-O
SOFA	I-O
)	I-O
score	I-O
within	O
30	O
days	O
,	O
where	O
death	O
was	O
scored	O
with	O
the	O
maximum	O
achievable	O
SOFA	O
score	O
.	O

Secondary	O
endpoints	O
were	O
area	B-O
under	I-O
the	I-O
death	I-O
-	I-O
adjusted	I-O
SOFA	I-O
score	I-O
(	I-O
AUCSOFA	I-O
)	I-O
,	O
mean	B-O
SOFA	I-O
score	I-O
,	O
admission	B-O
to	I-O
the	I-O
intensive	I-O
care	I-O
unit	I-O
,	O
mechanical	B-O
ventilation	I-O
,	O
and	O
death	B-O
.	O

Analyses	O
were	O
done	O
on	O
a	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
.	O

This	O
trial	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04353596	O
.	O

-DOCSTART-	O

Title	O
:	O
Traditional	B-I
Chinese	I-I
medicine	I-I
shenhuang	I-I
granule	I-I
in	O
patients	B-P
with	I-P
severe	I-P
/	I-P
critical	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
randomized	O
controlled	O
multicenter	O
trial	O
.	O

METHODS	O
:	O
This	O
was	O
an	O
open	O
-	O
label	O
,	O
multicenter	O
,	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O

At	O
4	O
medical	O
centers	O
,	O
a	B-P
total	I-P
of	I-P
111	I-P
severe	I-P
/	I-P
critical	I-P
patients	I-P
were	O
randomly	O
assigned	O
to	O
receive	O
Shenhuang	B-I
Granule	I-I
(	O
SHG	B-I
group	O
)	O
twice	O
a	O
day	O
for	O
14	O
days	O
,	O
in	O
addition	O
to	O
standard	B-I
care	I-I
,	O
or	O
to	O
receive	O
standard	B-C
care	I-C
alone	I-C
(	O
Control	O
group	O
)	O
.	O

The	O
maximal	O
follow	O
up	O
time	O
was	O
75	O
days	O
.	O

The	O
clinical	O
endpoint	O
was	O
clinical	O
improvement	O
and	O
mortality	O
.	O

-DOCSTART-	O

Title	O
:	O
Tofacitinib	B-I
in	O
Patients	B-P
Hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
Pneumonia	I-P
.	O

METHODS	O
:	O
We	O
randomly	O
assigned	O
,	O
in	O
a	O
1	O
:	O
1	O
ratio	O
,	O
hospitalized	B-P
adults	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
pneumonia	I-P
to	O
receive	O
either	O
tofacitinib	B-I
at	O
a	O
dose	O
of	O
10	O
mg	O
or	O
placebo	B-C
twice	O
daily	O
for	O
up	O
to	O
14	O
days	O
or	O
until	O
hospital	O
discharge	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
occurrence	I-O
of	I-O
death	I-O
or	O
respiratory	B-O
failure	I-O
through	O
day	O
28	O
as	O
assessed	O
with	O
the	B-O
use	I-O
of	I-O
an	I-O
eight	I-O
-	I-O
level	I-O
ordinal	I-O
scale	I-O
(	O
with	O
scores	O
ranging	O
from	O
1	O
to	O
8	O
and	O
higher	O
scores	O
indicating	O
a	O
worse	O
condition	O
)	O
.	O

All	B-O
-	I-O
cause	I-O
mortality	I-O
and	O
safety	B-O
were	O
also	O
assessed	O
.	O

-DOCSTART-	O

Title	O
:	O
Assessing	O
the	O
efficacy	O
and	O
safety	O
of	O
hydroxychloroquine	B-I
as	O
outpatient	O
treatment	O
of	O
COVID	O
-	O
19	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
in	O
Alberta	O
during	O
the	O
first	O
wave	O
of	O
the	O
COVID	O
-	O
19	O
pandemic	O
without	O
direct	O
contact	O
with	O
participants	O
.	O

Community	B-P
-	I-P
dwelling	I-P
individuals	I-P
with	I-P
confirmed	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
(	I-P
by	I-P
reverse	I-P
transcription	I-P
polymerase	I-P
chain	I-P
reaction	I-P
[	I-P
RT	I-P
-	I-P
PCR	I-P
]	I-P
viral	I-P
ribonucleic	I-P
acid	I-P
test	I-P
)	I-P
within	I-P
the	I-P
previous	I-P
4	I-P
days	I-P
,	I-P
and	I-P
symptom	I-P
onset	I-P
within	I-P
the	I-P
previous	I-P
12	I-P
days	I-P
,	O
were	O
randomly	O
assigned	O
to	O
oral	B-I
hydroxychloroquine	I-I
or	O
matching	B-C
placebo	I-C
for	O
5	O
days	O
.	O

Enrolment	O
began	O
Apr	O
.	O

15	O
,	O
2020	O
.	O

The	O
primary	O
outcome	O
was	O
the	B-O
composite	I-O
of	I-O
hospitalization	I-O
,	O
invasive	B-O
mechanical	I-O
ventilation	I-O
or	O
death	B-O
within	O
30	O
days	O
.	O

Secondary	O
outcomes	O
included	O
symptom	B-O
duration	I-O
and	O
disposition	B-O
at	O
30	O
days	O
.	O

Safety	B-O
outcomes	I-O
,	O
such	O
as	O
serious	B-O
adverse	I-O
events	I-O
and	O
mortality	B-O
,	O
were	O
also	O
ascertained	O
.	O

Outcomes	O
were	O
determined	O
by	O
telephone	O
follow	O
-	O
up	O
and	O
administrative	O
data	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
clinical	O
trial	O
"	O
olfactory	O
dysfunction	O
after	O
COVID	O
-	O
19	O
:	O
olfactory	B-C
rehabilitation	I-C
therapy	I-C
vs	O
.	O
intervention	O
treatment	O
with	O
Palmitoylethanolamide	B-I
and	O
Luteolin	B-I
"	O
:	O
preliminary	O
results	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
randomized	O
-	O
controlled	O
pilot	O
study	O
in	O
outpatients	B-P
with	I-P
history	I-P
of	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
with	I-P
post	I-P
-	I-P
infection	I-P
olfactory	I-P
impairment	I-P
that	I-P
persisted	I-P
?	I-P
90	I-P
days	I-P
after	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
negative	I-P
testing	I-P
.	O

Patients	O
were	O
randomized	O
to	O
two	B-C
times	I-C
a	I-C
day	I-C
olfactory	I-C
rehabilitation	I-C
alone	I-C
or	O
weekly	B-I
olfactory	I-I
rehabilitation	I-I
plus	O
daily	B-I
oral	I-I
supplement	I-I
with	I-I
PEA	I-I
and	O
Luteolin	B-I
.	O

Subjects	O
with	O
preexisting	O
olfactory	O
disorders	O
were	O
excluded	O
.	O

Sniffin	B-O
'	I-O
Sticks	I-O
assessments	I-O
were	O
performed	O
at	O
baseline	O
and	O
30	O
days	O
after	O
treatment	O
.	O

Data	O
on	O
gender	O
,	O
age	O
,	O
and	O
time	O
since	O
infection	O
were	O
collected	O
.	O

Kruskal	O
-	O
Wallis	O
(	O
KW	O
)	O
test	O
was	O
used	O
to	O
compare	O
variances	O
of	O
Sniff	O
scores	O
between	O
groups	O
over	O
time	O
,	O
and	O
Spearman	O
'	O
s	O
correlation	O
coefficients	O
were	O
calculated	O
to	O
assess	O
for	O
correlations	O
between	O
Sniff	O
Score	O
and	O
gender	O
or	O
duration	O
of	O
infection	O
.	O

-DOCSTART-	O

Title	O
:	O
Clinical	O
,	O
Biochemical	O
and	O
Molecular	O
Evaluations	O
of	O
Ivermectin	B-I
Mucoadhesive	I-I
Nanosuspension	I-I
Nasal	I-I
Spray	I-I
in	O
Reducing	O
Upper	O
Respiratory	O
Symptoms	O
of	O
Mild	O
COVID	O
-	O
19	O
.	O

METHODS	O
:	O
This	O
clinical	O
trial	O
included	O
114	B-P
patients	I-P
diagnosed	I-P
as	I-P
mild	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Patients	O
were	O
divided	O
randomly	O
into	O
two	O
age	O
and	O
sex	O
-	O
matched	O
groups	O
;	O
group	O
A	O
comprising	O
57	O
patients	O
received	O
ivermectin	B-I
nanosuspension	I-I
nasal	I-I
spray	I-I
twice	O
daily	O
plus	O
the	B-I
Egyptian	I-I
protocol	I-I
of	I-I
treatment	I-I
for	I-I
mild	I-I
COVID	I-I
-	I-I
19	I-I
and	O
group	O
B	O
comprising	O
57	O
patients	O
received	O
the	B-C
Egyptian	I-C
protocol	I-C
for	I-C
mild	I-C
COVID	I-C
-	I-C
19	I-C
only	I-C
.	O

Evaluation	O
of	O
the	O
patients	O
was	O
performed	O
depending	O
on	O
improvement	B-O
of	I-O
presenting	I-O
manifestations	I-O
,	O
negativity	B-O
of	I-O
two	I-O
consecutive	I-O
pharyngeal	I-O
swabs	I-O
for	I-O
the	I-O
COVID	I-O
-	I-O
19	I-O
nucleic	I-O
acid	I-O
via	O
rRT	B-O
-	I-O
PCR	I-O
and	O
assessments	O
of	O
hematological	B-O
and	O
biochemical	B-O
parameters	I-O
in	I-O
the	I-O
form	I-O
of	I-O
complete	I-O
blood	I-O
counts	I-O
,	O
C	B-O
-	I-O
reactive	I-O
protein	I-O
,	O
serum	B-O
ferritin	I-O
and	O
d	B-O
-	I-O
dimer	I-O
which	O
were	O
performed	O
at	O
presentation	O
and	O
7	O
days	O
later	O
.	O

-DOCSTART-	O

Title	O
:	O
The	O
effects	O
of	O
narrative	B-I
exposure	I-I
therapy	I-I
on	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
with	I-P
post	I-P
-	I-P
traumatic	I-P
stress	I-P
symptoms	I-P
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
111	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
near	I-P
the	I-P
discharge	I-P
stage	I-P
with	I-P
positive	I-P
screening	I-P
results	I-P
for	I-P
posttraumatic	I-P
stress	I-P
symptoms	I-P
(	I-P
PTSS	I-P
)	I-P
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
)	O
to	O
either	O
the	O
study	O
group	O
or	O
the	O
control	O
group	O
.	O

The	O
study	O
group	O
received	O
NET	B-I
and	O
personalized	B-I
psychological	I-I
intervention	I-I
,	O
while	O
the	O
control	O
group	O
only	O
received	O
personalized	B-C
psychological	I-C
intervention	I-C
.	O

PTSS	B-O
,	O
depression	B-O
,	O
anxiety	B-O
and	O
sleep	B-O
quality	I-O
were	O
measured	O
pre	O
-	O
and	O
post	O
-	O
intervention	O
to	O
evaluate	O
the	O
effect	O
of	O
NET	B-I
.	O

This	O
trial	O
was	O
registered	O
with	O
the	O
International	O
Standard	O
Randomized	O
Clinical	O
Trial	O
Registry	O
(	O
No	O
.	O

ChiCTR2000039369	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
CORonavirus	O
-	O
19	O
mild	O
to	O
moderate	O
pneumonia	O
Management	O
with	O
blood	B-I
Ozonization	I-I
in	O
patients	B-P
with	I-P
Respiratory	I-P
failure	I-P
(	O
CORMOR	O
)	O
multicentric	O
prospective	O
randomized	O
clinical	O
trial	O
.	O

METHODS	O
:	O
The	O
trial	O
(	O
ClinicalTrial	O
.	O
gov	O
NCT04388514	O
)	O
was	O
conducted	O
in	O
four	O
different	O
Italian	O
centers	O
(	O
April	O
-	O
October	O
2020	O
)	O
.	O

Patients	O
were	O
treated	O
according	O
to	O
best	B-I
available	I-I
standard	I-I
of	I-I
care	I-I
(	I-I
SoC	I-I
)	I-I
therapy	I-I
,	O
with	B-I
or	O
without	B-C
O3	I-C
-	I-C
autohemotherapy	I-C
(	I-C
O3	I-C
-	I-C
AHT	I-C
)	I-C
.	O

-DOCSTART-	O

Title	O
:	O
Effects	O
of	O
a	B-I
2	I-I
-	I-I
Week	I-I
5000	I-I
IU	I-I
versus	O
1000	B-C
IU	I-C
Vitamin	I-C
D3	I-C
Supplementation	I-C
on	O
Recovery	O
of	O
Symptoms	O
in	O
Patients	B-P
with	I-P
Mild	I-P
to	I-P
Moderate	I-P
Covid	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
69	I-P
reverse	I-P
transcriptase	I-P
polymerase	I-P
chain	I-P
reaction	I-P
(	I-P
RT	I-P
-	I-P
PCR	I-P
)	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
positive	I-P
adults	I-P
who	I-P
were	I-P
hospitalized	I-P
for	I-P
mild	I-P
to	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
disease	I-P
were	O
allocated	O
to	O
receive	O
once	B-I
daily	I-I
for	I-I
2	I-I
weeks	I-I
either	I-I
5000	I-I
IU	I-I
oral	I-I
vitamin	I-I
D3	I-I
(	O
n	O
=	O
36	O
,	O
21	O
males	O
;	O
15	O
females	O
)	O
or	O
1000	B-C
IU	I-C
oral	I-C
vitamin	I-C
D3	I-C
(	O
standard	O
control	O
)	O
(	O
n	O
=	O
33	O
,	O
13	O
males	O
;	O
20	O
females	O
)	O
.	O

Anthropometrics	B-O
were	O
measured	O
and	O
blood	O
samples	O
were	O
taken	O
pre	O
-	O
and	O
post	O
-	O
supplementation	O
.	O

Fasting	B-O
blood	I-O
glucose	I-O
,	O
lipids	B-O
,	O
serum	B-O
25	I-O
(	I-O
OH	I-O
)	I-O
D	I-O
,	O
and	O
inflammatory	B-O
markers	I-O
were	O
measured	O
.	O

COVID	B-O
-	I-O
19	I-O
symptoms	I-O
were	O
noted	O
on	O
admission	O
and	O
monitored	O
until	O
full	O
recovery	O
.	O

-DOCSTART-	O

Title	O
:	O
Ivermectin	B-I
to	O
prevent	O
hospitalizations	O
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
(	O
IVERCOR	O
-	O
COVID19	O
)	O
a	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
study	O
was	O
conducted	O
in	O
non	B-P
-	I-P
hospitalized	I-P
individuals	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
in	I-P
Corrientes	I-P
,	I-P
Argentina	I-P
.	O

Patients	B-P
with	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
positive	I-P
nasal	I-P
swabs	I-P
were	O
contacted	O
within	O
48	O
h	O
by	O
telephone	O
to	O
invite	O
them	O
to	O
participate	O
.	O

The	O
trial	O
randomized	O
501	B-P
patients	I-P
between	I-P
August	I-P
19	I-P
th	I-P
2020	I-P
and	I-P
February	I-P
22	I-P
nd	I-P
2021	I-P
.	O

Patients	O
were	O
randomized	O
to	O
ivermectin	B-I
(	O
N	O
=	O
250	O
)	O
or	O
placebo	B-C
(	O
N	O
=	O
251	O
)	O
arms	O
in	O
a	O
staggered	O
dose	O
,	O
according	O
to	O
the	O
patient	O
'	O
s	O
weight	O
,	O
for	O
2	O
days	O
.	O

The	O
efficacy	O
of	O
ivermectin	B-I
to	O
prevent	O
hospitalizations	B-O
was	O
evaluated	O
as	O
primary	O
outcome	O
.	O

We	O
evaluated	O
secondary	O
outcomes	O
in	O
relationship	O
to	O
safety	B-O
and	O
other	O
efficacy	O
end	O
points	O
.	O

-DOCSTART-	O

Title	O
:	O
Randomised	O
,	O
controlled	O
,	O
open	O
label	O
,	O
multicentre	O
clinical	O
trial	O
to	O
explore	O
safety	O
and	O
efficacy	O
of	O
hyperbaric	B-I
oxygen	I-I
for	O
preventing	O
ICU	O
admission	O
,	O
morbidity	O
and	O
mortality	O
in	O
adult	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
A	O
randomised	O
,	O
controlled	O
,	O
phase	O
II	O
,	O
open	O
label	O
,	O
multicentre	O
trial	O
.	O

200	B-P
subjects	I-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
at	I-P
least	I-P
two	I-P
risk	I-P
factors	I-P
for	I-P
mortality	I-P
will	O
be	O
included	O
.	O

Baseline	O
clinical	O
data	O
and	O
blood	O
samples	O
will	O
be	O
collected	O
before	O
randomisation	O
and	O
repeated	O
daily	O
for	O
7	O
days	O
,	O
at	O
days	O
14	O
and	O
30	O
.	O

Subjects	O
will	O
be	O
randomised	O
with	O
a	O
computer	O
-	O
based	O
system	O
to	O
HBO	B-I
,	O
maximum	O
five	O
times	O
during	O
the	O
first	O
7	O
days	O
plus	O
best	B-I
practice	I-I
treatment	I-I
or	O
only	B-C
best	I-C
practice	I-C
treatment	I-C
.	O

The	O
primary	O
endpoint	O
,	O
ICU	B-O
admission	I-O
,	O
is	O
defined	O
by	O
criteria	B-O
for	I-O
selection	I-O
for	I-O
ICU	I-O
.	O

We	O
will	O
evaluate	O
if	O
HBO	B-I
mitigates	O
the	B-O
inflammatory	I-O
reaction	I-O
in	I-O
COVID	I-O
-	I-O
19	I-O
using	O
molecular	O
analyses	O
.	O

All	O
parameters	O
are	O
recorded	O
in	O
an	O
electronic	O
case	O
report	O
form	O
.	O

An	O
independent	O
Data	O
Safety	O
Monitoring	O
Board	O
will	O
review	O
the	B-O
safety	I-O
parameters	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Umbilical	B-I
Cord	I-I
-	I-I
derived	I-I
Mesenchymal	I-I
Stem	I-I
Cells	I-I
modulate	O
TNF	O
and	O
soluble	O
TNF	O
Receptor	O
2	O
(	O
sTNFR2	O
)	O
in	O
COVID	B-P
-	I-P
19	I-P
ARDS	I-P
patients	I-P
.	O

METHODS	O
:	O
We	O
analyzed	O
plasma	O
samples	O
from	O
subjects	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
ARDS	I-P
(	I-P
n=24	I-P
)	I-P
enrolled	O
in	O
a	O
Phase	O
1	O
/	O
2	O
a	O
randomized	O
controlled	O
trial	O
of	O
UC	B-I
-	I-I
MSC	I-I
treatment	I-I
.	O

Plasma	O
samples	O
were	O
obtained	O
at	O
Day	O
0	O
(	O
baseline	O
,	O
before	O
UC	O
-	O
MSC	O
or	O
control	O
infusion	O
)	O
,	O
and	O
Day	O
6	O
post	O
infusion	O
.	O

Plasma	B-O
concentrations	I-O
of	I-O
sTNFR2	I-O
,	O
TNF?	B-O
,	O
and	O
TNF?	B-O
were	O
evaluated	O
using	O
a	B-O
quantitative	I-O
multiplex	I-O
protein	I-O
array	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Standard	B-C
prophylactic	I-C
versus	O
intermediate	B-I
dose	I-I
enoxaparin	I-I
in	O
adults	B-P
with	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
multi	O
-	O
center	O
,	O
open	O
-	O
label	O
,	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
multi	O
-	O
center	O
,	O
open	O
-	O
label	O
,	O
randomized	O
controlled	O
trial	O
comparing	O
standard	B-C
prophylactic	I-C
dose	I-C
versus	O
intermediate	B-I
dose	I-I
enoxaparin	I-I
in	O
adults	B-P
who	I-P
were	I-P
hospitalized	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
admitted	I-P
to	I-P
an	I-P
intensive	I-P
care	I-P
unit	I-P
(	I-P
ICU	I-P
)	I-P
and	I-P
/	I-P
or	I-P
had	I-P
laboratory	I-P
evidence	I-P
of	I-P
coagulopathy	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
in	O
a	O
1	O
:	O
1	O
ratio	O
to	O
receive	O
standard	B-C
prophylactic	I-C
dose	I-C
enoxaparin	I-C
or	O
intermediate	B-I
weight	I-I
-	I-I
adjusted	I-I
dose	I-I
enoxaparin	I-I
.	O

The	O
primary	O
outcome	O
was	O
all	B-O
-	I-O
cause	I-O
mortality	I-O
at	O
30	O
days	O
.	O

Secondary	O
outcomes	O
included	O
arterial	B-O
or	O
venous	B-O
thromboembolism	I-O
and	O
major	B-O
bleeding	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Evaluation	O
of	O
Ivermectin	B-I
as	O
a	O
Potential	O
Treatment	O
for	O
Mild	O
to	O
Moderate	O
COVID	O
-	O
19	O
:	O
A	O
Double	O
-	O
Blind	O
Randomized	O
Placebo	O
Controlled	O
Trial	O
in	O
Eastern	O
India	O
.	O

METHODS	O
:	O
A	O
double	O
blind	O
,	O
parallel	O
,	O
randomised	O
,	O
placebo	O
-	O
controlled	O
trial	O
conducted	O
among	O
adult	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
disease	I-P
severity	I-P
on	I-P
admission	I-P
in	I-P
a	I-P
COVID	I-P
dedicated	I-P
tertiary	I-P
healthcare	I-P
of	I-P
eastern	I-P
India	I-P
.	O

Enrolment	O
was	O
done	O
between	O
1	O
st	O
August	O
and	O
31	O
st	O
October	O
2020	O
.	O

On	O
day	O
1	O
and	O
2	O
post	O
enrolment	O
,	O
patients	O
in	O
the	O
intervention	O
arm	O
received	O
ivermectin	B-I
12	O
mg	O
while	O
the	O
patients	O
in	O
the	O
non	O
-	O
interventional	O
arm	O
received	O
placebo	B-C
tablets	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Oral	B-I
Azithromycin	I-I
vs	O
Placebo	B-C
on	O
COVID	O
-	O
19	O
Symptoms	O
in	O
Outpatients	B-P
With	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
Infection	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Randomized	O
clinical	O
trial	O
of	O
azithromycin	B-I
vs	O
matching	B-C
placebo	I-C
conducted	O
from	O
May	O
2020	O
through	O
March	O
2021	O
.	O

Outpatients	B-P
from	I-P
the	I-P
US	I-P
were	O
enrolled	O
remotely	O
via	O
internet	O
-	O
based	O
surveys	O
and	O
followed	O
up	O
for	O
21	O
days	O
.	O

Eligible	O
participants	O
had	O
a	O
positive	O
SARS	O
-	O
CoV	O
-	O
2	O
diagnostic	O
test	O
result	O
(	O
nucleic	O
acid	O
amplification	O
or	O
antigen	O
)	O
within	O
7	O
days	O
prior	O
to	O
enrollment	O
,	O
were	O
aged	O
18	O
years	O
or	O
older	O
,	O
and	O
were	O
not	O
hospitalized	O
at	O
the	O
time	O
of	O
enrollment	O
.	O

Among	O
604	O
individuals	O
screened	O
,	O
297	O
were	O
ineligible	O
,	O
44	O
refused	O
participation	O
,	O
and	O
263	O
were	O
enrolled	O
.	O

Participants	O
,	O
investigators	O
,	O
and	O
study	O
staff	O
were	O
masked	O
to	O
treatment	O
randomization	O
.	O

Participants	O
were	O
randomized	O
in	O
a	O
2	O
:	O
1	O
fashion	O
to	O
a	B-I
single	I-I
oral	I-I
1	I-I
.	I-I
2	I-I
-	I-I
g	I-I
dose	I-I
of	I-I
azithromycin	I-I
(	O
n	O
=	O
171	O
)	O
or	O
matching	B-C
placebo	I-C
(	O
n	O
=	O
92	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
absence	B-O
of	I-O
self	I-O
-	I-O
reported	I-O
COVID	I-O
-	I-O
19	I-O
symptoms	I-O
at	O
day	O
14	O
.	O

There	O
were	O
23	O
secondary	O
clinical	O
end	O
points	O
,	O
including	O
all	B-O
-	I-O
cause	I-O
hospitalization	I-O
at	O
day	O
21	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Canakinumab	B-I
vs	O
Placebo	B-C
on	O
Survival	O
Without	O
Invasive	O
Mechanical	O
Ventilation	O
in	O
Patients	B-P
Hospitalized	I-P
With	I-P
Severe	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
This	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
phase	O
3	O
trial	O
was	O
conducted	O
at	O
39	O
hospitals	O
in	O
Europe	O
and	O
the	O
United	O
States	O
.	O

A	B-P
total	I-P
of	I-P
454	I-P
hospitalized	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
pneumonia	I-P
,	I-P
hypoxia	I-P
(	I-P
not	I-P
requiring	I-P
invasive	I-P
mechanical	I-P
ventilation	I-P
[	I-P
IMV	I-P
]	I-P
)	I-P
,	I-P
and	I-P
systemic	I-P
hyperinflammation	I-P
defined	I-P
by	I-P
increased	I-P
blood	I-P
concentrations	I-P
of	I-P
C	I-P
-	I-P
reactive	I-P
protein	I-P
or	I-P
ferritin	I-P
were	O
enrolled	O
between	O
April	O
30	O
and	O
August	O
17	O
,	O
2020	O
,	O
with	O
the	O
last	O
assessment	O
of	O
the	O
primary	O
end	O
point	O
on	O
September	O
22	O
,	O
2020	O
.	O

Patients	O
were	O
randomly	O
assigned	O
1	O
:	O
1	O
to	O
receive	O
a	B-I
single	I-I
intravenous	I-I
infusion	I-I
of	I-I
canakinumab	I-I
(	O
450	O
mg	O
for	O
body	O
weight	O
of	O
40	O
-	O
<	O
60	O
kg	O
,	O
600	O
mg	O
for	O
60	O
-	O
80	O
kg	O
,	O
and	O
750	O
mg	O
for	O
>	O
80	O
kg	O
;	O
n	O
=	O
227	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
227	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
survival	B-O
without	I-O
IMV	I-O
from	O
day	O
3	O
to	O
day	O
29	O
.	O

Secondary	O
outcomes	O
were	O
COVID	B-O
-	I-O
19	I-O
-	I-O
related	I-O
mortality	I-O
,	O
measurements	B-O
of	I-O
biomarkers	I-O
of	I-O
systemic	I-O
hyperinflammation	I-O
,	O
and	O
safety	B-O
evaluations	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Dapagliflozin	B-I
in	O
patients	B-P
with	I-P
cardiometabolic	I-P
risk	I-P
factors	I-P
hospitalised	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
(	O
DARE	O
-	O
19	O
)	O
:	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
phase	O
3	O
trial	O
.	O

METHODS	O
:	O
DARE	O
-	O
19	O
was	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
patients	B-P
hospitalised	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
with	I-P
at	I-P
least	I-P
one	I-P
cardiometabolic	I-P
risk	I-P
factor	I-P
(	I-P
ie	I-P
,	I-P
hypertension	I-P
,	I-P
type	I-P
2	I-P
diabetes	I-P
,	I-P
atherosclerotic	I-P
cardiovascular	I-P
disease	I-P
,	I-P
heart	I-P
failure	I-P
,	I-P
and	I-P
chronic	I-P
kidney	I-P
disease	I-P
)	I-P
.	O

Patients	O
critically	O
ill	O
at	O
screening	O
were	O
excluded	O
.	O

Patients	O
were	O
randomly	O
assigned	O
1	O
:	O
1	O
to	O
dapagliflozin	B-I
(	O
10	O
mg	O
daily	O
orally	O
)	O
or	O
matched	B-C
placebo	I-C
for	O
30	O
days	O
.	O

Dual	O
primary	O
outcomes	O
were	O
assessed	O
in	O
the	O
intention	O
-	O
to	O
-	O
treat	O
population	O
:	O
the	B-O
outcome	I-O
of	I-O
prevention	I-O
(	O
time	B-O
to	I-O
new	I-O
or	O
worsened	B-O
organ	I-O
dysfunction	I-O
or	O
death	B-O
)	O
,	O
and	O
the	B-O
hierarchial	I-O
composite	I-O
outcome	I-O
of	I-O
recovery	I-O
(	O
change	O
in	O
clinical	B-O
status	I-O
by	O
day	O
30	O
)	O
.	O

Safety	B-O
outcomes	I-O
,	O
in	O
patients	O
who	O
received	O
at	O
least	O
one	O
study	O
medication	O
dose	O
,	O
included	O
serious	B-O
adverse	I-O
events	I-O
,	O
adverse	B-O
events	I-O
leading	I-O
to	I-O
discontinuation	I-O
,	O
and	O
adverse	B-O
events	I-O
of	I-O
interest	I-O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04350593	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
Brazilian	B-I
green	I-I
propolis	I-I
(	O
EPP	B-I
-	I-I
AF	I-I
)	O
as	O
an	O
adjunct	O
treatment	O
for	O
hospitalized	B-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
:	O
A	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O

METHODS	O
:	O
In	O
a	O
randomized	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
single	O
-	O
center	O
trial	O
,	O
hospitalized	B-P
adult	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
were	O
treated	O
with	O
a	B-I
standardized	I-I
green	I-I
propolis	I-I
extract	I-I
(	O
EPP	B-I
-	I-I
AF?	I-I
)	O
as	O
an	O
adjunct	O
therapy	O
.	O

Patients	O
were	O
allocated	O
to	O
receive	O
standard	B-I
care	I-I
plus	O
an	B-I
oral	I-I
dose	I-I
of	I-I
400	I-I
mg	I-I
or	O
800	B-I
mg	I-I
/	I-I
day	I-I
of	I-I
green	I-I
propolis	I-I
for	O
seven	O
days	O
,	O
or	O
standard	B-C
care	I-C
alone	I-C
.	O

Standard	B-I
care	I-I
included	O
all	O
necessary	O
interventions	O
,	O
as	O
determined	O
by	O
the	O
attending	O
physician	O
.	O

The	O
primary	O
end	O
point	O
was	O
the	B-O
time	I-O
to	I-O
clinical	I-O
improvement	I-O
,	O
defined	O
as	O
the	B-O
length	I-O
of	I-O
hospital	I-O
stay	I-O
or	O
oxygen	B-O
therapy	I-O
dependency	I-O
duration	I-O
.	O

Secondary	O
outcomes	O
included	O
acute	B-O
kidney	I-O
injury	I-O
and	O
need	B-O
for	I-O
intensive	I-O
care	I-O
or	O
vasoactive	B-O
drugs	I-O
.	O

Patients	O
were	O
followed	O
for	O
28	O
days	O
after	O
admission	O
.	O

-DOCSTART-	O

Title	O
:	O
Doxycycline	B-I
for	O
community	O
treatment	O
of	O
suspected	O
COVID	O
-	O
19	O
in	O
people	B-P
at	I-P
high	I-P
risk	I-P
of	I-P
adverse	I-P
outcomes	I-P
in	I-P
the	I-P
UK	I-P
(	O
PRINCIPLE	O
)	O
:	O
a	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
adaptive	O
platform	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
national	O
,	O
open	O
-	O
label	O
,	O
multi	O
-	O
arm	O
,	O
adaptive	O
platform	O
randomised	O
trial	O
of	O
interventions	O
against	O
COVID	O
-	O
19	O
in	O
older	O
people	O
(	O
PRINCIPLE	O
)	O
across	O
primary	O
care	O
centres	O
in	O
the	O
UK	O
.	O

We	O
included	O
people	B-P
aged	I-P
65	I-P
years	I-P
or	I-P
older	I-P
,	I-P
or	I-P
50	I-P
years	I-P
or	I-P
older	I-P
with	I-P
comorbidities	I-P
(	I-P
weakened	I-P
immune	I-P
system	I-P
,	I-P
heart	I-P
disease	I-P
,	I-P
hypertension	I-P
,	I-P
asthma	I-P
or	I-P
lung	I-P
disease	I-P
,	I-P
diabetes	I-P
,	I-P
mild	I-P
hepatic	I-P
impairment	I-P
,	I-P
stroke	I-P
or	I-P
neurological	I-P
problem	I-P
,	I-P
and	I-P
self	I-P
-	I-P
reported	I-P
obesity	I-P
or	I-P
body	I-P
-	I-P
mass	I-P
index	I-P
of	I-P
35	I-P
kg	I-P
/	I-P
m2	I-P
or	I-P
greater	I-P
)	I-P
,	I-P
who	I-P
had	I-P
been	I-P
unwell	I-P
(	I-P
for	I-P
?14	I-P
days	I-P
)	I-P
with	I-P
suspected	I-P
COVID	I-P
-	I-P
19	I-P
or	I-P
a	I-P
positive	I-P
PCR	I-P
test	I-P
for	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
in	I-P
the	I-P
community	I-P
.	O

Participants	O
were	O
randomly	O
assigned	O
using	O
response	O
adaptive	O
randomisation	O
to	O
usual	B-C
care	I-C
only	I-C
,	O
usual	B-I
care	I-I
plus	O
oral	B-I
doxycycline	I-I
(	O
200	O
mg	O
on	O
day	O
1	O
,	O
then	O
100	O
mg	O
once	O
daily	O
for	O
the	O
following	O
6	O
days	O
)	O
,	O
or	O
usual	B-I
care	I-I
plus	O
other	B-I
interventions	I-I
.	O

The	O
interventions	O
reported	O
in	O
this	O
manuscript	O
are	O
usual	B-I
care	I-I
plus	O
doxycycline	B-I
and	O
usual	B-C
care	I-C
only	I-C
;	O
evaluations	O
of	O
other	O
interventions	O
in	O
this	O
platform	O
trial	O
are	O
ongoing	O
.	O

The	O
coprimary	O
endpoints	O
were	O
time	B-O
to	I-O
first	I-O
self	I-O
-	I-O
reported	I-O
recovery	I-O
,	O
and	O
hospitalisation	B-O
or	O
death	B-O
related	I-O
to	I-O
COVID	I-O
-	I-O
19	I-O
,	O
both	O
measured	O
over	O
28	O
days	O
from	O
randomisation	O
and	O
analysed	O
by	O
intention	O
to	O
treat	O
.	O

This	O
trial	O
is	O
ongoing	O
and	O
is	O
registered	O
with	O
ISRCTN	O
,	O
86534580	O
.	O

-DOCSTART-	O

Title	O
:	O
Therapeutic	O
Anticoagulation	O
with	O
Heparin	B-I
in	O
Noncritically	B-P
Ill	I-P
Patients	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
In	O
this	O
open	O
-	O
label	O
,	O
adaptive	O
,	O
multiplatform	O
,	O
controlled	O
trial	O
,	O
we	O
randomly	O
assigned	O
patients	B-P
who	I-P
were	I-P
hospitalized	I-P
with	I-P
Covid	I-P
-	I-P
19	I-P
and	I-P
who	I-P
were	I-P
not	I-P
critically	I-P
ill	I-P
(	I-P
which	I-P
was	I-P
defined	I-P
as	I-P
an	I-P
absence	I-P
of	I-P
critical	I-P
care	I-P
-	I-P
level	I-P
organ	I-P
support	I-P
at	I-P
enrollment	I-P
)	I-P
to	O
receive	O
pragmatically	O
defined	O
regimens	O
of	O
either	O
therapeutic	B-I
-	I-I
dose	I-I
anticoagulation	I-I
with	I-I
heparin	I-I
or	O
usual	B-C
-	I-C
care	I-C
pharmacologic	I-C
thromboprophylaxis	I-C
.	O

The	O
primary	O
outcome	O
was	O
organ	B-O
support	I-O
-	I-O
free	I-O
days	I-O
,	O
evaluated	O
on	O
an	B-O
ordinal	I-O
scale	I-O
that	O
combined	O
in	B-O
-	I-O
hospital	I-O
death	I-O
(	O
assigned	O
a	O
value	O
of	O
-	O
1	O
)	O
and	O
the	B-O
number	I-O
of	I-O
days	I-O
free	I-O
of	I-O
cardiovascular	I-O
or	O
respiratory	B-O
organ	I-O
support	I-O
up	O
to	O
day	O
21	O
among	O
patients	O
who	O
survived	O
to	O
hospital	O
discharge	O
.	O

This	O
outcome	O
was	O
evaluated	O
with	O
the	O
use	O
of	O
a	O
Bayesian	O
statistical	O
model	O
for	O
all	O
patients	O
and	O
according	O
to	O
the	O
baseline	O
d	O
-	O
dimer	O
level	O
.	O

-DOCSTART-	O

Title	O
:	O
The	B-I
Humanoid	I-I
Robot	I-I
Sil	I-I
-	I-I
Bot	I-I
in	I-I
a	I-I
Cognitive	I-I
Training	I-I
Program	I-I
for	O
Community	B-P
-	I-P
Dwelling	I-P
Elderly	I-P
People	I-P
with	I-P
Mild	I-P
Cognitive	I-P
Impairment	I-P
during	I-P
the	I-P
COVID	I-P
-	I-P
19	I-P
Pandemic	I-P
:	O
A	O
Randomized	O
Controlled	O
Trial	O
.	O

METHODS	O
:	O
A	O
randomized	O
controlled	O
trial	O
was	O
conducted	O
with	O
135	B-P
volunteers	I-P
without	I-P
cognitive	I-P
impairment	I-P
aged	I-P
60	I-P
years	I-P
old	I-P
or	I-P
older	I-P
.	O

Participants	O
were	O
first	O
randomized	O
into	O
two	O
groups	O
.	O

One	O
group	O
consisted	O
of	O
90	O
participants	O
who	O
would	O
receive	O
cognitive	B-I
training	I-I
and	O
45	O
who	O
would	O
not	O
receive	O
any	B-C
training	I-C
(	I-C
NI	I-C
)	I-C
.	O

The	B-I
cognitive	I-I
training	I-I
group	O
was	O
randomly	O
divided	O
into	O
two	O
groups	O
,	O
45	O
who	O
received	O
traditional	B-C
cognitive	I-C
training	I-C
(	I-C
TCT	I-C
)	I-C
and	O
45	O
who	O
received	O
robot	B-I
-	I-I
assisted	I-I
cognitive	I-I
training	I-I
(	I-I
RACT	I-I
)	I-I
.	O

The	O
training	O
for	O
both	O
groups	O
consisted	O
of	O
a	O
daily	O
60	O
min	O
session	O
,	O
twice	O
a	O
week	O
for	O
six	O
weeks	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
convalescent	B-I
plasma	I-I
for	O
treatment	O
of	O
COVID	O
-	O
19	O
in	O
Uganda	O
.	O

METHODS	O
:	O
Patients	B-P
with	I-P
a	I-P
positive	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
reverse	I-P
transcriptase	I-P
(	I-P
RT	I-P
)	I-P
-	I-P
PCR	I-P
test	I-P
irrespective	I-P
of	I-P
disease	I-P
severity	I-P
were	O
hospitalised	O
and	O
randomised	O
to	O
receive	O
either	O
COVID	B-I
-	I-I
19	I-I
CCP	I-I
plus	O
standard	B-I
of	I-I
care	I-I
(	I-I
SOC	I-I
)	I-I
or	O
SOC	B-C
alone	I-C
.	O

The	O
primary	O
outcome	O
was	O
time	B-O
to	I-O
viral	I-O
clearance	I-O
,	O
defined	O
as	O
having	B-O
two	I-O
consecutive	I-O
RT	I-O
-	I-O
PCR	I-O
-	I-O
negative	I-O
tests	I-O
by	O
day	O
28	O
.	O

Secondary	O
outcomes	O
included	O
time	B-O
to	I-O
symptom	I-O
resolution	I-O
,	O
clinical	B-O
status	I-O
on	O
the	B-O
modified	I-O
WHO	I-O
Ordinal	I-O
Clinical	I-O
Scale	I-O
(	O
?1	O
-	O
point	O
increase	O
)	O
,	O
progression	B-O
to	I-O
severe	I-O
/	I-O
critical	I-O
condition	I-O
(	O
defined	O
as	O
oxygen	B-O
saturation	I-O
<	I-O
93	I-O
%	I-O
or	O
needing	B-O
oxygen	I-O
)	O
,	O
mortality	B-O
and	O
safety	B-O
.	O

-DOCSTART-	O

Title	O
:	O
Inhaled	B-I
budesonide	I-I
for	O
COVID	B-P
-	I-P
19	I-P
in	I-P
people	I-P
at	I-P
high	I-P
risk	I-P
of	I-P
complications	I-P
in	I-P
the	I-P
community	I-P
in	I-P
the	I-P
UK	I-P
(	O
PRINCIPLE	O
)	O
:	O
a	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
adaptive	O
platform	O
trial	O
.	O

METHODS	O
:	O
PRINCIPLE	O
is	O
a	O
multicentre	O
,	O
open	O
-	O
label	O
,	O
multi	O
-	O
arm	O
,	O
randomised	O
,	O
controlled	O
,	O
adaptive	O
platform	O
trial	O
done	O
remotely	O
from	O
a	O
central	O
trial	O
site	O
and	O
at	O
primary	O
care	O
centres	O
in	O
the	O
UK	O
.	O

Eligible	O
participants	O
were	O
aged	B-P
65	I-P
years	I-P
or	I-P
older	I-P
or	I-P
50	I-P
years	I-P
or	I-P
older	I-P
with	I-P
comorbidities	I-P
,	I-P
and	I-P
unwell	I-P
for	I-P
up	I-P
to	I-P
14	I-P
days	I-P
with	I-P
suspected	I-P
COVID	I-P
-	I-P
19	I-P
but	I-P
not	I-P
admitted	I-P
to	I-P
hospital	I-P
.	O

Participants	O
were	O
randomly	O
assigned	O
to	O
usual	B-C
care	I-C
,	O
usual	B-I
care	I-I
plus	O
inhaled	B-I
budesonide	I-I
(	O
800	O
?g	O
twice	O
daily	O
for	O
14	O
days	O
)	O
,	O
or	O
usual	B-I
care	I-I
plus	O
other	B-I
interventions	I-I
,	O
and	O
followed	O
up	O
for	O
28	O
days	O
.	O

Participants	O
were	O
aware	O
of	O
group	O
assignment	O
.	O

The	O
coprimary	O
endpoints	O
are	O
time	B-O
to	I-O
first	I-O
self	I-O
-	I-O
reported	I-O
recovery	I-O
and	O
hospital	B-O
admission	I-O
or	O
death	B-O
related	I-O
to	I-O
COVID	I-O
-	I-O
19	I-O
,	O
within	O
28	O
days	O
,	O
analysed	O
using	O
Bayesian	O
models	O
.	O

The	O
primary	O
analysis	O
population	O
included	O
all	O
eligible	O
SARS	O
-	O
CoV	O
-	O
2	O
-	O
positive	O
participants	O
randomly	O
assigned	O
to	O
budesonide	B-I
,	O
usual	B-C
care	I-C
,	O
and	O
other	B-I
interventions	I-I
,	O
from	O
the	O
start	O
of	O
the	O
platform	O
trial	O
until	O
the	B-I
budesonide	I-I
group	O
was	O
closed	O
.	O

This	O
trial	O
is	O
registered	O
at	O
the	O
ISRCTN	O
registry	O
(	O
ISRCTN86534580	O
)	O
and	O
is	O
ongoing	O
.	O

-DOCSTART-	O

Title	O
:	O
Nature	O
and	O
Dimensions	O
of	O
Systemic	O
Hyperinflammation	O
and	O
its	O
Attenuation	O
by	O
Convalescent	B-I
Plasma	I-I
in	O
Severe	O
COVID	O
-	O
19	O
.	O

METHODS	O
:	O
First	O
,	O
to	O
characterize	O
key	O
cytokines	O
and	O
their	O
dynamics	O
in	O
this	O
hyperinflammatory	O
condition	O
,	O
we	O
assessed	O
abundance	O
and	O
correlative	O
expression	O
of	O
a	O
panel	O
of	O
48	O
cytokines	O
in	O
patients	B-P
progressing	I-P
to	I-P
ARDS	I-P
as	I-P
compared	I-P
to	I-P
patients	I-P
with	I-P
mild	I-P
disease	I-P
.	O

Then	O
,	O
in	O
an	O
ongoing	O
randomized	O
controlled	O
trial	O
of	O
convalescent	B-I
plasma	I-I
therapy	I-I
(	I-I
CPT	I-I
)	I-I
,	O
we	O
analyzed	O
rapid	O
effects	O
of	O
CPT	B-I
on	O
the	O
systemic	B-O
cytokine	I-O
dynamics	I-O
as	O
a	O
correlate	O
for	O
the	B-O
level	I-O
of	I-O
hypoxia	I-O
experienced	I-O
by	I-O
the	I-O
patients	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Combined	O
use	O
of	O
a	B-I
broad	I-I
-	I-I
panel	I-I
respiratory	I-I
multiplex	I-I
PCR	I-I
and	O
procalcitonin	B-I
to	O
reduce	O
duration	O
of	O
antibiotics	O
exposure	O
in	O
patients	B-P
with	I-P
severe	I-P
community	I-P
-	I-P
acquired	I-P
pneumonia	I-P
(	O
MULTI	O
-	O
CAP	O
)	O
:	O
a	O
multicentre	O
,	O
parallel	O
-	O
group	O
,	O
open	O
-	O
label	O
,	O
individual	O
randomised	O
trial	O
conducted	O
in	O
French	O
intensive	O
care	O
units	O
.	O

METHODS	O
:	O
The	B-I
multiplex	I-I
PCR	I-I
and	O
procalcitonin	B-I
to	O
reduce	O
duration	O
of	O
antibiotics	O
exposure	O
in	O
patients	B-P
with	I-P
severe	I-P
-	I-P
CAP	I-P
(	I-P
MULTI	I-P
-	I-P
CAP	I-P
)	I-P
trial	I-P
is	O
a	O
multicentre	O
(	O
n=20	O
)	O
,	O
parallel	O
-	O
group	O
,	O
superiority	O
,	O
open	O
-	O
label	O
,	O
randomised	O
trial	O
.	O

Patients	O
are	O
included	O
if	O
adult	B-P
admitted	I-P
to	I-P
intensive	I-P
care	I-P
unit	I-P
for	I-P
a	I-P
CAP	I-P
.	O

Diagnosis	O
of	O
pneumonia	O
is	O
based	O
on	O
clinical	O
criteria	O
and	O
a	O
newly	O
appeared	O
parenchymal	O
infiltrate	O
.	O

Immunocompromised	O
patients	O
are	O
excluded	O
.	O

Subjects	O
are	O
randomised	O
(	O
1	O
:	O
1	O
ratio	O
)	O
to	O
either	O
the	O
intervention	O
arm	O
(	O
experimental	B-I
strategy	I-I
)	O
or	O
the	O
control	O
arm	O
(	O
usual	B-C
strategy	I-C
)	O
.	O

In	O
the	O
intervention	O
arm	O
,	O
the	B-I
microbiological	I-I
diagnosis	I-I
combines	O
a	B-I
respiratory	I-I
multiplex	I-I
PCR	I-I
(	I-I
mPCR	I-I
)	I-I
and	O
conventional	B-I
microbiological	I-I
investigations	I-I
.	O

An	O
algorithm	O
of	O
early	O
antibiotic	O
de	O
-	O
escalation	O
or	O
discontinuation	O
is	O
recommended	O
,	O
based	O
on	O
mPCR	O
results	O
and	O
the	O
procalcitonin	O
value	O
.	O

In	O
the	O
control	O
arm	O
,	O
only	O
conventional	B-C
microbiological	I-C
investigations	I-C
are	O
performed	O
and	O
antibiotics	O
de	O
-	O
escalation	O
remains	O
at	O
the	O
clinician	O
'	O
s	O
discretion	O
.	O

The	O
primary	O
endpoint	O
is	O
the	B-O
number	I-O
of	I-O
days	I-O
alive	I-O
without	I-O
any	I-O
antibiotic	I-O
from	O
the	O
randomisation	O
to	O
day	O
28	O
.	O

Based	O
on	O
our	O
hypothesis	O
of	O
2	O
days	O
gain	O
in	O
the	O
intervention	O
arm	O
,	O
we	O
aim	O
to	O
enrol	O
a	O
total	O
of	O
450	O
patients	O
over	O
a	O
30	O
-	O
month	O
period	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
of	O
two	B-I
siddha	I-I
polyherbal	I-I
decoctions	I-I
,	O
Nilavembu	B-I
Kudineer	I-I
and	O
Kaba	B-I
Sura	I-I
Kudineer	I-I
,	O
along	O
with	O
standard	B-I
allopathy	I-I
treatment	I-I
in	O
the	O
management	O
of	O
mild	B-P
to	I-P
moderate	I-P
symptomatic	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
-	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
clinical	O
trial	O
.	O

METHODS	O
:	O
The	O
study	O
was	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
comparative	O
clinical	O
trial	O
,	O
with	O
the	O
primary	O
objective	O
of	O
determining	O
the	O
efficacy	O
of	O
KSK	B-I
and	O
NVK	B-I
.	O

Patients	B-P
(	I-P
n=125	I-P
)	I-P
diagnosed	I-P
with	I-P
mild	I-P
to	I-P
moderate	I-P
COVID	I-P
-	I-P
19	I-P
symptoms	I-P
were	O
enrolled	O
in	O
the	O
study	O
over	O
a	O
period	O
of	O
4	O
months	O
(	O
Aug	O
2020	O
-	O
Dec	O
2020	O
)	O
.	O

Participants	O
were	O
randomized	O
into	O
3	O
arms	O
;	O
placebo	B-C
-	O
decaffeinated	B-C
tea	I-C
in	O
Arm	O
I	O
,	O
NVK	B-I
in	O
Arm	O
II	O
,	O
and	O
KSK	B-I
in	O
Arm	O
III	O
.	O

Each	O
arm	O
received	O
60	O
ml	O
of	O
the	O
respective	O
treatment	O
twice	O
a	O
day	O
,	O
post	O
morning	O
and	O
evening	O
meals	O
,	O
along	O
with	O
standard	B-I
allopathy	I-I
treatment	I-I
for	O
a	O
maximum	O
of	O
10	O
days	O
.	O

The	O
main	O
outcome	O
measures	O
of	O
the	O
study	O
were	O
the	O
reduction	O
in	O
SARS	B-O
-	I-O
CoV	I-O
-	I-O
2	I-O
viral	I-O
load	I-O
,	O
hospital	B-O
stay	I-O
,	O
and	O
time	B-O
taken	I-O
by	I-O
the	I-O
patients	I-O
to	I-O
become	I-O
asymptomatic	I-O
from	I-O
symptomatic	I-O
.	O

Efficacy	O
assessments	O
included	O
clinical	B-O
symptoms	I-O
(	O
fever	B-O
,	O
cough	B-O
,	O
and	O
breathlessness	B-O
)	O
each	O
day	O
and	O
real	B-O
-	I-O
time	I-O
reverse	I-O
transcription	I-O
-	I-O
polymerase	I-O
chain	I-O
reaction	I-O
(	I-O
RT	I-O
-	I-O
PCR	I-O
)	I-O
,	O
liver	B-O
function	I-O
test	I-O
(	I-O
LFT	I-O
)	I-O
,	O
renal	B-O
function	I-O
test	I-O
(	I-O
RFT	I-O
)	I-O
,	O
and	O
electrolytes	B-O
and	I-O
electrocardiogram	I-O
(	I-O
ECG	I-O
)	I-O
at	O
baseline	O
(	O
day	O
0	O
)	O
and	O
days	O
3	O
,	O
6	O
,	O
and	O
10	O
.	O

Post	O
-	O
treatment	O
,	O
participants	O
were	O
followed	O
up	O
for	O
30	O
days	O
via	O
phone	O
for	O
adverse	O
effects	O
if	O
any	O
.	O

Effects	O
of	O
drugs	O
on	O
inflammatory	B-O
markers	I-O
(	O
IL6	B-O
)	O
at	O
the	O
end	O
of	O
treatment	O
were	O
also	O
recorded	O
.	O

Adverse	B-O
events	I-O
(	I-O
AE	I-O
)	I-O
were	O
monitored	O
throughout	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Metoprolol	B-I
in	O
Critically	B-P
Ill	I-P
Patients	I-P
With	I-P
COVID	I-P
-	I-P
19	I-P
.	O

METHODS	O
:	O
A	B-P
total	I-P
of	I-P
20	I-P
COVID	I-P
-	I-P
19	I-P
patients	I-P
with	I-P
ARDS	I-P
on	I-P
invasive	I-P
mechanical	I-P
ventilation	I-P
were	O
randomized	O
to	O
metoprolol	B-I
(	O
15	O
mg	O
daily	O
for	O
3	O
days	O
)	O
or	O
control	O
(	O
no	B-C
treatment	I-C
)	O
.	O

All	O
patients	O
underwent	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
before	O
and	O
after	O
metoprolol	B-I
/	O
control	O
.	O

The	O
safety	O
of	O
metoprolol	B-I
administration	O
was	O
evaluated	O
by	O
invasive	B-O
hemodynamic	I-O
and	O
electrocardiogram	B-O
monitoring	I-O
and	O
echocardiography	B-O
.	O

-DOCSTART-	O

Title	O
:	O
In	O
vivo	O
evaluation	O
of	O
the	O
virucidal	O
efficacy	O
of	O
chlorhexidine	B-I
and	O
povidone	B-I
-	O
iodine	B-I
mouthwashes	I-I
against	O
salivary	O
SARS	O
-	O
CoV	O
-	O
2	O
.	O

A	O
randomized	O
-	O
controlled	O
clinical	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomized	O
-	O
controlled	O
clinical	O
trial	O
,	O
studied	O
group	O
comprised	O
laboratory	B-P
-	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
positive	I-P
patients	I-P
through	I-P
nasopharyngeal	I-P
swabs	I-P
.	O

Participants	O
were	O
divided	O
into	O
3	O
groups	O
.	O

For	O
30	O
s	O
,	O
the	O
control	O
group	O
mouthrinsed	O
with	O
distilled	B-C
water	I-C
,	O
the	B-I
Chlorhexidine	I-I
group	O
mouthrinsed	O
with	O
0	B-I
.	I-I
2	I-I
%	I-I
Chlorhexidine	I-I
and	O
the	B-I
Povidone	I-I
-	O
iodine	B-I
group	O
gargled	O
with	O
1	B-I
%	I-I
Povidone	I-I
-	O
iodine	B-I
.	O

Saliva	O
samples	O
were	O
collected	O
before	O
and	O
5	O
min	O
after	O
mouthwash	O
.	O

SARS	B-O
-	I-O
CoV	I-O
-	I-O
2	I-O
rRT	I-O
-	I-O
PCR	I-O
was	O
then	O
performed	O
for	O
each	O
sample	O
.	O

Evaluation	O
of	O
the	O
efficacy	O
was	O
based	O
on	O
difference	O
in	O
cycle	B-O
threshold	I-O
(	I-O
Ct	I-O
)	I-O
value	I-O
.	O

The	O
analysis	O
of	O
data	O
was	O
carried	O
out	O
using	O
GraphPad	O
Prism	O
version	O
5	O
for	O
Windows	O
.	O

Kristal	O
wullis	O
and	O
Paired	O
t	O
-	O
test	O
were	O
used	O
.	O

A	O
probability	O
value	O
of	O
less	O
than	O
0	O
.	O
05	O
was	O
regarded	O
as	O
statistically	O
significant	O
.	O

